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Abstract 
Hepatitis C virus causes a chronic infection in ~3% of the world’s population and is 
a leading cause of liver diseases such as cirrhosis and hepatocellular carcinoma. It 
is a positive-sense single-stranded RNA virus that persists in ~85% of infections. 
Viral genome replication occurs within a specialised membranous compartment, 
termed replication factories. This provides an environment suitable for the 
production of infectious virus, and correct formation and maintenance is critical for 
virus replication. The process is coordinated by the non-structural proteins in a 
macromolecular protein assembly, but the precise mechanisms of biogenesis and 
protein organisation within replication factories are unknown. 
New super-resolution light microscopy approaches allow resolutions of tens of 
nanometres, 10-fold higher than standard wide-field or confocal microscopy. The 
goal of this research was to use these techniques to determine the organisation 
and architecture of proteins within replication factories. 
Super-resolution imaging revealed clusters of viral proteins that were equivalent to 
the diffraction limited puncta observed by wide-field microscopy. A detailed analysis 
of protein clusters identified significant differences in size and organisation between 
the non-structural proteins NS3 and NS5A with a defined minimum distance to the 
cluster centroid. Additional investigations into the functions of NS5A revealed 
altered cluster phenotypes with both pharmacological inhibition and mutants 
defective in phosphorylation. A number of strategies were also explored to facilitate 
fluorescence labelling of viral components in replication factories. 
In parallel, investigations into the biogenesis of replication factories were explored 
by characterising interactions between hepatitis C virus and autophagy. This study 
identified a requirement of HCV replication for early steps in the formation of 
autophagosomes. 
The findings from this research are the first descriptions using super-resolution 
microscopy to understand the hepatitis C virus replication complex and provide 
insight into the organisation and architecture of the non-structural proteins during 
infection.  
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Chapter 1 - Introduction 
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1.1     Hepatitis C virus 
1.1.1     Identification and classification 
Hepatitis is a term used to describe inflammation of the liver and is predominantly 
caused by viral infection from one of the human hepatitis A–E viruses. Prior to the 
identification of hepatitis C virus (HCV), most cases of viral hepatitis were attributed 
to hepatitis A virus (HAV) or hepatitis B virus (HBV) infection. The identification of a 
novel pathogen came after the majority of post-transfusion hepatitis cases were 
unreactive in HAV or HBV diagnostic tests (Feinstone et al., 1975). A small 
enveloped virus was attributed to non-A non-B hepatitis (NANBH) after 
transmission of infectious plasma to chimpanzees through intravenous injection 
(Bradley et al., 1985, 1983). Isolation of a cDNA clone derived from NANBH 
identified an RNA molecule which encoded an antigen associated specifically with 
NANBH infections (Choo et al., 1989). Termed hepatitis C virus, this single 
infectious agent was later attributed to the majority of post-transfusion NANBH 
(Choo et al., 1990). 
Significant sequence homology with members of the Flavivirus genus classified 
HCV into the Flaviviridae family (Figure 1.1). HCV is most closely related to the 
genera Pestivirus and Pegivirus and became the prototype member of the 
Hepacivirus genus. The origin of HCV has long been a mystery with George-Barker 
virus B, which causes hepatitis in tamarins (Stapleton et al., 2011), the only other 
Hepacivirus member. Recently the most closely related virus to HCV was identified, 
termed non-primate hepacivirus (NPHV). Originally isolated from domestic dogs 
(Kapoor et al., 2011), NPHV has subsequently only been identified in horses 
(Burbelo et al., 2012; Lyons et al., 2012). Following the discovery of NPHV, deep 
sequencing has identified a wide range of highly divergent hepaciviruses and 
pegiviruses in rodent and bat species (Kapoor et al., 2013; Quan et al., 2013). 
Following the identification of HCV in 1989, the substantial diversity of isolates from 
different individuals and countries became apparent. A unified nomenclature 
(Simmonds et al., 2005) originally classified HCV into 6 different genotypes, further 
divided into subtypes (a, b, c, etc.). This has subsequently been expanded to 7 
genotypes and 67 subtypes (Smith et al., 2014). The genotypes of HCV differ by 
30–35% in nucleotide sequence across the genome with <15% variation between 
each subtype (Smith et al., 2014). 
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Figure 1.1: Phylogenetic analysis of the Flaviviridae family and HCV genotypes. 
A: Phylogenetic tree of conserved regions in the RNA-dependent RNA polymerase 
within the Flaviviridae family, reproduced from (Kapoor et al., 2011). 
B: Phylogenetic tree from 129 complete HCV coding sequences, adapted from 
(Smith et al., 2014). 
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1.1.2     Epidemiology and transmission 
Current estimates indicate that ~2.8% of the world’s population are seropositive for 
HCV, corresponding to >185 million infected individuals (Mohd Hanafiah et al., 
2013). The distribution of HCV genotypes varies globally, along with prevalence 
within the population (Figure 1.2) (Messina et al., 2015). Genotype 1 and 3 
infections account for the majority of infections worldwide with approximately 46% 
and 30% seroprevalence respectively. Genotype 1 infections are mostly attributed 
to subtypes 1a and 1b and are widely distributed globally, whereas genotype 3 
dominates in south Asia (Messina et al., 2015). The other five genotypes account 
for the remaining ~25% of infections and are more geographically constrained. 
Hepatitis C virus is a blood borne pathogen and transmission requires contact with 
contaminated blood products. Medical blood transfusion was the leading cause of 
HCV transmission until the introduction of screening for liver disease, increased 
serum alanine aminotransferase (ALT) levels and HCV antibodies, which 
dramatically reduced the incidence rate (Donahue et al., 1992; Schreiber et al., 
1996). However, this still remains a route of transmission in most developing 
countries due to the continued use of unsafe healthcare practises. Currently the 
most common cause of transmission is through intravenous drug use which is 
estimated to account for around 80% of new infections in the developed world (Sy 
and Jamal, 2006). Other routes of transmission include sexual contact and perinatal 
transmission, however these are much less common, typically <10%. 
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Figure 1.2: Global distribution and prevalence of HCV. 
Size of pie chart proportional to the number of seroprevalent cases, adapted from 
(Messina et al., 2015). 
 
1.1.3     Pathology 
Acute infection with HCV is often undiagnosed because around 70–80% of cases 
are asymptomatic (McCaughan et al., 1992). Symptoms that do present occur 
within 3–12 weeks after exposure and include malaise, nausea and jaundice (Alter 
and Seeff, 2000; Thimme et al., 2001). The levels of HCV RNA increase rapidly 
within the first few weeks, peaking at 105–107 IU/ml, which coincides with the peak 
of serum ALT levels and onset of symptoms (Chen and Morgan, 2006). Acute 
infection can be severe, but fulminant liver failure is rare (Farci et al., 1996; Younis 
et al., 2015; Yu et al., 2005). 
However, in the majority of cases (75–85%), acute hepatitis is not resolved and 
patients develop a chronic infection (Figure 1.3). This is defined by the presence of 
HCV RNA within the blood after 6 months. Risk factors associated with the 
development of chronic infection include genotype, age, gender, race, presence of 
symptoms during acute infection and immunosuppression or human 
immunodeficiency virus (HIV) coinfection (Chen and Morgan, 2006; Núñez and 
Soriano, 2005). 
Persistent infection with HCV causes progressive damage of the liver resulting in 
liver fibrosis, developing to cirrhosis in 10–20% of cases. This is typically an 
asymptomatic process and diagnosis with HCV usually occurs when patients 
present with the complications of end-stage liver disease and failure (Chen and 
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Morgan, 2006). Following diagnosis of cirrhosis there is an additional risk, 1–4% per 
year, of developing hepatocellular carcinoma (HCC).  
The risk factors associated with disease progression are varied and include age at 
time of infection, gender, coinfection with HIV or HBV, and excessive consumption 
of alcohol (Chen and Morgan, 2006). Additionally, differences in disease 
progression exist between genotypes. Patients infected with genotype 4 are more 
likely to develop chronic infection, whereas genotype 3 infections are often cleared 
during acute infection but have a faster progression to liver fibrosis and steatosis in 
chronic infections (Lehmann et al., 2004; Núñez and Soriano, 2005). Liver failure 
and HCC caused by HCV infection is a leading cause of liver transplantation in 
many countries, with the added complication of graft re-infection in most cases 
(Rubín et al., 2011).  
Regular screening is therefore important for monitoring the development of liver 
fibrosis to cirrhosis and HCC. These tests typically include liver biopsies and 
histological staining to score the extent of fibrosis and hepatocyte death (Theise, 
2007). Advances in techniques for grading liver fibrosis using biochemical markers, 
ultrasound and magnetic resonance now provide more suitable methods for regular 
screening and monitoring of disease progression which are less invasive (Faria et 
al., 2009; Huwart and van Beers, 2008). However, these approaches do not reach 
sufficient diagnostic accuracy to replace the gold standard of liver biopsies 
(Papastergiou et al., 2012). 
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Figure 1.3: Disease progression of HCV infection. 
The natural progression of HCV infection in the absence of therapeutic treatment. 
Adapted from (Chen and Morgan, 2006). 
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1.1.4     HCV therapies 
A cure for HCV is classified by a sustained virological response (SVR), defined as 
undetectable HCV RNA 12–24 weeks following cessation of treatment. Historically, 
the standard of care (SOC) for chronic HCV infection was pegylated-interferon 
alpha (Peg-IFNα) and ribavirin (RBV) therapy which achieved SVR in 54–63% of 
cases depending of virus genotype (Hadziyannis et al., 2004; Manns et al., 2001). A 
90% chance of resolving infection could be achieved with Peg-IFNα monotherapy 
for 24 weeks if HCV infection was identified early in symptomatic acute infections 
(Jaeckel et al., 2001; Santantonio et al., 2005; Wiegand et al., 2006).  
However, major drawbacks to these therapies are the side effects which manifest 
as headaches, myalgia, nausea and flu-like symptoms. The severity of side effects 
during a 24–48 week therapy reduce the adherence of patients to the treatment 
regimen and therefore its success (Manns et al., 2001). Other than patients 
withdrawing from treatment a proportion are non-responders, those who do not 
achieve viral clearance at the end of therapy, or relapsers, who initially achieve 
SVR but HCV RNA levels are then detectable at a later date (Pearlman and Traub, 
2011). There are also patients with a partial response who achieve a 1–2log10 drop 
in HCV RNA levels.  
Predicting the patient response to therapy is therefore a major consideration in the 
clinical setting. Along with HCV genotype, a number of host genetic variants have 
recently been identified which strongly correlate with therapy response and 
spontaneous clearance of HCV, reviewed in (Rau et al., 2012). Interferon-λ 3 
(previously interleukin 28B) is the best understood with multiple single nucleotide 
polymorphisms (SNP) reported across the IL28B locus. Genotyping of both HCV 
and the patient have become mandatory in the clinical setting for determining the 
best treatment regimen. 
Recently a number of direct acting antivirals (DAA) have been approved for use by 
the Food and Drug Administration (FDA). These have considerably improved the 
clinical outcomes for HCV infected patients (Table 1.1). The DAAs described to 
date are targeted towards the HCV non-structural proteins NS3/4A, NS5A or NS5B. 
The first two DAAs licenced by the FDA were the NS3/4A protease inhibitors 
boceprevir and telaprevir in combination with RBV and Peg-IFNα. Both of which are 
linear peptidomimetic structures that reversibly form a covalent bond with the 
catalytic serine of NS3/4A (Hazuda et al., 2013; Kwong et al., 2011). The addition of 
a single DAA into the RBV and Peg-IFNα treatment regimen improved SVR rates 
for genotype 1 infected patients from 46% to 70% (Manns and von Hahn, 2013).  
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Despite these improvements in SVR both boceprevir and telaprevir have a number 
of limitations including a narrow genotype specificity, low barrier to resistance and 
adverse side effects. The resistance-associated variant (RAV) Arg155 in NS3 
reduces the binding properties of these drugs with minimal effect on the natural 
substrate (Romano et al., 2012, 2010). Additional first generation NS3/4A inhibitors 
were trialled with improved tolerability and similar antiviral efficacy profiles, but from 
a number of candidates only simeprevir was approved in combination therapy with 
Peg-IFNα and RBV (Zeuzem et al., 2014). Since their original licencing in 2011, 
Merck and Vertex have voluntarily discontinued production of boceprevir and 
telaprevir due to the rapid developments of second generation NS3/4A inhibitors 
and pan-genotypic therapies. The second generation NS3/4A protease inhibitor 
grazoprevir retains NS3/4A binding properties in the context of the R155K mutation 
and was recently licensed in a combination therapy with the NS5A inhibitor elbasvir 
(Romano et al., 2012; Summa et al., 2012).  
The viral polymerase NS5B is another key target for DAA therapy with drugs 
classed as either nucleotide or non-nucleotide inhibitors (Sofia et al., 2012). Non-
nucleotide inhibitors bind NS5B and inhibit the polymerase through an allosteric 
mechanism before or at the point of initiation, inhibiting the transition to elongation. 
Beclabuvir (Rigat et al., 2014) and dasabuvir (Kati et al., 2015) are examples of 
non-nucleotide inhibitors. However, due to their low barrier to resistance, only 
dasabuvir is licenced in the multi DAA therapy Viekira Pak. 
Nucleotide inhibitors on the other hand are metabolically activated from prodrugs 
and compete with the incoming nucleotide triphosphates (Sofia et al., 2012). They 
typically show pan-genotypic activity with a high barrier to resistance making them 
attractive candidates. Resistance-associated variants that do occur are typically 
less fit and exhibit catalytic deficiency (Dutartre et al., 2006; Svarovskaia et al., 
2014; Tong et al., 2014). The major limitation in their development to the clinic are 
toxic side effects (Feld, 2014). The nucleotide inhibitor sofosbuvir was the first DAA 
licenced without the need for co-administration with Peg-IFNα as part of the Sovaldi 
treatment and has since become a common part of Peg-IFNα free therapies 
alongside NS5A inhibitors.  
The most potent HCV inhibitors target the NS5A protein and are active at pM 
concentrations (Belema et al., 2014). The absence of an enzymatic activity for 
NS5A has raised additional questions as to the mechanism of action of these 
inhibitors and is discussed further in Section 1.3.7.5. Daclatasvir, ledipasvir and 
ombitasvir are all currently licenced and when in combination with sofosbuvir can 
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achieve SVR rates >90% with no benefit from RBV addition (Afdhal et al., 2014; 
Kowdley et al., 2014). The biggest challenge for NS5A inhibitors is the emergence 
of RAVs which are generally fit and persist within the patient (Krishnan et al., 2015), 
a challenge currently being addressed with second generation NS5A inhibitors with 
pan-genotypic properties. The Epclusa formation, composed of second generation 
velpatasvir with sofosbuvir, was recently licenced and is the first therapy effective 
against genotypes 1 through 6 (Feld et al., 2015). The effectiveness of NS5A 
inhibitors in combination with the nucleotide inhibitor sofosbuvir indicate that this 
combination will become common components of many if not all therapies in the 
future. 
The development of DAAs has dramatically changed the landscape of HCV 
treatment with improved tolerability and SVR rates. However the high price 
associated has so far limited their use to patients with advanced liver disease 
(Trooskin et al., 2015). This approach will not tackle the ongoing transmission and 
development of advanced liver disease and HCC in those patients not yet at 
end-stage liver failure (Nuys et al., 2015). Despite the price of DAA therapies, their 
cost of cure is comparable to Peg-IFNα and ribavirin therapy due to the improved 
SVR rates (Rosenthal and Graham, 2016). However, the cost of treatment has 
limited access of new therapies and become a major stalling point for the treatment 
of HCV. 
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Brand Name (Company) DAA (target) Combination therapy Genotype Approval date 
Victrelis
1
 (Merck) Boceprevir (NS3/4A protease) RBV & Peg-IFNα 1 13/05/2011 
Incivek
1
 (Janssen – Vertex) Telaprevir (NS3/4A protease) RBV & Peg-IFNα 1 23/05/2011 
Olysio (Medvir – Janssen) Simeprevir (NS3/4A protease) RBV & Peg-IFNα 1 or 4 22/11/2013 
Sovaldi (Gilead) Sofosbuvir (NS5B polymerase) RBV
2
 1, 2, 3 or 4 06/12/2013 
Harvoni (Gilead) 
Ledipasvir (NS5A) 
Sofosbuvir (NS5B polymerase) 
3
 1, 4, 5 or 6 10/10/2014 
Viekira Pak (AbbVie) 
Paritaprevir (NS3/4A protease) 
Ombitasvir (NS5A) 
Dasabuvir (NS5B polymerase) 
Ritonavir (Cytochrome P450-3A4) 
4
 1 19/12/2014 
Technivie (AbbVie) 
Paritaprevir (NS3/4A protease) 
Ombitasvir (NS5A) 
Ritonavir (Cytochrome P450-3A4) 
RBV 4 24/07/2015 
Daklinza (Bristol Myers Squibb – 
Gilead) 
Daclatasvir (NS5A) 
Sofosbuvir (NS5B polymerase) 
n/a 1 or 3 24/07/2015 
Zepatier (Merck Sharp Dohme) 
Grazoprevir (NS3/4A protease) 
Elbasvir (NS5A) 
5
 1 or 4 28/01/2016 
Epclusa (Gilead) 
Velpatasvir (NS5A) 
Sofosbuvir (NS5B polymerase) 
6 
1, 2, 3, 4, 5 or 6 28/06/2016 
1 discontinued voluntarily due to scientific advancement and improved tolerability of other therapies 
2 with Peg-IFN — for patients with genotype 1 or 4 
3 with ribavirin — dependent on genotype, amount of liver damage and prior treatment history 
4 with ribavirin — for genotype 1a, or genotype 1b with cirrhosis 
5 with ribavirin — dependent on baseline NS5A polymorphisms and prior treatment history 
6 with ribavirin — for patients with decompensated cirrhosis 
Table 1.1: Current FDA approved therapies for HCV as of 29/09/2016 from www.fda.gov. 
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1.2     Molecular biology 
1.2.1     Genome organisation 
HCV is a single stranded RNA virus of positive polarity. The genome of around 
9.6 kb contains a number of complex RNA structures and encodes for a single open 
reading frame (ORF) flanked by untranslated regions (UTR) (Figure 1.4A) (Davis et 
al., 2008; Mauger et al., 2015; Simmonds, 2004).  
The 5’ UTR can be divided into four domains (I–IV) which share more than 90% 
sequence identity among HCV genotypes (Figure 1.4A inset) (Brown et al., 1992; 
Honda et al., 1999, 1996; Smith et al., 2014). Domains II–IV constitute a type III 
internal ribosome entry site (IRES) which drives translation of the ~3000 amino acid 
HCV polyprotein via a cap-independent mechanism (Brown et al., 1992). The first 
40 nucleotides of the 5’ UTR constitute domain I which is not essential for 
translation and is involved in replication (Friebe et al., 2001; Luo et al., 2003). 
Domains II and III contain a number of complex RNA structures including hairpin 
loops (Klinck et al., 2000), a novel tetraloop fold (Lukavsky et al., 2000), and a 
pseudoknot (Wang et al., 1995), all of which are critical for IRES activity. The 
initiation codon AUG is located in a single stranded loop region of a small stem loop 
in domain IV (Honda et al., 1996). 
Within the 5’UTR are two microRNA-122 (miRNA-122) binding sites, a highly 
abundant and liver-specific miRNA (Jopling et al., 2005). In comparison to the usual 
mechanisms of miRNAs in negative regulation, miRNA-122 functions to enhance 
HCV RNA replication and IRES translation, and protects the viral RNA from 
degradation (Niepmann, 2013). Additional RNA regulatory elements within the core 
and NS5B coding regions are involved in long range RNA-RNA interactions that 
modulate different stages of the HCV life cycle (Tuplin et al., 2004; You et al., 
2004). In particular the cis-acting replication element (CRE) at the 3’ end of the 
ORF exerts an inhibitory effect on IRES function (Romero-López et al., 2012). 
The last 200–235 nucleotides of HCV constitute the 3’ UTR which stimulates HCV 
IRES translation and facilitates HCV encapsidation (Figure 1.4A inset)  (Shi et al., 
2016; Song et al., 2006). This can be subdivided into three distinct domains, a 
variable region, a poly(U/UC) tract and a 98 nucleotide X region (Blight and Rice, 
1997; Kolykhalov et al., 1996; Tanaka et al., 1996, 1995; Yamada et al., 1996). 
Highly conserved within genotypes, the variable domain immediately follows the 
termination codon and ranges in length from 27 to 70 nucleotides (Kolykhalov et al., 
1996; Yanagi et al., 1998). The variable domain is required with the other domains 
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in the 3’ UTR for the 3’UTR-40S ribosomal subunit interactions (Bai et al., 2013). 
The length of the poly(U/UC) tract region is variable between genotypes and 
correlates with replication capability (Friebe and Bartenschlager, 2002; Kolykhalov 
et al., 1996; Tanaka et al., 1996; Yanagi et al., 1998; Yi and Lemon, 2003). The X 
region contains three stem loops and is involved in translation, functioning much 
like the poly(A) sequence of mRNAs (Wood et al., 2001). 
1.2.2     Virion architecture 
The architecture and composition of the HCV particle has long remained enigmatic. 
Filtration and electron microscopy (EM) studies have identified predominately 
spherical particles with a heterogenous diameter of 40–80 nm (Bradley et al., 1985; 
Catanese et al., 2013; Gastaminza et al., 2010; Merz et al., 2011). 
Negative stain and cryoelectron microscopy studies have identified the HCV virion 
is membrane enveloped with a smooth surface and displays the two glycoproteins, 
E1 and E2, which direct cell receptor binding (Figure 1.4B and C). The core protein 
forms a nucleocapsid which surrounds a single copy of the virus genome. This  
nucleocapsid is discernible in cryoelectron micrographs (Figure 1.4B) and exhibits a 
similar size to non-enveloped particles which co-purify with membrane enveloped 
particles (Gastaminza et al., 2010).  
Serum- and cell culture-derived HCV particles are associated with lipoprotein 
components such as apolipoprotein A-I (apoA-I), apoB-48, apoB-100, apoC-I and 
apoE (Figure 1.4C) (Catanese et al., 2013; Diaz et al., 2006; Felmlee et al., 2010; 
Gastaminza et al., 2010; Kono et al., 2003; Merz et al., 2011; Thomssen et al., 
1992), and their lipid composition is similar to serum lipoproteins (Merz et al., 2011). 
Due to the interactions with lipoproteins, infectious HCV particles have an unusually 
low and heterogenous buoyant density for an enveloped virus (Hijikata et al., 1993; 
Lindenbach et al., 2005). It is therefore proposed that HCV particles form hybrid 
lipoviral particles (LVP), either through transient interactions with serum lipoproteins 
in the two-particle model, or by directly sharing an envelope with a low-density 
lipoprotein (LDL) in the single particle model (Figure 1.4D) (Lindenbach and Rice, 
2013). 
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Figure 1.4: Organisation of the HCV genome and virion architecture. 
A: Genome organisation of HCV with 5’ and 3’ UTRs (insets). Protein organisation 
within the polyprotein is indicated. B: Electron cryomicrographs of purified virus. 
Scale bar 100 nm. Adapted from (Gastaminza et al., 2010). C: Immunogold 
labelling of purified HCV particles (a) E2, (b) apoE, (c) apoA-I, (d) apoB, (e) E2 
(arrows, 8 nm gold) and apoE (arrowheads, 18 nm gold). Scale bar 100 nm. 
Adapted from (Catanese et al., 2013). D: Models of HCV virion architecture; 
two-particle model with transient interaction between serum lipoproteins 
(high-density lipoprotein [HDL] and low-density lipoprotein [LDL]) and HCV 
particles. Single particle model with membrane sharing between HCV and 
low-density lipoprotein. Adapted from (Lindenbach and Rice, 2013). 
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1.2.3     HCV entry 
Hepatocytes are the cellular target of HCV and account for 60–70% of the liver cell 
mass (Lee and Luk, 2010). They adopt a polarised architecture and are infected by 
HCV from the blood at the basolateral surface (Lindenbach and Rice, 2013). HCV 
particles bind receptors on the cell surface of hepatocytes and are internalised by 
clathrin-mediated endocytosis (Blanchard et al., 2006). Unlike other viruses, HCV 
requires binding and attachment to a number of receptors on the cell surface in a 
receptor binding cascade (Figure 1.5).  
Initial receptor binding occurs via the virion-associated apoE onto 
low-density-lipoprotein receptor (LDLR) and glycosaminoglycans (GAGs) present 
on heparin sulphate proteoglycans (Agnello et al., 1999; Germi et al., 2002; 
Monazahian et al., 1999). The presentation of apoE on the surface of HCV is 
important for facilitating HCV entry into cells. Polymorphisms in the apoE gene, 
specifically the ε3 allele, are associated with increased risk of developing persistent 
infection (Price et al., 2006). Stabilisation of receptor binding by scavenger receptor 
class B member 1 (SRB1) to virus-associated lipoproteins and subsequent lipid 
transfer activity, in a post-binding event, are then required for productive HCV entry 
(Dao Thi et al., 2012; Zahid et al., 2013). SRB1 then interacts with the 
hypervariable region 1 (HVR1) of E2, altering its confirmation, to facilitate E2 
binding to CD81 (Bankwitz et al., 2010; Dao Thi et al., 2012; Scarselli et al., 2002). 
Binding of CD81 to E2, is thought to prime HCV for pH-dependent fusion (Sharma 
et al., 2011), and this interaction requires the tight junction protein claudin 1 
(CLDN1) (Harris et al., 2010). 
Tight junctions are a critical component in liver architecture which maintain tissue 
integrity, cellular interactions and cell-cell communications (Lee and Luk, 2010). 
Both CLDN1 and occludin are multiple transmembrane spanning proteins at the 
tight junction which mediate HCV internalisation in a post binding step (Evans et al., 
2007; Harris et al., 2010; Ploss et al., 2009; Sourisseau et al., 2013). Although 
CLDN1 does not bind HCV directly, interaction with CD81 mediates HCV 
internalisation (Evans et al., 2007; Harris et al., 2010). Additional receptors such as 
transferrin receptor 1 and Niemann-Pick C1-like 1 are also important for HCV entry, 
although their roles in HCV entry remain to be elucidated (Sainz et al., 2012). 
Following receptor binding a number of intracellular signal transduction pathways 
are activated which facilitate HCV entry. Binding of E2 to CD81 facilitates the lateral 
movement of HCV on the cell surface to the tight junction (Brazzoli et al., 2008). 
This is through modification of cortical actin filaments after activation of 
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Rho-GTPases by CD81 (Brazzoli et al., 2008; Farquhar et al., 2012). Further 
interactions with epidermal growth factor receptor (EGFR) promote the 
CD81-CLDN1 interaction (Lupberger et al., 2011) and mediate the step between 
receptor engagement and clathrin-mediated endocytosis (Diao et al., 2012).  
After clathrin-mediated endocytosis, HCV particles are trafficked to endosomal 
compartments (Coller et al., 2009; Farquhar et al., 2012), where fusion of 
endosomal membranes with the HCV envelope releases the genome into the 
cytoplasm. This requires acidification of endosomal compartments (Tscherne et al., 
2006) which is thought to induce rearrangements in the glycoproteins to mediate 
membrane fusion at pH 5.0 (Haid et al., 2009; Lavillette et al., 2006). Although the 
precise mechanism is yet be fully elucidated, the E1 glycoprotein harbours a 
putative fusion peptide (Drummer et al., 2007). Support for this fusion peptide was 
reported recently with the discovery of resistance mutations within E1 to a 
compound that inhibits HCV membrane fusion (Perin et al., 2016).  
HCV can also be directly transmitted through cell to cell contact which is dependent 
on the tight junction proteins CLDN1 and occludin, and SRB1 and CD81 
(Brimacombe et al., 2011; Timpe et al., 2008). Originally thought to be independent 
of CD81, this process does require CD81 along with the full complement of HCV 
proteins including E1 and E2 (Brimacombe et al., 2011; Timpe et al., 2008; 
Witteveldt et al., 2009). 
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Figure 1.5: Entry of HCV into the cell. 
Step 1: HCV lipoviral particles associate with the cell surface by interactions with 
heparin sulphate proteoglycans (HSPG), low-density-lipoprotein receptor (LDLR) 
and scavenger receptor class B member 1 (SRB1) before interaction with CD81.  
Step 2: Interaction of E2 with CD81 mediates epidermal growth factor receptor 
(EGFR) signalling through Rho GTPases. Step 3: Lateral movement of HCV to sites 
of cell-to-cell contact. Step 4: Interaction of CD81 with claudin 1 (CLDN1) initiates 
HCV internalisation by clathrin-mediated endocytosis. Step 5: The low pH of the 
endosomal compartment induces HCV membrane fusion and genome release. 
Niemann-Pick C1-like 1 (NPC1L1), occludin (OCLN). Reproduced from 
(Lindenbach and Rice, 2013). 
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1.2.4     Polyprotein translation 
Most eukaryotic mRNA translation is initiated by binding of the 5’-m7G cap-structure 
to the cap-binding complex and subsequent recruitment of the 40S ribosomal 
subunit and associated eukaryotic initiation factors (eIF) (Jackson et al., 2010; 
Sonenberg and Hinnebusch, 2009). This pre-initiation complex then scans along 
the mRNA until an initiation AUG codon is encountered. 
HCV bypasses this process by recruiting the 40S ribosomal subunit directly via 
interactions with the IRES in the 5’ UTR (Fukushi et al., 1997; Honda et al., 1996; 
Pestova et al., 1998; Rijnbrand et al., 1995; Rijnbrand and Lemon, 2000). Since the 
discovery of this mechanism for virus translation several cellular IRES have been 
identified and studied (Komar and Hatzoglou, 2011). For HCV, this process only 
requires eIF3 and eIF2, which bring the initiator methionyl-tRNA to the 40S 
ribosomal unit, and is mediated by domain III of the IRES (Figure 1.4A inset) (Ji et 
al., 2004; Otto and Puglisi, 2004; Pestova et al., 1998; Rijnbrand et al., 1995). The 
basal portion of domain III forms the core interaction with the 40S subunit and 
involves a conserved GGG motif within IIId, while the apical portion (IIIb) interacts 
with eIF3 (Kieft et al., 2001; Kolupaeva et al., 2000; Lytle et al., 2002, 2001).  
Binding of the HCV IRES to the 40S ribosomal subunit induces rotation of the head 
domain and opening of the mRNA binding channel (Spahn et al., 2001). 
Subsequent recruitment of the 60S ribosomal subunit forms an active 80S ribosome 
positioned directly on the HCV initiation AUG codon (Reynolds et al., 1996, 1995). 
Correct positioning of the ribosome on the start codon requires both sequence and 
structural stability of domain IV (Honda et al., 1996).  
Translation of the HCV open reading frame produces a polyprotein of approximately 
3000 amino acids which is later cleaved into the individual proteins (Figure 1.6). 
The signal peptide sequence at the core-E1 boundary stalls polyprotein translation 
and directs the ribosome to the endoplasmic reticulum through the signal 
recognition particle (Hüssy et al., 1996; McLauchlan, 2000; McLauchlan et al., 
2002; Reid and Nicchitta, 2015; Santolini et al., 1994). Signal peptidase cleavage of 
the core-E1 junction, and a series of further signal sequences at the E1-E2, E2-p7 
and p7-NS2 boundaries. liberate the structural proteins and p7 (Griffin et al., 2005; 
Hijikata et al., 1993). Autocatalysis by NS2 at the NS2-3 boundary frees NS2 from 
the polyprotein (Grakoui et al., 1993; Hijikata et al., 1993), before the remaining 
HCV proteins are released by NS3 (Bartenschlager et al., 1994). The cofactor 
NS4A is required to complete the NS3 protease domain and anchor the protein to 
the ER (Bartenschlager et al., 1995). All HCV proteins are membrane associated 
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and this is required for their function (Figure 1.6) (Brass et al., 2008; Elazar et al., 
2004; Gosert et al., 2005; Moradpour et al., 2003; Schmidt-Mende et al., 2001). 
1.2.5     Genome replication 
Positive strand RNA viruses replicate in close association with cytoplasmic host cell 
membranes (Paul and Bartenschlager, 2015). These virally-induced structures are 
specialised sites for genome replication termed viral replication factories. HCV 
infection induces the production of single, double and multi-membrane vesicles in 
the cytoplasm, termed the “membranous web”, which give infected hepatocytes a 
“sponge-like” appearance by EM (Egger et al., 2002; Gosert et al., 2003). The 
formation and architecture of these membranous structures are a major focus of 
this study and are discussed in further detail in (Section 1.4). 
 
 
 
 
 
Figure 1.6: Membrane topologies and major functions of HCV proteins. 
Each protein is membrane bound by one or several transmembrane helices, except 
core and NS5A which use amphipathic helices. Only NS5A is represented as a 
dimer, although most, if not all form homo- heterodimers or oligomeric complexes. 
Adapted from (Bartenschlager et al., 2013). 
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Genome replication and polyprotein translation are two inter-linked processes 
controlled by HCV RNA regulatory elements and cellular proteins (Isken et al., 
2007; Romero-López et al., 2014; Romero-López and Berzal-Herranz, 2009). HCV 
genome replication is mediated by the virally encoded RNA-dependent RNA 
polymerase NS5B (Appleby et al., 2015). The synthesis of negative strand RNA 
appears to be rate-limiting for HCV replication as positive strand copies are 
generated in 5–10-fold excess (Quinkert et al., 2005). The control between genome 
replication and translation is postulated to be instigated by genome circularisation 
(Isken et al., 2007). This prevents conflict between translating ribosomes travelling 
5’–3’ versus the 3’–5’ movement of NS5B in negative strand synthesis.  
Another feature of HCV genomes are their genetic variability. HCV circulates as a 
quasispecies of closely related genomes (Martell et al., 1992). This is due to the low 
fidelity of NS5B with an error rate, in vivo, of ~2.5x10-5 mutations per nucleotide per 
genome replication (Ribeiro et al., 2012). A consequence of this is the high genetic 
diversity of HCV genotypes and the rapid occurrence of resistance mutations to the 
recently licensed DAAs. 
1.2.6     Assembly and release 
The assembly and release of HCV particles crucially depends on an association of 
core protein with cytosolic lipid droplets (cLDs) following synthesis and maturation 
on the ER (Figure 1.7) (Boulant et al., 2006; Miyanari et al., 2007). Cytosolic lipid 
droplets are a lipid storage organelle containing a hydrophobic core with a 
phospholipid monolayer that is derived from the outer leaflet of the ER membrane 
(Gross and Silver, 2014). The complete processing of core by signal peptide 
peptidase is important for this association with cLDs, as disruption of processing 
reduces HCV titres (Okamoto et al., 2008; Targett-Adams et al., 2008b).  
Multiple interactions between the HCV proteins facilitate the assembly and egress 
of virus particles. NS5A contains three domains (I, II and III) and is a key player in 
this process (Miyanari et al., 2007). The regulation of the switch between NS5A 
involvement in replication and assembly is thought to occur by phosphorylation 
(Masaki et al., 2008; Tellinghuisen et al., 2008a). Two distinct regions in domain III, 
comprising a cluster of basic amino acids and a separate cluster of serine’s, are 
involved in recruitment of replication complexes to core, and transfer of HCV RNA 
to core respectively (Zayas et al., 2016).  
Another two non-structural proteins, p7 and NS2 are required for the correct 
organisation and recruitment of non-structural proteins and core-containing cLDs to 
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the assembly complex (Gentzsch et al., 2013; Jirasko et al., 2010; C. T. Jones et 
al., 2007; Popescu et al., 2011). Although not involved in replication, p7 deletions in 
HCV do not produce infectious particles (C. T. Jones et al., 2007; Lohmann et al., 
1999; Steinmann et al., 2007).  
The NS2 requirement for virus production does not depend on its catalytic activity 
as this is dispensable in the assembly process (Jirasko et al., 2010). Instead, the 
NS2 transmembrane domains are required which recruit the E1/E2 and NS3/4A 
complexes to sites of core associated cLDs (Counihan et al., 2011; Phan et al., 
2009).  
The recruitment of NS3/4A may be required for helicase-dependent packaging of 
HCV genomes. Accordingly, the NS3 helicase domain has been shown to be 
required for HCV particle production at a step after the association of core and 
NS5A but before the assembly of progeny virions (Ma et al., 2008; Yi et al., 2007). 
Progeny virions then bud from the assembly complex using the ESCRT (endosomal 
sorting complex required for transport) pathway which involves ubiquitination of  
NS2 to facilitate direct interactions with the ESCRT machinery (Ariumi et al., 2011; 
Barouch-Bentov et al., 2016; Corless et al., 2010; Tamai et al., 2012). The process 
of RNA packaging and budding is most likely a coordinated process comparable to 
other enveloped viruses (Welsch et al., 2009) as no preformed capsids are 
identified within cells. 
After assembly, virions travel through the trans-Golgi network (TGN) and endosome 
pathways in a process of maturation where the E1/E2 envelope proteins are 
glycosylated (Gastaminza et al., 2008; Mankouri et al., 2016; Vieyres et al., 2010). 
This process disrupts the TGN architecture in an NS2-dependent manner, resulting 
in TGN redistribution to regions containing HCV core on lipid droplets (Mankouri et 
al., 2016).  
After glycosylation of the E1/E2 proteins in the Golgi, HCV virions are released at 
the plasma membrane by trafficking through the endosome network in a 
VAMP-1-dependent manner (Coller et al., 2012). The endosome pathway appears 
to be important for multiple stages of the HCV lifecycle as the early endosome 
protein Rab5 is required for HCV genome replication (Manna et al., 2010; Stone et 
al., 2007). 
Serum-derived HCV particles are associated with lipoprotein components and 
share a similar lipid composition (Section 1.2.2). However, there is conflicting data 
whether HCV virions associate with serum lipoproteins during egress. Assembly 
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has been reported to depend on the apolipoprotein apoE due to a specific 
interaction with NS5A (Benga et al., 2010; Counihan et al., 2011; Jiang and Luo, 
2009). However, more recent studies indicate that HCV release may be 
independent of the very-low-density lipoprotein (VLDL) pathway (Mankouri et al., 
2016). Accordingly, the VLDL pathway requirements apoB and microsomal 
triglyceride transfer protein are dispensable for HCV particle assembly (Benga et 
al., 2010; Jiang and Luo, 2009). 
 
 
 
 
Figure 1.7: HCV assembly. 
Viral RNA is transferred from replication complexes to core on cytosolic lipid 
droplets, the site of virus assembly. The transfer of viral RNA is proposed to be 
mediated by NS5A. The non-structural proteins p7 and NS2 are critical for the 
recruitment of core, E1/E2 and NS proteins at the site of assembly. Virus particles 
assemble by recruitment of E1/E2 complexes and budding into the ER. Reproduced 
from (Lindenbach and Rice, 2013). 
 
  24 
1.3     Individual HCV proteins 
1.3.1     Core – nucleocapsid protein 
The mature core protein is a 21 kDa RNA binding protein which binds the genomic 
RNA and forms the HCV nucleocapsid (Gawlik and Gallay, 2014). The protein is 
divided into two domains, DI and DII which have different hydrophobicity profiles 
(Boulant et al., 2006, 2005). The N-terminal domain is hydrophilic and rich in basic 
amino acid residues, whereas the C-terminus is hydrophobic. The DI domain is 
mostly involved in RNA binding and oligomerization which are required for particle 
formation (Ivanyi-Nagy et al., 2006; Majeau et al., 2004). The amino acids 1–82 of 
DI are intrinsically disordered (Duvignaud et al., 2009) and this property is thought 
to be vital for genomic RNA packaging into the virus particle (Cristofari et al., 2004). 
The DII domain contains two amphipathic α-helices which coordinate core 
localisation to the ER and lipid droplet (LD) membranes (Boulant et al., 2006). The 
association of core with lipid droplets is critical for protein function and may be 
regulated by palmitoylation of Cys-172 (Majeau et al., 2009). 
1.3.2     E1 and E2 – envelope glycoproteins 
The E1 and E2 envelope glycoproteins are present on the surface of HCV virions 
and mediate receptor binding at the cell surface. Both E1 and E2 are type I 
transmembrane proteins with an ectodomain facing the ER lumen and a C-terminal 
transmembrane domain (Cocquerel et al., 2002). They are synthesised on the ER 
where they form non-covalent heterodimers (Dubuisson et al., 1994; Rouillé et al., 
2006), an interaction mediated by their transmembrane domains and ectodomains 
(Albecka et al., 2011; Ciczora et al., 2007). The N-glycosylation of both E1 and E2 
control their protein folding and heterodimerisation (Goffard et al., 2005; Meunier et 
al., 1999) with complex glycans added during trafficking through the Golgi during 
virion maturation (Mankouri et al., 2016; Vieyres et al., 2010).  
Structures for the E1 amino-terminal portion and E2 core domain were solved by 
X-ray crystallography in recent years (El Omari et al., 2014; A. G. Khan et al., 2014; 
Kong et al., 2013). The E2 core is formed of a compact immunoglobulin-like fold 
and an additional novel domain comprising a central β-sheet surrounded by loops, 
short helices and two β strands (A. G. Khan et al., 2014; Kong et al., 2013). Like 
E2, the E1 amino-terminal portion also adopts a novel architecture composed 
of  β strands with a single long α-helix sandwiched between two and three 
antiparallel β strands (El Omari et al., 2014). Other members of the Flaviviridae 
family encode class II fusion proteins which mediate virion envelope fusion with the 
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host cell membrane (Kielian, 2006). The structural data of E1 and E2 contradict the 
prediction that they are also class II fusion proteins and indicate that HCV 
membrane fusion might proceed by another mechanism which is currently not 
understood (El Omari et al., 2014; A. G. Khan et al., 2014; Khan et al., 2015; Kong 
et al., 2013).  
1.3.3     p7 – viroporin 
The p7 protein of HCV is a viroporin of only 63 amino acids. It is a transmembrane 
protein that crosses the membrane twice and displays its N- and C-termini towards 
the cytoplasm (Lin et al., 1994). p7 is localised predominately at ER membranes 
with some association on mitochondria or lipid droplets, and is mostly colocalised 
with E2 (Vieyres et al., 2013). Oligomerisation of p7 into hexameric or heptameric  
cation-selective ion channels facilitate proton conductance across membranes 
(Griffin et al., 2003; Premkumar et al., 2004). This reduces the acidic conditions in 
the virion egress and release pathway which would otherwise damage maturing 
virions (Gentzsch et al., 2013; Wozniak et al., 2010). In contrast to the M2 protein of 
influenza virus that forms a proton channel in the viral envelope (Pielak and Chou, 
2011), p7 is not incorporated into HCV virions (Vieyres et al., 2013). 
1.3.4     NS2 – autoprotease 
The NS2 protein is 23 kDa and contains an N-terminal transmembrane domain and 
a C-terminal cytoplasmic domain. The C-terminal domain is a cysteine protease 
which processes the NS2–3 boundary of the HCV polyprotein by autoprotease 
activity (Grakoui et al., 1993; Hijikata et al., 1993). The establishment of 
sub-genomic replicons (SGR) demonstrated that NS2 is not required for genome 
replication (Lohmann et al., 1999). However, the C terminal catalytic domain was 
shown to be required for virus assembly (C. T. Jones et al., 2007). Additionally, 
NS2 has been implicated in host cell modulation with involvements in ER stress and 
apoptosis (von dem Bussche et al., 2010; Welbourn and Pause, 2006). 
1.3.5     NS3/4A – protease/helicase 
The 70 kDa NS3 is a two domain protein that encodes two enzymatic activities. The 
N-terminal and C-terminal domains encode for a serine protease and 
NTPase-dependent RNA helicase, respectively  (Lin, 2006).  
The N-terminal protease domain is involved in polyprotein processing and 
maturation of the remaining non-structural proteins. Efficient protease processing of 
NS3 requires the NS4A cofactor which both contributes to the protease fold of NS3 
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and anchors the NS3/4A protein to membranes (Bartenschlager et al., 1995, 1994). 
After polyprotein processing, the NS3/4A protease is involved in virus host 
interactions such as innate immunity interference (Li et al., 2005). NS3/4A efficiently 
cleaves and inactivates MAVS, an essential component in the RIG-I cytosolic 
sensory pathway (Foy et al., 2003), and the adaptor protein TRIF in the TLR3 
pathway (Li et al., 2005). 
The C-terminal helicase domain is a member of the DExH helicase superfamily-2 
and exhibits polynucleotide-stimulated NTPase activity (Suzich et al., 1993) which 
drives unwinding of RNA in a 3’–5’ direction (Kim et al., 1995; Tai et al., 1996). 
Crystallographic structures of three conformations during helicase activity identified 
a “ratchet” mechanism for the unidirectional translocation along RNA with a step 
size of one base per nucleotide hydrolysis (Gu and Rice, 2010).  
The purpose of linking two enzymatic activities onto a single protein remains 
elusive. Recent studies hypothesise that the helicase helps evade the immune 
response by binding pathogen associated molecular patterns, bringing the protease 
near immune receptors for cleavage (Corby et al., 2016). 
1.3.6     NS4B – transmembrane protein 
The 27 kDa hydrophobic protein NS4B is ER associated and contains 
4 transmembrane domains and 2 helices at its N- and C-terminus (Gouttenoire et 
al., 2010). Within the middle of the protein on the cytosolic side is a nucleotide 
binding domain (Gouttenoire et al., 2010) which has been implicated in GTP and 
ATP binding and hydrolysis (Einav et al., 2004). The expression of NS4B alone in 
cells has been shown to induce formation of the membranous web and is thought to 
occur through oligomerisation  (Egger et al., 2002; Paul et al., 2013). Therefore it 
plays a key role in replication complex formation and is involved in interactions with 
other viral proteins (Aligo et al., 2009; David et al., 2015), RNA (Einav et al., 2004) 
and the production of virus (Han et al., 2013). 
1.3.7     NS5A – multifunctional phosphoprotein 
1.3.7.1     Structure of NS5A 
NS5A is a 49 kDa protein, however 56 and 58 kDa forms, termed basal- and 
hyper-phosphorylated respectively, are resolvable by SDS-PAGE analysis 
(Neddermann et al., 1999). It is composed of three domains (I, II and III) separated 
by loop regions, termed low complexity sequences (LCS) (Tellinghuisen et al., 
2004) (Figure 1.8). 
  27 
At its N-terminus is a short (33 amino acid) amphipathic helix which is required for 
HCV replication and directs NS5A membrane association (Penin et al., 2004). This 
is followed by domain I which is the only domain with a crystal structure (Lambert et 
al., 2014; Love et al., 2009; Tellinghuisen et al., 2005). The structures revealed that 
domain I coordinates a zinc atom within a tetracysteine motif, has a disulphide bond 
at the C terminus, and the presence of a basic RNA-binding groove between the 
NS5A dimer interface.  
Although dimeric in the crystal structure, limited evidence exits to support a dimeric 
structure in vivo (Lim et al., 2012). Models for NS5A dimer associated with the 
membrane have been proposed, however these lack experimental evidence (Ross-
Thriepland and Harris, 2015). Both the tetracysteine motif and disulphide bond are 
required for maintaining the structure of domain I.  
The second two domains of NS5A are intrinsically disordered (Hanoulle et al., 2010, 
2009b; Liang et al., 2007, 2006; Verdegem et al., 2011). Nuclear magnetic 
resonance studies have identified α-helical structures within domain II (Feuerstein 
et al., 2012). NS5A is a multifunctional protein known to interact with a large 
number of cellular interaction partners (Tripathi et al., 2013). This promiscuity is 
proposed to derive from the ability of domains II and III to adopt a multitude of 
different conformations (Ross-Thriepland and Harris, 2015). Consistent with an 
unstructured and disordered peptide sequence, domains II and III are able to 
tolerate gene insertions at a number of discrete positions (Arumugaswami et al., 
2008; Remenyi et al., 2014). These have been exploited for insertions of protein 
tags (e.g. GFP) to monitor NS5A trafficking within cells (D. M. Jones et al., 2007; 
Moradpour et al., 2004; Schaller et al., 2007). 
Recently, a number of HCV related hepaciviruses have been identified which share 
a high degree of sequence homology with domain I but not domains II and III 
(Burbelo et al., 2012; Kapoor et al., 2013, 2011; Lauck et al., 2013). Secondary 
structure prediction programs indicate that the organisation of NS5A into three 
domains separated by LCS are shared among the hepaciviruses (Lauck et al., 
2013). 
1.3.7.2     Roles of NS5A during HCV infection 
NS5A is involved in stages of genome replication and virus assembly, the 
separation of which is controlled by different domains. Domains I and II are required 
for genome replication (Ross-Thriepland et al., 2013; Tellinghuisen et al., 2004). In 
comparison, although domain III contributes to genome replication it is dispensable 
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(Tellinghuisen et al., 2008b) and is instead required for HCV assembly (Hughes et 
al., 2009b; Zayas et al., 2016).  
The separation of these two functions are spatiotemporally regulated and 
fluorescence microscopy studies have revealed multiple populations of NS5A 
(Shulla and Randall, 2015). Live cell imaging studies with GFP-tagged NS5A have 
identified large immobile structures and smaller faster moving structures (D. M. 
Jones et al., 2007; Wölk et al., 2008), the movement of which is dependent on 
dynein (Eyre et al., 2014). 
Disruption of the protein fold in the N-terminus of domain I by mutation of the 
tetracysteine motif inhibits HCV replication (Tellinghuisen et al., 2004). This region 
also contains an important PTPPL sequence which associates NS5A to lipid 
droplets and is required for release of infectious HCV (Miyanari et al., 2007). In line 
with its involvement in genome replication, domain I is responsible for double 
membrane vesicle formation (Romero-Brey et al., 2015). However, a 
comprehensive description of domain I functions are not yet reported despite the 
detailed structural information. 
Domain II has been more extensively studied and is known to interact with host and 
viral proteins (Evans et al., 2004; Goh et al., 2001; Shirota et al., 2002). Studies 
with different genotypes have identified that deletions of 15–35 amino acids in the 
C-terminus abrogate replication, of which 23 were found to be essential (Appel et 
al., 2008; Tellinghuisen et al., 2008b). Conversely, deletion in the N-terminus has 
no effect on replication.  
NS5A domain III is mostly involved in virus assembly, in particular the C-terminal 38 
amino acids are required (Appel et al., 2008). Genotype 2 isolates contain an 
additional 18 amino acids within this C-terminal region that, conversely, is 
dispensable for assembly, with deletion only modestly effecting genome replication 
(Hughes et al., 2009b). A cluster of serines within the last 15 residues of domain III 
are phosphorylated and required for the interaction with core (Masaki et al., 2008). 
NS5A is reported to localise to core containing lipid droplets (Miyanari et al., 2007), 
and this localisation is mediated by the interaction and activity of diacylglycerol 
acyltransferase, a cellular enzyme involved in triglyceride synthesis in hepatocytes 
(Camus et al., 2013; Yen et al., 2008). 
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Figure 1.8: Structure of NS5A. 
A: Schematic of NS5A protein organisation. NS5A is composed of three domains 
separated by low complexity sequences (LCS) with an N-terminal amphipathic helix 
(AH). B: Crystal structure of genotype 1b NS5A domain I. The zinc atom 
coordinated by the tetracysteine motif is shown in red. (PDB ID No. 1ZH1). 
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1.3.7.3     Interaction partners 
Proteomic approaches with NS5A have identified over 130 cellular interaction 
partners (Tripathi et al., 2013), of which 60 have a reported functional consequence 
(Figure 1.9) (Ross-Thriepland and Harris, 2015). These interactions are likely 
spatially and temporally separated with only a subset occurring at any one time 
(Shulla and Randall, 2015). The ability of NS5A to interact with numerous partners 
likely stems from domains II and III which are intrinsically disordered and may adopt 
multiple conformations (Feuerstein et al., 2012).  
HCV replication is intrinsically linked to lipid metabolism in hepatocytes. Inhibition of 
phosphatidylinositol 4-phosphate (PI4P), cholesterol and fatty acid biosynthesis all 
disrupt HCV replication (Kapadia and Chisari, 2005; Reiss et al., 2011). NS5A 
directly interacts and activates the phosphatidylinositol 4-kinase (PI4K) IIIα which 
increases the quantity of PI4P (Reiss et al., 2011), and is required to maintain the 
membranous web (Section 1.4.1). A short seven amino acid region in domain I of 
NS5A is responsible for this interaction, and negative regulation of NS5A 
hyperphosphorylation was also reported (Reiss et al., 2011).  
Cyclophilins play an important role in the replication of HCV as inhibition of their 
activity abrogates HCV replication (Nakagawa et al., 2005, 2004; Watashi et al., 
2003). This is mediated through a direct interaction of cyclophilin A (CypA) with the 
C-terminus of domain II (Chatterji et al., 2010; Coelmont et al., 2010; Hanoulle et 
al., 2009a) and domain III (Verdegem et al., 2011). Cyclophilins are a family of 
peptidyl-prolyl isomerases (PPIase) that catalyse the cis–trans isomerisation of the 
peptide bond preceding a proline residue and are the target of the 
immunosuppressive drug cyclosporin A (CsA) (Handschumacher et al., 1984). 
Mutations that confer resistance to CsA are reported in both domain II and III, 
although these mutations do not prevent binding of either CsA or CypA to NS5A 
(Coelmont et al., 2010). The precise role of CypA isomerisation of NS5A is not 
known, although the multifunctional nature of NS5A suggests that this may provide 
another mechanism for switching the functions of domains II and III. Accordingly, a 
binding site for CypA on domain II of NS5A is shared with the HCV polymerase, 
NS5B (Rosnoblet et al., 2012). 
A number of cellular proteins contain Src homology 3 (SH3) domains which mediate 
protein-protein interactions (Mayer, 2001). These are bound by NS5A through the 
polyproline motif (PxxPxxR) within LCSII of NS5A which is completely conserved 
across all HCV genotypes (Macdonald et al., 2004; Tan et al., 1999). Mutation of 
this motif does not affect replication or virus production in cell culture (Hughes et al., 
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2009a), but is required to establish infection in the chimpanzee model (Nanda et al., 
2006). NS5A protein interactions utilising the polyproline motif include the regulation 
of apoptosis (Mankouri et al., 2009) through the SH3-domain-containing kinase 
mixed lineage kinase 3 (Amako et al., 2013) and amphiphysin II  (Zech et al., 2003), 
and trafficking of epidermal growth factor receptor (Mankouri et al., 2008) through 
the Cas ligand with multiple SH3 domains (Igloi et al., 2015). 
Other than cellular interaction partners, NS5A also binds HCV RNA (Foster et al., 
2010; Huang et al., 2005; Hwang et al., 2010). These studies identified that NS5A 
preferentially binds short (5–6 nucleotide) uracil-rich RNAs (Hwang et al., 2010) and 
exhibits a higher affinity for the poly(U/UC) tract in the 3’ UTR than the X region 
(Foster et al., 2010). The regulation of NS5A RNA binding may coordinate different 
stages of the HCV life cycle such as the switch from replication to assembly. 
Although no evidence to support or dispute this hypothesis is reported, domain II 
RNA-binding is stimulated by CypA in vitro (Foster et al., 2010) and CypA inhibition 
reduces NS5A RNA binding in HCV infected cells (Nag et al., 2012). 
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Figure 1.9: Organisation of NS5A with interaction partners. 
Amphipathic helix (AH), tetracysteine coordinated zinc (Tellinghuisen et al., 2005), 
daclatasvir resistance mutants (Fridell et al., 2010), lipid droplet binding motif 
(Miyanari et al., 2007), PI4KIIIα-binding motif (Reiss et al., 2011), cyclophilin A 
binding site (Hanoulle et al., 2009a; Coelmont et al., 2010), and P2 polyproline 
SH3-binding motif (Hughes et al., 2009a) are indicated. Known phosphorylation 
sites are highlighted (red). Sequence presented is genotype 2a (JFH1). Adapted 
from (Ross-Thriepland and Harris, 2015). 
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1.3.7.4     Phosphorylation of NS5A 
Phosphorylation is a posttranslational modification that regulates an estimated 30% 
of proteins in mammalian cells (Cohen, 2000). Serine, threonine and tyrosine 
phosphorylation are the mostly widely studied but phosphorylation of histidine, 
lysine, arginine, aspartate, glutamate and cysteine also occur (Cieśla et al., 2011). 
NS5A is a highly phosphorylated protein existing as both basal and 
hyperphosphorylated species within infected cells (Neddermann et al., 1999). Mass 
spectrometry studies have identified multiple phosphorylation sites within the NS5A 
LCS and indicate a complex regulation of NS5A functions (Lemay et al., 2013; 
Masaki et al., 2014; Ross-Thriepland and Harris, 2014). Mutation of serines in LCSI 
(S225, S232 and S235) to alanine all impair replication, whereas no effect was 
observed with mutation to aspartate, a phosphomimetic residue (Ross-Thriepland 
and Harris, 2014). Additionally, the first serine within LCSI, S222, was identified in 
all three studies and is a hallmark of the hyperphosphorylated species as the final 
phosphorylated residue in the phosphorylation cascade of LCSI (Ross-Thriepland 
and Harris, 2014).  
The precise regulatory roles of NS5A phosphorylation remain elusive despite recent 
findings. Opposite effects are observed with mutation of the same serines between 
genotype 1b (Con1) compared to 2a (JFH1) (Appel et al., 2005; Ross-Thriepland 
and Harris, 2014). In genotype 1b, the role of hyperphosphorylation negatively 
effects replication (Evans et al., 2004), and the culture adaptive mutation S2204I 
(corresponding to S232 in genotype 1b) abrogates hyperphosphorylation and 
confers a 20,000-fold increase in replication efficiency (Blight et al., 2000). This 
particular mutation is adaptive in genotypes 3a, 4a, 5a and 6a (Kim et al., 2014; 
Kinge et al., 2014; Saeed et al., 2012; M. Yu et al., 2014), but not 2a or the recently 
described 1a cell culture adapted virus TNcc (Li et al., 2012). 
Interestingly, S146 in genotype 2a appears to negatively regulate 
hyperphosphorylation with a reduction of hyperphosphorylation observed in S146D 
mutant replicons (Ross-Thriepland and Harris, 2014). The consequence of this 
particular residue is unclear as in all other genotypes, except 1a, S146 is an 
alanine. In contrast, mutation of S225 to alanine resulted in deficient HCV 
replication (Ross-Thriepland and Harris, 2014) which correlated with an altered 
cellular distribution (Ross-Thriepland et al., 2015). Again, the mechanism 
underlying this is unclear. 
A number of kinases are reported to phosphorylate NS5A including casein kinase I 
(CKI) and CKII, Polo-like kinase (Plk), and cAMP-dependent protein kinase (PKA) 
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(Chen et al., 2010; Cordek et al., 2014; Quintavalle et al., 2007). CKI-α was shown 
to phosphorylate S232 dependent on S229 phosphorylation (Quintavalle et al., 
2007). Inhibition and siRNA silencing studies have confirmed the activity of CKI-α 
on NS5A in vivo (Masaki et al., 2014; Quintavalle et al., 2007). Plk phosphorylates 
NS5A in vitro to both the 56 and 58 kDa forms, although specific residues were not 
identified (Chen et al., 2010). Lastly, T356 within domain III of NS5A is 
phosphorylated by PKA (Cordek et al., 2014). Inhibition of PKA reduces the 
infectivity of secreted virus particles with no effect on replication or the formation of 
intracellular infectious particles (Farquhar et al., 2008). 
1.3.7.5     NS5A as a target for direct acting antivirals 
The most potent direct acting antivirals target NS5A, which has no intrinsic 
enzymatic activity. Daclatasvir (DCV), developed by Bristol-Myers Squibb, was 
identified from cell based screening assays for compounds that inhibited SGR 
activity (Gao et al., 2010). It exhibits extraordinary potency, specificity and pan 
genotypic activity. The half maximal effective concentration (EC50) is <100 pM but 
>10 µM for other viruses (Gao et al., 2004). Additionally, the half maximum 
cytotoxic concentration (CC50) is >50 µM, providing a therapeutic index >100,000.  
NS5A was confirmed as the target after no effect of DCV on NS3 or NS5B activities 
and the development of resistance mutations specifically within the amphipathic 
helix and domain I of NS5A (Gao et al., 2010). Resistance mutations typically occur 
at positions 28, 30, 31 or 93 and can provide up to 10,000-fold increase in EC50 
values (Fridell et al., 2010). Since its first description alternative first generation 
molecules ledipasvir and ombitasvir have been described. Although each first 
generation NS5A inhibitor exhibits a low barrier to resistance, they have proven 
effective in the clinic in combination with either NS3/4A or NS5B inhibitors 
(Pawlotsky, 2014). Second generation elbasvir and velpatasvir have since been 
described with comparable potency and specificity to the first generation inhibitors 
but with an improved resistance barrier profile (Nakamoto et al., 2014). The FDA 
has approved all five of these NS5A inhibitors in various combination therapies 
(Table 1.1). 
Although these drugs have reached the clinic, the precise mode of action against 
NS5A remains obscure. Based on the EC50 value of DCV it is estimated that 1 
molecule can inhibit ~10,000 molecules of NS5A (Belda and Targett-Adams, 2012). 
The drug molecules are large (>700 Da) dimeric molecules and therefore are 
proposed to interact with the dimeric form of NS5A in a number of models (Barakat 
et al., 2015; Kazmierski et al., 2014; Lambert et al., 2014; Nettles et al., 2014; 
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O’Boyle Ii et al., 2013). Direct binding of DCV to NS5A has been observed in cells 
using a biotin-tagged derivative (Berger et al., 2014; Gao et al., 2010), supported by 
in vitro evidence demonstrating a loss of binding with the Y93H resistance mutation 
and a reduction in RNA binding by domain I (Ascher et al., 2014).  
Global effects on NS5A have also been observed with DCV, including 
relocalisation, altered fractionation patterns and reductions in hyperphosphorylation 
(Fridell et al., 2011; Lee et al., 2011; Qiu et al., 2011). Other studies have identified 
abrogation of the HCV induced membrane rearrangements independent of RNA 
replication and NS5A redistribution (Berger et al., 2014). Furthermore, treatment of 
cells established with HCV infection show no effect on pre-formed replication 
complexes but rapidly block virion assembly and release (McGivern et al., 2014).  
The effects of DCV treatment agree with the model of NS5A as a multifunctional 
protein with distinct populations in the cell involved in different stages of the HCV 
life cycle. These populations may be differentially accessible to DCV and explain 
the observed temporal difference in DCV inhibition. For example cytosolic exposed 
NS5A involved in virion assembly and membrane enclosed involved in replication. 
Although these observations have provided initial insight into the mode of action of 
this family of compounds, further investigations are required to fully elucidate their 
mechanism. 
1.3.8     NS5B – RNA-dependent RNA polymerase 
NS5B is the virally encoded RNA-dependent RNA polymerase (RdRp) of 62 kDa 
which is anchored into membranes by a C-terminal transmembrane domain (Lee et 
al., 2004). De novo priming by NS5B for negative strand synthesis occurs at the 
3’ UTR and requires two nucleotide binding sites within the enzyme to synthesise a 
dinucleotide primer (Ferrari et al., 2008). High concentrations of GTP have been 
shown to stimulate de novo initiation by binding to an allosteric site (Bressanelli et 
al., 2002). Structural studies have identified significant conformational changes in 
NS5B after binding GTP which open the catalytic pocket and allow double stranded 
RNA (dsRNA) binding (Mosley et al., 2012; Scrima et al., 2012). This appears to 
encourage transition from primer-dinucleotide formation to elongation and 
productive RNA synthesis (Ranjith-Kumar and Kao, 2006). This model is supported 
by the X-ray crystallography structure of NS5B from the highly replication 
competent HCV isolate JFH1 in which the polymerase finger and thumb domains 
are connected, producing a “closed” conformation which facilitates efficient de novo 
initiation (Simister et al., 2009). 
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1.4     HCV replication complex 
1.4.1     HCV membrane rearrangements 
A common phenotype of all positive strand RNA virus infections is the 
rearrangement of intracellular membranes in the cytoplasm, creating an 
environment suitable for replication (Figure 1.10) (Romero-Brey and 
Bartenschlager, 2014). These structures are commonly referred to as replication 
factories and serve several functions. 
First, they spatially separate the different steps of the virus lifecycle, namely RNA 
translation, replication and packaging into new virions. Second, the membranous 
compartments serve to sequester the viral non-structural proteins and required 
cellular proteins and metabolites, facilitating efficient RNA replication. Finally, they 
act to protect or shield the HCV components, for example double stranded RNA 
intermediates, from cellular immune surveillance and degradation, reviewed in 
(Romero-Brey and Bartenschlager, 2014). 
Electron microscopy studies have revealed that HCV infection results in the 
accumulation of membrane vesicles, mostly double membrane vesicles (DMV), 
embedded in a compact membrane network (Figure 1.10) (Egger et al., 2002; 
Ferraris et al., 2012, 2010; Romero-Brey et al., 2012). More recently, soft X-ray 
microscopy has supported EM studies and provided a detailed description of HCV 
induced membrane structures in whole intact cells (Pérez-Berná et al., 2016). The 
production of DMV increases during infection and correlates with the kinetics of 
HCV replication (Romero-Brey et al., 2012). Therefore, they are suggested to play 
an important role in viral RNA replication. Accordingly, purified DMV contain active 
polymerase and the presence of both NS5A and double stranded RNA (Ferraris et 
al., 2010; Paul et al., 2013). As infection progresses, larger and more complex 
structures of multi-membrane vesicles (MMV) are observed (Figure 1.10D), 
although whether MMV play a role during infection is not clear (Ferraris et al., 2012; 
Romero-Brey et al., 2012). Treatment of infected cells with the antiviral drug 
Silibinin inhibits HCV in a genotypic specific manner and is associated with an 
increased number of MMV (Esser-Nobis et al., 2013). 
 
 
 
 
  37 
 
Figure 1.10: Vesicle structures produced during HCV infection. 
Electron micrographs from high-pressure-frozen and freeze-substituted naïve and 
HCV infected cells depicting the membranous rearrangements induced by HCV. 
Yellow squares indicate the areas shown in higher magnification on the right of 
each subpanel. ER, endoplasmic reticulum; m, mitochondria; MWB, multi-vesicular 
bodies; LD, lipid droplet; DMV, double membrane vesicle; DMT; double membrane 
tubule (labelled with black arrow). Adapted from (Romero-Brey et al., 2012). 
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The average diameter of DMVs measured by electron microscopy is approximately 
200 nm, although structures vary from ~100–1000 nm (Ferraris et al., 2012; 
Romero-Brey et al., 2012). DMV are typically associated with the ER and around 
10% were observed with an opening or pore into the cytoplasm (Romero-Brey et 
al., 2012). Additionally, the accumulation of DMV were observed around 
cytoplasmic lipid droplets (Romero-Brey et al., 2012), an important cellular 
organelle for HCV which is associated with both core and NS5A (Miyanari et al., 
2007). 
1.4.2     Formation of double membrane vesicles 
The double membrane nature of HCV induced structures are morphologically 
similar to the cellular structures produced by autophagy. During times of nutrient 
starvation or stress, the engulfment of cytoplasmic contents from the expansion of 
ER membranes results in the production of double membrane vesicles, termed 
autophagosomes (Figure 1.11) (Tanida, 2011). Fusion of autophagosomes with 
lysosomes results in bulk degradation and recycling of the vesicle contents (Tanida, 
2011). This process is dynamic and involves multiple protein complex interactions 
in a sequential pathway.  
Initiation of autophagy starts with ER localisation of the ULK complex, composed of 
ULK1, ULK2, Atg13, FIP200 and Atg101 (Hosokawa et al., 2009; Jung et al., 2009). 
Subsequent recruitment of the class III phosphatidylinositol 3-kinase (PI3K) 
complex (Atg14-Vps34-Beclin1) (Wirth et al., 2013) produces a local pool of 
phosphatidylinositol 3-phosphate (PI3P). Increased local concentration of PI3P 
recruits PI3P effector proteins such as double FYVE-domain containing protein 1 
(DFCP1) and the WIPI family of proteins which form an ER derived structure 
termed the omegasome (Axe et al., 2008; Karanasios et al., 2013; Koyama-Honda 
et al., 2013; Polson et al., 2010). PI3P effector proteins in turn recruit the 
Atg12-Atg5-Atg16 complex and Atg3-LC3 conjugate (Dooley et al., 2014). 
Assembly of these complexes results in conjugation of LC3 onto 
phosphatidylethanolamine, converting LC3-I to LC3-II (Fujita et al., 2008). 
Progressive accumulation of LC3-II results in membrane engulfment of cytoplasmic 
contents and autophagosome formation (Mizushima, 2010). Finally, fusion of the 
autophagosome outer membrane with lysosomes forms the autolysosome and 
degradation of autophagosomal contents (Gutierrez et al., 2004; Jäger et al., 2004). 
The induction of autophagy is well documented during HCV infection and is 
proposed to provide the membrane structures for the formation of HCV replication 
factories (Chan and Egan, 2005; Ke and Chen, 2011; Mohl et al., 2012; Shinohara 
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et al., 2013). Accordingly, pharmacological inhibition and downregulation of 
autophagy proteins inhibit HCV replication (Dreux et al., 2009; Mizui et al., 2010; 
Mohl et al., 2016; Sir et al., 2008). Although autophagy is induced by HCV, the 
process is manipulated by direct interactions with viral proteins (Aweya et al., 2013; 
Guévin et al., 2010; Su et al., 2011) which alter the maturation of autophagosomes 
and prevent fusion with lysosomes (Sir et al., 2008).  
The morphological similarities between HCV DMV and autophagosomes indicate 
they may arise from a common biogenesis pathway. Recently, the autophagy 
elongation complex (Atg5-12-19L1) was shown to be critical for the formation of the 
membranous web, and the presence of Atg5-12 and Atg16L1 were identified in 
purified HCV membranes with the non-structural proteins (Fahmy and Labonté, 
2017). Interestingly, LC3 recruitment and the formation of LC3-II was not required, 
demonstrating a key subversion to the conventional cellular pathway (Fahmy and 
Labonté, 2017) 
1.4.3     HCV replication factory composition 
The formation of bona fide HCV replication factories requires additional 
modifications to the DMV scaffold such as modification of its lipid profile to expand 
the size, increase positive membrane curvature and recruit additional accessory 
factors (Paul and Bartenschlager, 2015). The local alteration of membrane 
environments, for example the production of PI3P during autophagosome 
formation, are critical modifications to biological membranes involved in recruitment 
of factors and cellular signalling (van Meer et al., 2008). 
The alteration of lipid metabolism during the HCV lifecycle is well documented and 
reported to account for the pathology associated with chronic infection (Popescu et 
al., 2014). High-throughput lipidomic profiling of HCV infected cells have revealed 
significant alterations to lipid compositions (Diamond et al., 2010). The 
phosphatidylinositol 4-kinase IIIα (PI4KIIIα) and its product phosphatidylinositol 
4-phosphate (PI4P) was shown in multiple studies to be important for functionality 
and integrity of HCV membrane structures (Berger et al., 2009; Borawski et al., 
2009; Q. Li et al., 2009; Reiss et al., 2011; Tai et al., 2009; Trotard et al., 2009). 
Colocalisation of PI4P with NS5A indicated activation of PI4KIIIα at sites of HCV 
replication and direct interactions between PI4KIIIα, NS5A and NS5B were 
observed in coimmunoprecipitation experiments (Reiss et al., 2011). PI4P addition 
to membranes is known to alter membrane curvature (Furse et al., 2012) and 
disruption of PI4KIIIα by pharmacological inhibition or knockdown of expression 
during HCV infection reduces DMV diameter (Reiss et al., 2011). 
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Addition of PI4P to membranes also functions to recruit lipid transfer proteins for the 
addition of other lipids such as cholesterol and sphingolipids (Holthuis and Menon, 
2014). The modification of DMV with a number of lipids is consistent with the 
reported association of replication complexes with intracellular detergent-resistant 
lipid-raft-like assemblies (Shi et al., 2003, p. 2–). HCV replication factories are 
~9-fold enriched in cholesterol over ER membranes and removal from DMV 
reduces their size and HCV genome stability (Paul et al., 2013). Additionally, 
oxidation of cholesterol by the cholesterol 25-hydroxylase abrogates HCV 
replication (Chen et al., 2014). The cholesterol transport protein oxysterol-binding 
protein (OSBP) and glycosphingolipid transporter four-phosphate adaptor protein 2 
are both required for HCV replication (I. Khan et al., 2014; Wang et al., 2014). This 
is mediated by the adaptor proteins VAP-A and VAP-B which are also required for 
HCV replication and interact directly with NS5A and OSBP (Hamamoto et al., 2005; 
Tu et al., 1999). Although the precise details of sphingolipids in HCV replication are 
unknown, their upregulation in infected cells stimulates NS5B activity (Hirata et al., 
2012; Weng et al., 2010).  
Other than lipid composition, the introduction of amphipathic α-helices and 
oligomerisation of integral membrane proteins asymmetrically into membranes can 
alter local membrane curvature (Kozlov et al., 2014; McMahon and Gallop, 2005). 
The recruitment of proline-serine-threonine phosphatase interacting protein 2 by 
NS4B and NS5A is crucial for replication (Chao et al., 2012). Dimerization of this 
protein yields a concave-shaped structure which induces positive membrane 
curvature and is involved in endocytosis and intracellular trafficking (Qualmann et 
al., 2011; Rao and Haucke, 2011). 
However, the major components of HCV replication factories are the non-structural 
proteins which are all membrane associated (Moradpour et al., 2003). The 
expression of NS3–5B alone is sufficient to induce DMV structure indistinguishable 
from those produced during infection (Romero-Brey et al., 2012). NS4B was 
proposed as the major determinant for induced DMV formation (Egger et al., 2002), 
although recent evidence suggest that NS5A alone produces DMV (Romero-Brey et 
al., 2012). The insertion of amphipathic helices into the membrane from both NS4B 
and NS5A likely contribute to membrane curvature (Palomares-Jerez et al., 2012, 
2013, 2010). Expression of NS3/4A or NS5B alone resulted in altered vesicle 
architectures, suggesting a less critical role in DMV formation (Romero-Brey et al., 
2012). 
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The membrane structure and architecture of HCV induced DMV are well 
characterised, however a detailed understanding of the associated protein 
organisation is lacking. Using light microscopy, antibody labelling for NS3 and 
NS5A result in diffraction limited dot-like structures in the cytoplasm (El-Hage and 
Luo, 2003; Gosert et al., 2003; Mottola et al., 2002; Shi et al., 2003). Although 
immunolabelling and NS5B polymerase activity confirmed the presence of active 
replication complexes within nuclease and protease protected DMV, the low 
labelling efficiency of immunogold labelling precluded a detailed description of 
protein organisation (Ferraris et al., 2010; Paul et al., 2013; Romero-Brey et al., 
2012). 
 
 
 
 
 
Figure 1.11: Diagram of autophagosome biogenesis. 
1: ULK1 and PI3K complexes recruited to curved mitochondrial-associated ER 
membranes (MAM). 2: DFCP1 and WIPI2b recruitment to PI3P-rich membrane. 
3: Recruitment of Atg5-Atg12-Atg16L1 complex and Atg3-LC3-I. 4: Lipidation of 
LC3-I onto phosphatidyethanolamine producing LC3-II. 5: Phagophore membrane 
expansion from Atg9 containing vesicles. 6: Engulfment of cytoplasmic contents 
and autophagosome closure. 7: Fusion of autophagosomes with lysosomes for 
degradation. 
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1.5     Light microscopy 
1.5.1     History of light microscopy 
A great deal of knowledge about biological processes derives from the ability to 
observe them at the cellular and sub-cellular level. Microscopes use a lens system 
to provide magnified images of objects which are too small to see with the naked 
eye. The first description of microscopes in the study of biological structures dates 
to the 17th century with Antonie Van Leeuwenhoek and Robert Hooke (Hooke, 
1667; Leewenhoeck, 1677). Using simple illumination techniques, Robert Hooke 
coined the word cell after observing plant cell walls in cork (Hooke, 1667). Although 
detailed illustrations of animals such as the flea and gnat were recorded by Hooke, 
the contrast from these bright-field images is low and comes from absorbance of 
the transmitted light with dense regions of the sample. To improve the contrast of 
bright-field microscopy a number of techniques were developed such as phase 
contrast and dark field (Murphy, 2002). However, these techniques are limited in 
their applications as no specific labelling of cellular structures is achieved. 
The application of fluorescence probes conjugated to a designated target 
revolutionised light microscopy and allowed the direct visualisation of cellular 
processes within cells (Giepmans et al., 2006). The number of techniques for 
labelling targets of interest have developed over the years and the analysis of 
protein trafficking within live cells are routine laboratory experiments (Giepmans et 
al., 2006). Using different strategies such as antibody labelling and genetic tag 
incorporation, targets of interest can be specifically visualised using fluorescent 
dyes, quantum dots and fluorescent proteins (Giepmans et al., 2006). 
1.5.2     Diffraction in light microscopy 
Although microscopy techniques have increased the understanding of a number of 
biological processes, image magnification does not translate to an increase in the 
resolution of small details. An ideal lens focuses light rays from each point on the 
object to the image plane. However, the properties of light as a wave mean it is 
subject to diffraction, caused by interaction of the wave with an obstacle or slit 
(Born and Wolf, 2000). Diffraction prevents perfect convergence of light rays from 
the sample at the image plane and causes the image of point objects to blur into a 
finite-sized spot (Born and Wolf, 2000). In a microscope system, light from a point 
object travels through a lens with a circular aperture, producing the Airy pattern in 
the image (Airy, 1835). For a point object, this three dimensional intensity 
distribution is called the point spread function (PSF).  
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The size of the PSF determines the resolution, level of detail, that can be obtained 
from an image and is related to the wavelength of light and the numerical aperture 
(NA) of the objective (Abbe, 1873). Commonly referred to as the Abbe diffraction 
limit, this is defined as:  
 
𝛥𝑥𝑦  ≈  
0.61𝜆
𝑁𝐴
 
Equation 1: Abbe diffraction limit 
where λ is the wavelength of light, and NA is the numerical aperture of the 
objective; defined as NA = n•sinα with n the refractive index of the medium and α 
the half-opening angle of the objective. The axial width of the PSF is around 2–3 
times larger than the lateral width. 
Resolution is defined as the smallest separation distance between the diffraction 
images of two point sources in which they can still be distinguished from each 
other. Using the Rayleigh criterion, this minimum distance is equal to the principal 
diffraction maximum of one PSF coinciding with the minimum of the other 
(Rayleigh, 1896). For light microscopy with visible light (λ ≈ 550 nm) and a high oil 
immersion objective with an NA = 1.4, the PSF is ~240 nm in the lateral dimension 
and ~500 nm axially. This diffraction limit is significantly larger than many 
subcellular structures which are on the order of tens of nanometers, and thus 
precludes a detailed investigation of their arrangement. 
Resolution is directly related to the wavelength of the illumination source, therefore 
a shorter wavelength can achieve a higher resolution. Electron and X-ray 
microscopy use illumination sources with wavelengths much shorter than light and 
therefore provide much higher resolutions (Milne et al., 2013; Sakdinawat and 
Attwood, 2010). 
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1.5.3     Extending the optical image resolution 
Other than using a different illumination source a number of imaging methods have 
been developed to extend the resolution of optical microscopy. Combining a 
focused laser beam and a pinhole in confocal microscopy can in principle achieve a 
√2 improvement in image resolution (Pawley, 2012). Contraction of the pinhole to 
much smaller than the image of a point emitter directly minimises the size of the 
scanned focal point (Pawley, 2012). However, this reduces the quantity of light 
detected and the resolution improvement afforded is often outweighed by the low 
signal to noise ratio (Pawley, 2012).  
An alternative technique takes advantage of two-photon absorption to reduce the 
effective size of the excitation PSF (Zipfel et al., 2003). However, this decrease in 
PSF size is counteracted by the increased wavelength of light required for 
excitation (Zipfel et al., 2003). The advantages of both techniques over wide-field 
illumination are the reduction of out-of-focus fluorescence, therefore a greater 
sectioning and axial resolution is achieved.  
Structured illumination microscopy (SIM) increases the spatial resolution of light 
microscopy by using a patterned illumination field (Figure 1.12) (Gustafsson, 2000; 
Gustafsson et al., 2008). Combining the spatial frequency components from the 
illumination pattern and the sample from multiple orientations, higher frequency 
information can be collected resulting in ~100 nm lateral and ~300 nm axial image 
resolution (Gustafsson, 2000). Other techniques using constructive interference of 
light fields include 4Pi and I5M microscopy (Gustafsson et al., 1999; Hell and 
Stelzer, 1992). 
A separate SIM approach was described more recently and takes advantage of a 
multifocal excitation pattern that is scanned across the image with contracted 
pinholes either computationally or using optical hardware (York et al., 2013, 2012). 
In this set-up, each pixel of the detector is considered a tightly closed confocal 
pinhole with a degree of transverse misalignment (York et al., 2012). This 
misalignment shifts the image and decreases signal but does not change the shape 
of the measured feature or degrade the transverse resolution (Sheppard, 1988). 
Processing by correcting the image displacement and summing the images 
produces the √2 improvement in resolution of a tightly closed pinhole without the 
loss of signal (York et al., 2012). A major advantage of the multifocal approaches 
over original SIM methods are the rapid image acquisition rates (~100 frames per 
second) which facilitate live cell imaging with ~100 nm resolution (York et al., 2013). 
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Figure 1.12: Diagram illustrating structured illumination microscopy. 
The sample is illuminated with multiple stripe-shaped sinusoidal interference 
patterns derived from laser light passing through optical grating. This nonuniform 
wide-field illumination combines with sample information below the diffraction limit 
producing moiré fringes. This places high spatial frequency information into the 
lower spatial frequency band of the microscope. Mathematical reconstruction 
produces an image with ~2-fold improvement in resolution. Adapted from 
(Schermelleh et al., 2010). 
 
Despite these approaches extending the image resolution, the best achievable 
resolution improvement equates to ~100 nm in all three dimensions, as 
demonstrated for I5S microscopy (Shao et al., 2008). This stems from each of 
these methods remaining fundamentally limited by the diffraction of light. 
1.5.4     Breaking the diffraction limit 
Recently a number of techniques have been described which break the diffraction 
barrier by exploiting photophysics and photochemistry; they are collectively termed 
super-resolution microscopy (Huang et al., 2010).  
Stimulated emission depletion microscopy (STED) was first demonstrated in 1999 
and uses a second laser, with an intensity of zero at its centre, to suppress 
fluorescence around the centre of excitation (Figure 1.13) (Klar et al., 2000). This 
suppression is achieved through stimulated emission, where photons of the same 
energy as an excited fluorophore cause it to be brought back to the ground state. 
The result is a smaller effective PSF controlled by the size of the zero intensity in 
the STED laser (Klar et al., 2000). Super-resolution imaging is conducted by 
scanning this effective PSF over the sample, and has achieved resolutions in the 
x-y plane of ~30 nm (Harke et al., 2008). By performing STED in a 4Pi geometry, 
axial resolution of ~50 nm has also been reported (Dyba et al., 2003). The depletion 
of fluorescence can also be accomplished by using fluorophores which switch 
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between fluorescent on and off states, termed RESOLFT (reversible saturable 
optical linear fluorescence transitions), which has the advantage of a much lower 
depletion laser power (A. Schwentker et al., 2007).  
Additional developments in SIM (described in Section 1.5.3) can further increase 
the resolution by exploiting the non-linear dependence of the fluorescence emission 
rate on the illumination intensity (Gustafsson, 2005). In saturated SIM, the sample 
is illuminated with a sinusoidal excitation pattern of high intensity which produces 
an emission pattern that contains higher spatial frequency information than the 
illumination pattern (Gustafsson, 2005). Super-resolution images are then 
reconstructed analogous to SIM and have achieved a 2 dimensional resolution of 
~50 nm (Gustafsson, 2005) 
 
 
 
 
Figure 1.13: Diagram illustrating stimulated emission depletion microscopy. 
The sample is scanned with two overlapping laser beams. Depletion of 
fluorescence excited with the first laser by a doughnut-shaped laser drives excited 
fluorophores back to the ground state by stimulated emission. The volume through 
which emitted light is detected is smaller than the diffraction limit, producing a 
smaller effective PSF. Adapted from (Schermelleh et al., 2010). 
. 
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1.5.4.1     Localisation microscopy 
1.5.4.1.1     Principle 
An alternative super-resolution approach involves determining the precise 
localisation of individual fluorescent events for each probe position on a labelled 
sample (Huang et al., 2010). These techniques were independently developed by 
three labs as STORM (stochastic optical reconstruction microscopy) (Rust et al., 
2006), PALM (photoactivated localisation microscopy) (Betzig et al., 2006), and 
FPALM (fluorescence photoactivation localisation microscopy) (Hess et al., 2006), 
which are collectively called single molecule localisation microscopy (SMLM). 
STORM was described with dual fluorophore labelled targets in an 
activator-reporter combination whereas PALM and FPALM utilised photoactivated 
fluorescent proteins (FP). 
Each of these methods rely on determining the origin of the PSF from a single 
fluorescent event, the precision of which is significantly higher than the diffraction 
limit (Thompson et al., 2002). Determining the true position of the fluorophore 
depends on the size of the PSF and the number of photons emitted and is called 
the localisation precision (Thompson et al., 2002). This can be approximated by: 
 
𝛥𝑙𝑜𝑐 ≈
𝛥
√𝑁
 
Equation 2: Localisation precision 
where Δloc is the localisation precision, Δ the size of the PSF and N the number of 
photons. 
The localisation precision directly scales with the photon number and with bright 
fluorescent particles precisions as high as ~1 Å have been achieved 
(Abbondanzieri et al., 2005). However, localisation becomes inaccurate when 
multiple molecules are within close proximity as the fluorophore images overlap 
(Thompson et al., 2002).  
Biological samples typically contain thousands of fluorophores at high density; 
therefore significant overlap prevents accurate localisation of fluorophore positions. 
In order to visualise individual fluorophores their activation to a fluorescent state is 
separated in time to allow a subset of spatially distinct fluorophores to be localised 
(Betzig et al., 2006; Hess et al., 2006; Rust et al., 2006) (Figure 1.14). Cycles of 
different fluorophore activation, localisation and deactivation to a dark state allow 
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precise localisation of multiple fluorophores within a diffraction limited volume. 
Conducted over a wide-field imaging system the coordinates of all localised 
fluorophores can then be plotted to reconstruct a super-resolution image. 
For each of the original methods, target molecules were imaged using 
photoswitchable fluorescent dyes or proteins which are activated with a spectrally 
distinct wavelength from the imaging light that excites fluorescence and deactivates 
fluorophores (Betzig et al., 2006; Hess et al., 2006; Rust et al., 2006). Variations of 
these techniques have subsequently been reported such as spectral precision 
distance microscopy (Lemmer et al., 2009), ground state depletion and single 
molecule return (Fölling et al., 2008) and direct STORM (dSTORM) (Heilemann et 
al., 2008). dSTORM uses reducing buffer conditions to induce the reversible 
photoswitching of fluorescent dyes to a long-lived dark state (triplet state), thereby 
allowing some conventional fluorescent dyes to be used. 
1.5.4.1.2     Multi-colour and three dimensional super-resolution imaging 
First described in two dimensions, a number of challenges had to be overcome for 
three dimensional imaging to distinguish separate channels. Fluorophores could be 
identified based on the emission colour, however, this requires either spectral 
demixing of the emission channels (Lampe et al., 2012), post-acquisition correction 
of chromatic aberrations (Erdelyi et al., 2013), or splitting the channels and using 
geometrically fixed filter sets (Zhao et al., 2015). Chromatic aberrations arise from 
imperfections in the optical imaging setup which leads to asymmetries and 
coordinate-dependent variations in the optical transfer function of the microscope 
(Stallinga and Rieger, 2010). These distortions are dependent on the wavelength 
and can result in offsets of 50–150 nm between different channels (Bock et al., 
2007; van de Linde et al., 2009). This impedes analysis of colocalisation in SMLM 
studies which routinely achieve localisation precisions of ~20 nm. 
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Figure 1.14: Diagram illustrating localisation microscopy image collection. 
Activation of spatially distinct fluorophores with wide-field illumination allows 
observation of single molecule fluorescent events. Mathematical fitting of single 
emitters allows precise determination of the fluorescent event origin. Cycles of 
activation, fitting and deactivation allow reconstruction of super-resolution images 
from the coordinates of multiple single molecule emitters. Adapted from 
(Schermelleh et al., 2010). 
 
Despite these limitations, multi-colour methodologies have been implemented, 
facilitating the analysis of protein-protein interactions at 10-fold improvements in 
image resolution compared to wide-field (Bates et al., 2007; Lampe et al., 2012). In 
the STORM methodologies, altering the activator fluorophore allows differentially 
labelled samples to be distinguished from the activation wavelength (Bates et al., 
2007). Three colour imaging of DNA, mitochondria and microtubules have all been 
demonstrated by this approach (Bates et al., 2007; Huang et al., 2008b).  
For PALM and FPALM, the implementation of two colour imaging was initially 
complicated by the overlap of red-emitting FP preactivation emission wavelengths 
with postactivation fluorescence of green-emitting FP, for example the green 
fluorescence of mEos derivatives before activation to red fluorescence (McKinney 
et al., 2009; Zhang et al., 2012). This has been overcome by the developments of 
FP with shifted emission profiles such as bsDronpa (Andresen et al., 2008), or FP 
which are activated from a dark state such as photoactivated-mCherry (Subach et 
al., 2009). However, the poor photon yield from these short-wavelength FP 
compromises localisation precision and therefore image resolution. 
Additional, developments have extended methodologies to resolve cellular 
structures in sub-diffraction-limited resolution in all three dimensions (Huang et al., 
2008b). First implemented by inserting a cylindrical lens into the light path which 
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distorts the PSF of single emitters to an elliptical shape in x and y dependent on the 
axial position (Figure 1.15) (Huang et al., 2008b). The centroid of the PSF provides 
the lateral positions and the ellipticity the axial position. Localisation precisions of 
~20 nm and ~50 nm have been reported for the lateral and axial position, 
respectively (Huang et al., 2008b).  
A separate implementation of 3 dimensional super-resolution imaging used 
two-focal-plane imaging (Juette et al., 2008). This method achieved an axial 
resolution of ~75 nm by splitting the emitted light onto two regions of the camera 
with different path lengths. This allowed simultaneous detection of fluorescence 
from two different focal planes (Juette et al., 2008). The defocused shape of 
individual images were fitted to a 3D PSF derived from a fluorescent bead to 
determine the x, y and z coordinate positions over several microns (Juette et al., 
2008). 
1.5.4.1.3     Resolution in SMLM 
Resolution in wide-field microscopy is defined by the size of the PSF (Equation 1), 
whereas the resolution in SMLM is limited by a number of factors including 
localisation precision (Equation 2), labelling density and fluorescent probe size.  
The precision of determining the position of a localised molecule describes the 
uncertainty around the fluorophore origin, and is therefore a principal measure of 
resolution (Hendrik Deschout et al., 2014). This defines the physical limit of the 
smallest structure it can resolve. Accordingly the localisation precision should be 
smaller than the desired resolution. A robust approach for measuring the 
localisation precision is from the standard deviation of localisations from the same 
emitter from multiple imaging frames (Hendrik Deschout et al., 2014). 
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Figure 1.15: Determination of axial coordinates in 3D-STORM using astigmatism. 
A: Simplified optical diagram illustrating z coordinate determination of fluorescent 
object from ellipticity of image by cylindrical lens in imaging path. B: calibration 
curve of the image widths in Wx and Wy as a function of z. Data were fit to a 
defocusing curve (red). C: Three dimensional localisation distributions of single 
molecules. Histogram distributions were fit to a Gaussian function with standard 
deviation of 9 nm in x, 11 nm in y, and 22 nm in z. Reproduced from (Huang et al., 
2008b). 
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The labelling density of biological samples is an additional consideration when 
considering image resolution. Because SMLM images are constructed from 
thousands of fluorophore coordinates, insufficient labelling produces artefacts such 
as the observation of gaps in continuous structures. Labelling density can be 
quantified by the Nyquist criterion which states that the distance between two 
neighbouring emitters must be smaller than half of the sample feature that can be 
resolved (Shannon, 1949). Thus the smallest resolvable feature follows: 
 
𝛥𝑁𝑦𝑞𝑢𝑖𝑠𝑡 =
2
𝑁1 𝐷⁄
 
Equation 3: Nyquist criterion 
where N is the density of labelling and D is the dimension of the structure to be 
imaged. 
From this formula, to achieve 20 nm resolution in 2D, a labelling density of 104 
randomly distributed localisations per µm2 are required. However, in practice lower 
labelling densities are sufficient as heterogeneous biological structures often 
occupy smaller regions than the total observed space. Therefore, regions of high 
local density can resolve structures despite low overall density. 
The last consideration for image resolution is the displacement of detected 
fluorescent probes from the target. The conventional labelling methodology of 
antibodies can displace the fluorophore by around 10–15 nm (Huang et al., 2008a). 
In comparison, Fab fragments and FPs position fluorophores ~6 nm and ~4 nm 
away respectively. Therefore the choice of target detection is a compromise, 
between genetically encoded but less than ideal photophysical FPs, and 
displacement of bright and well localised fluorescent dyes on antibodies. 
Approaches to combine the benefits of both involve coupling organic dyes directly 
onto proteins with genetic tags, for example the tetracysteine tag (Griffin et al., 
1998) or enzymatic reactions (Chen et al., 2005; Fernández-Suárez et al., 2007; 
Popp et al., 2007). 
Measuring image resolution therefore depends on both localisation precision and 
labelling density. However, it was shown recently that the Nyquist criterion can 
overestimate the increase of resolution with label density (Fitzgerald et al., 2012). In 
continuing efforts to define the image resolution in SMLM imaging, methods to 
directly measure the resolution from reconstructed images have been explored 
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using Fourier ring correlation (FRC) (Banterle et al., 2013; Nieuwenhuizen et al., 
2013), which is commonly used to assess the resolution in single-particle 
reconstructions in cryoelectron microscopy (Saxton and Baumeister, 1982; Unser et 
al., 1987). This was demonstrated for both line-like (microtubules) and ring-like 
(nuclear pore) structures (Banterle et al., 2013; Nieuwenhuizen et al., 2013). 
However, simulated datasets reconstructed with the same localisation precision and 
label density but different spatial frequencies, identified that the FRC curve decays 
quicker as the image contains structures with lower spatial frequencies (Legant et 
al., 2016). Therefore the application of FRC should be interpreted with caution 
when comparing between samples with different labels or structures.  
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1.6     Aims and objectives 
There remain a number of questions regarding the architecture of the HCV 
replication complex, in particular the organisation of the non-structural proteins and 
how DMV are formed. The NS5A protein is critical during the virus lifecycle with a 
number of known functions, one of which is the hypothesised link between HCV 
replication and assembly. This study aimed to address the current lack of 
knowledge in these areas. 
In chapter 3, advances in light microscopy were used to observe the protein 
organisation of non-structural proteins below the diffraction limit. In particular, the 
study was aimed at determining the organisation of non-structural proteins 
associated with DMV. In parallel, the localisation of NS5A in cells was investigated 
when targeted using direct acting antivirals, or by mutation of key phosphorylation 
residues. 
In chapter 4, the interactions of HCV replication complexes with the 
autophagosome biogenesis machinery were investigated. A cellular protein 
involved in the early stages of omegasome formation was targeted, and interactions 
with the HCV replication complex analysed. 
Lastly, in chapter 5, a number of fluorescence labelling strategies were explored to 
visualise HCV replication complex components for super-resolution imaging. These 
included the insertion of genetic tags into non-structural proteins, identifying 
non-antibody binding proteins to the HCV polymerase, and incorporating a 
nucleotide analogue into actively replicating HCV RNA. 
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Chapter 3 - Materials and Methods 
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3.1     General materials 
3.1.1     Bacterial strains 
Escherichia coli (E. coli) DH5α: Genotype; F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rk-, mk-) phoA supE44 λ- thi-1 gyrA96 relA1 used for cloning 
were purchased from Life Technologies. 
E. coli BL21 (DE3): Genotype; F- ompT hsdSB(rB
- mB
-) gal dcm λ(DE3 [lacI 
lacUV5-t7 gene 1 ind1 sam7 nin5]) used for protein expression were purchased 
from Life Technologies. 
Chemically competent bacteria were produced using the Z-competent kit (Zymo 
Research). 
3.1.2     Mammalian cell lines 
HuH7 cells are a human hepatoma carcinoma cell line (Nakabayashi et al., 1982) 
capable of supporting replication of HCV sub-genomic replicons (Lohmann et al., 
1999). HuH7.5 cells are a sub-population of cells derived by clearing SGRs from 
HuH7 cells, using IFN, which support greater levels of HCV infection (Blight et al., 
2002). This cell line was a kind gift from Charles Rice, The Rockefeller University, 
New York. 
A polyclonal population of cells stably expressing SGR-Feo-JFH1 (Genotype 2a; 
(Wyles et al., 2009)) or SGR-Feo-Con1 (Genotype1b; (Lohmann et al., 1999)) were 
produced in HuH7.5 cells by Yutaka Amako at the University of Leeds. 
Stable cell lines expressing SGR-Neo-JFH1 with or without NS5A phosphorylation 
mutations were produced in HuH7 cells as a polyclonal population by Niluka 
Goonawardane at the University of Leeds. 
SGR-Feo-S52 (Genotype 3a AII variant; (Saeed et al., 2012)) stably expressing 
cells were produced in HuH7.5 cells as a polyclonal population by Lorna Kelly at the 
University of Leeds. 
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3.1.3     Antibodies – Primary 
Target Species Source Comments Concentration 
αNS5A 
Sheep 
(Macdonald et 
al., 2003) 
Polyclonal serum 
WB: 1:4,000  
IF: 1:2,000 
Mouse 
(Lindenbach et 
al., 2005) 
Monoclonal 
(9E10) 
0.2 μg/ml 
αNS3 Mouse 
Thomas 
Pietschmann 
Monoclonal (HZT) 2 μg/ml 
αNS5B Sheep In house Polyclonal serum 1:500 
αCore Mouse 
ThermoFisher 
Scientific 
Monoclonal (C7-
50) 
2 μg/ml 
αE2 Mouse 
(Owsianka et 
al., 2005) (via 
Genentech) 
Monoclonal 
(AP33) 
5.6 μg/ml 
αGAPDH Mouse 
Abcam 
(ab8245) 
Monoclonal (6C5) 0.2 μg/ml 
αHis6 Mouse Sigma 
Monoclonal, 
ascites fluid (HIS-
1) 
1:1,000 
αLC3B Rabbit 
Abcam 
(ab51520) 
Polyclonal 1 μg/ml 
αHistone 
H3 
Rabbit 
Cell Signalling 
Technology 
(#4499) 
Monoclonal 20 ng/ml 
αFibrillarin Rabbit 
Cell Signalling 
Technology 
(#2639) 
Monoclonal 
(C13C3) 
30 ng/ml 
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3.1.4     Secondary antibodies and fluorescent reagents 
Species/Name Target Source Comments Concentration 
Donkey αSheep 
Life 
Technologies 
Fluorescence 
various 
2 μg/ml 
Chicken αMouse 
Life 
Technologies 
Fluorescence 
various 
2 μg/ml 
Chicken αRabbit 
Life 
Technologies 
Fluorescence 
various 
2 μg/ml 
Goat αMouse LI-COR 
Fluorescence 
700 nm 
0.1 μg/ml 
Donkey 
αGoat/She
ep 
LI-COR 
Fluorescence 
800 nm 
0.1 μg/ml 
LipidTOX™ 
Lipid 
droplets 
ThermoFisher 
Scientific 
Fluorescence 
647 nm 
1:1,000 
Alexa Fluor® 
488 azide 
5-ethynyl 
uridine 
Thermofisher 
Scientific 
Fluorescence 
488 nm 
5 μM 
 
3.1.5     SGR and virus constructs 
HCV sequences were obtained from the EU HCV database with the Genbank 
accession numbers AB047639 (JFH1), AJ238799 (Con1) and GU814264 (S52). 
DNA constructs pJFH1 (Wakita et al., 2005) and pSGR-Feo-JFH1 (Wyles et al., 
2009) were used as reported. A sub-clone of JFH1 (mSUB: Mair Hughes Leeds 
Thesis) using the NsiI/HindIII fragment was generated in pLitmus28i (NEB). 
3.1.6     Expression constructs 
pNS5B ΔC21 from JFH1 (Simister et al., 2009) was a kind gift from Volker 
Lohmann, University Heidelberg. pCMV NS3–5B was provided by Dan Jones at the 
University of Glasgow (D. M. Jones et al., 2007). 
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3.2     General Methods 
3.2.1     Nucleic acid manipulation 
3.2.1.1     Transformation of Z-competent bacteria 
Plasmid DNA was incubated with Z-competent DH5α cells at a volume ratio of 1:10 
on ice for 5 min before incubation at 37 C in lysogeny broth (10 g/L tryptone, 
10 g/L NaCl, 5 g/L yeast extract [LB]) for 60 min. After incubation transformed cells 
were pelleted at 3,000 x g for 5 min. Pelleted cells were re-suspended in LB, plated 
onto agar containing appropriate antibiotic and incubated until colony formation. 
Ampicillin and kanamycin were used at 100 μg/ml and 50 μg/ml respectively. 
Transformed bacteria were grown at 37 C, or 30 C if plasmid DNA contained the 
NS5A protein sequence. 
3.2.1.2     Preparation of plasmid DNA from bacterial cultures 
Single colonies from 3.2.1.1 were picked and grown for 16 h in LB in a rotary 
shaking incubator at 200 rpm in the presence of antibiotic before centrifugation at 
4,000 x g  for 15 min at 4 C. Plasmid DNA was purified by alkaline lysis using 
GeneJET Plasmid Miniprep/Midiprep kit (Thermo Scientific) using the 
manufacturers protocol. For long term storage of plasmids, glycerol stocks of 
bacterial cultures were prepared from 1 ml cultures re-suspended in 30% (v/v) 
glycerol : 70% (v/v) LB and frozen at -80 C. 
3.2.1.3     Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify sequences for cloning. 
Oligonucleotide primers (Appendix 1) purchased from Integrated DNA Technologies 
were re-suspended in de-ionised water (dH2O) to a final concentration of 100 μM 
and stored at -20 C. 50 μl PCR reactions used Vent DNA polymerase (New 
England Biolabs: NEB) with 50 ng plasmid DNA, 0.1 μM forward and reverse 
primers and 0.2 μM of each deoxynucleotide triphosphate (dNTP). In the event of a 
poor PCR yield the addition of 3% (v/v) dimethyl sulfoxide (DMSO) was included in 
subsequent reactions to disrupt DNA secondary structures and facilitate annealing 
of primers (Jensen et al., 2010). PCR reactions were incubated for an initial 
denaturation step of 95 C for 5 min before 30 cycles of 30 sec denaturation, 60 sec 
annealing and 60 sec/kilobase (kb) extension at 72 C. Annealing temperatures 
were determined for each primer set based on the calculated Tm (Appendix 1). A 
final extension of 72 C for 5 min was undertaken before reactions were stored at 
4 C. 
  63 
3.2.1.4     Site-directed mutagenesis 
Complementary site-directed mutagenesis primers were designed with the mutant 
sequence encoded within the centre of primer sequences (Appendix 1). 50 μl PCR 
reactions used PfuUltra II Fusion HS DNA polymerase (Agilent Technologies) and 
contained 0.2 μM forward and reverse primers, 0.2 μM each dNTP, 3% (v/v) DMSO 
and 1% (v/v) glycerol. Reactions were incubated at 95 C for 5 min before 5 cycles 
of 30 sec at 95 C, 60 sec at 55 C and 2 min/kb at 68 C. A second round of PCR 
was conducted using 30 cycles of 30 sec at 95 C, 60 sec at primer pair annealing 
temperature and 5 min plus 2 min/kb at 68 C. A final 5 min extension at 68 C was 
carried out before storage at 4 C. Input PCR template was then degraded with 1 μl 
DpnI (NEB) for 60 min at 37 C prior to transformation of Z-competent bacteria with 
10 μl PCR reaction as described (Section 3.2.1.1). 
3.2.1.5     Restriction digestion 
Restriction digestion enzymes were supplied by NEB. Reactions were carried out in 
20 μl with the recommended buffers at the suggested temperature. Reactions were 
incubated for a minimum of 1 hour with at least 1 Unit of enzyme per μg of DNA. 
3.2.1.6     Agarose gel electrophoresis 
DNA gels of 1% (w/v) agarose in TAE buffer (40 mM Tris-HCl, 0.11% (v/v) acetic 
acid, 1 mM ethylenediaminetetraacetic acid [EDTA]) with 1:10,000 SYBR Safe 
DNA Gel Stain (Invitrogen) were used to separate DNA fragments. DNA samples 
were loaded onto agarose gels in DNA loading buffer (1% (w/v) sucrose, 
0.0125% (w/v) bromophenol blue in ddH2O) and run in TAE buffer at 8 V/cm. DNA 
fragments were compared to Hyperladder I markers (Bioline). 
3.2.1.7     DNA fragment extraction from agarose gels 
DNA fragment bands were imaged under blue light illumination with an orange filter 
and those of interest excised. Gel pieces containing DNA were purified using 
QIAquick Gel Extraction kit (QIAGEN). 
3.2.1.8     DNA/RNA quantification 
DNA and RNA was quantified using the absorbance at 260 nm on a NanoDrop 
1000 by the following equation, using the relationship that A260 of 1.0 = 50 μg.ml
-1 
pure dsDNA: 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝜇𝑔. 𝑚𝑙−1 = (𝐴260 − 𝐴320) ×  50 𝜇𝑔. 𝑚𝑙
−1 
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The purity of DNA and RNA from contaminating protein was determined by the 
260/280 nm absorbance ratio. 
3.2.1.9     Ligation 
DNA fragments were mixed in a vector : insert ratio of 1 : 3 for “sticky” end cloning, 
and 1 : 10 for “blunt”, on ice for 10 min. Reactions were made up to 20 μl and DNA 
fragments ligated using 10,000 Units of T4 DNA ligase (NEB) in a room 
temperature (RT) water bath cooled to 4 °C overnight in a cold room. 5 μl of the 
resultant reaction was transformed into Z-competent DH5α as described previously. 
3.2.1.10     Construct verification 
For single restriction site cloning, colonies were screened using colony PCR to 
determine insert orientation. Colonies were picked and re-suspended in ddH2O with 
0.2 μM forward and reverse primers and 0.2 μM dNTPs. PCR reactions were run 
for 30 cycles with 30 sec denaturation at 95 C, 60 sec annealing at 55 C and 
60 sec/kb at 72 C with an initial denaturation of 95 C for 5 min and a final 
extension of 72 C for 5 min using Vent® DNA polymerase. The resultant PCR 
products were analysed by agarose gel electrophoresis as described (Section 
3.2.1.6). Bacteria re-suspended in ddH2O from colony PCR, or picked from 
colonies, were inoculated into LB containing antibiotic and grown at the appropriate 
temperature for 16 h at 200 rpm. Plasmid DNA was prepared (Section 3.2.1.2) for 
each construct and sequenced to confirm correct sequence identity at Beckman 
Coulter Genomics. 
3.2.1.11     Preparation of linear DNA 
For the generation of virus and SGR RNA, 10 μg of plasmid DNA was linearised 
with XbaI at 37 °C overnight. Denaturation of XbaI at 65 °C for 20 min was 
conducted before degradation of 5’ overhangs using Mung Bean Nuclease (NEB) 
for 45 min at 30 °C and purification using phenol/chloroform extraction and ethanol 
precipitation. Linear DNA was mixed in an equal volume of phenol : chloroform : 
isoamylalcohol (25 : 24 : 1 [pH8.0]), vortexed for 10 sec and centrifuged at 
17,000 x g for 5 min. The upper aqueous phase was extracted, mixed in a 1 : 1 ratio 
with chloroform, vortexed for 10 sec and centrifuged at 17,000 x g for 5 min.  The 
second upper aqueous phase was extracted and the purified DNA precipitated in 3 
sample volumes of 100% (v/v) ethanol with 75 mM sodium acetate at -20 C for at 
least 1 hour. DNA was pelleted at 20,000 x g for 30 min, washed in 70% (v/v) 
ethanol and centrifuged at 20,000 x g for 5 min. The resultant DNA pellet was air 
dried before re-suspension in ddH2O. 
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3.2.1.12     In vitro transcription of RNA 
All solutions used for RNA preparation were firstly treated to remove RNases by 
incubation with 1:1000 diethylpyrocarbonate (DEPC) at 37 C for 16 h. Excess 
DEPC was subsequently removed by autoclaving. RNA was generated using the 
T7 RiboMAX™ Large Scale RNA Production System (Promega) using 1 μg of linear 
DNA generated from Section 3.2.1.11 as a template. Reactions were incubated at 
37 °C for 60 min before degradation of template DNA using 1 Unit of DNase for 
15 min at 37 °C. In vitro transcribed RNA was subsequently purified by 
phenol/chloroform extraction [pH 6.0] and isopropanol precipitation. 
Phenol/chloroform extraction was conducted as described for DNA. Purified RNA 
was pelleted using 3 sample volumes of isopropanol and 75 mM sodium acetate at 
17,000 x g for 20 min. Pellets were washed in 70% (v/v) ethanol, centrifuged at 
17,000 x g for 5 min and air dried. Pelleted RNA was subsequently re-suspended in 
DEPC treated ddH2O, quantified, and stored in aliquots at -80 °C. 
3.2.1.13     Denaturing RNA electrophoresis 
In vitro transcribed RNA was analysed by denaturing agarose gel electrophoresis 
(1% (w/v) agarose, 1X MOPS (40 mM 3-(N-morpholino)-propanesulfonic acid 
[pH 7.0], 10 mM sodium acetate, 1 mM EDTA), 4.7% (v/v) formaldehyde) at 70 V 
for 1 h in 1X MOPS running buffer. RNA samples were loaded onto gels after 
denaturation at 65 °C for 10 min in RNA loading buffer (47.5% (v/v) formamide, 
9 mM EDTA, 0.0125% (w/v) SDS, xylene cyanol and bromophenol blue). RNA was 
visualised under blue light illumination and compared to ssRNA ladder (NEB). 
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3.3     Protein biochemistry 
3.3.1     SDS-PAGE electrophoresis 
Protein samples were analysed by separation using Tris-Glycine polyacrylamide gel 
electrophoresis (12–15% [resolving] or 6% [stacking] (v/v) acrylamide, 
0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate (APS), 0.01% (v/v) 
N,N,N’,N’-tetrmethylethylenediamine (TEMED), in 375 mM Tris-HCl [pH8.8] or 
126 mM Tris-HCl [pH 6.8] for resolving and stacking respectively. Protein samples 
were loaded onto gels after boiling at 95 C for 5 min in Laemmli buffer (17.5 mM 
Tris-HCl [pH 6.8], 9% (v/v) glycerol, 1% (w/v) SDS, 2.5% (v/v) β-mercaptoethanol, 
0.05% (w/v) bromophenol blue) and run in SDS-PAGE running buffer (25 mM 
Tris-HCl, 192 mM glycine, 0.1% (w/v) SDS) at 180 V for 50–60 min. Protein size 
was compared to ColorPlus Prestained Protein Marker, Broad Range (7–175 kDa) 
(NEB). 
3.3.2     Coomassie blue staining 
Protein bands were visualised using Coomassie Brilliant Blue R-250 stain 
(41% (v/v) methanol, 18% (v/v) acetic acid, 0.2% (w/v) Coomassie Brilliant Blue 
R-250) for at least 1 hour. Gels were de-stained using 50% (v/v) methanol, 
10% (v/v) acetic acid. 
3.3.3     Western blot analysis 
Proteins resolved by SDS-PAGE were transferred to polyvinylidene fluoride (PVDF) 
Immobilon-FL Transfer Membrane (Immobilon) using a dry transfer unit at 
40 mA/membrane for 1 hour. PVDF membranes were first activated in methanol 
before being soaked in transfer buffer (25 mM Tris-HCl, 193 mM glycine, 20% (v/v) 
methanol). Transferred membranes were subsequently blocked in 50% (v/v) 
Odyssey Blocking buffer (LI-COR) in TBS (50 mM Tris-HCl, 150 mM NaCl) for 
15–30 min. Primary and secondary antibodies were incubated in 25% (v/v) 
Odyssey Blocking buffer for at least 1 h at RT or 4 C overnight at the appropriate 
dilution. After each antibody incubation transfer membranes were washed 3–5 
times in TBS to remove unbound antibody. Blots were allowed to dry before 
imaging using an Odyssey Imager (LI-COR). 
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3.3.4     Protein quantification 
Mixed protein samples were quantified using Bradford’s reagent (8.5% (v/v) H3PO4, 
5% methanol, 0.005% Coomassie Brilliant Blue G-250) (Bradford, 1976). 
Absorbance at 570 nm was measured and protein concentration calculated from a 
standard curve of bovine serum albumin (BSA). 
Pure protein samples were quantified by absorbance at 280 nm with the 
corresponding molar extinction coefficients and molecular weight (ExPASy 
Bioinformatics Resource Portal) on a NanoDrop 1000. 
3.4     In vitro methods 
3.4.1     Protein expression 
Single colonies of BL21 (DE3) cells carrying the desired expression plasmid were 
grown in 10 mL of LB with antibiotic for 16 h at 37 C. Overnight cultures were 
pelleted at 4000 x g for 15 min, re-suspended in 10 ml of LB and inoculated 1:1000 
into LB containing antibiotic. Bacterial cultures were grown to an OD600 of 0.6–0.8 
before induction of protein expression using 0.1 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) at 25 C for 4 h. Final cultures were centrifuged 
at 4000 x g for 15 min and stored at -20 C. 
3.4.2     NS5B C21 expression 
Pelleted cultures from Section 3.4.1 were lysed in NS5B lysis buffer I (100 mM 
Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM MgCl2, 2% (v/v) Triton X-100, 2 mg/ml 
lysozyme [Alfa Aesar], 1 Unit/ml Benzonase [Sigma]) (5B-LB-I) for 30 min on ice 
and centrifuged at 20,000 x g at 4 C for 15 min. The resultant pellet was 
re-suspended in NS5B lysis buffer II (20 mM sodium phosphate [pH 7.5], 500 mM 
NaCl, 0.1% (v/v) β-octylglucopyranoside, 20 mM imidazole, 50% (v/v) glycerol) 
(5B-LB-II). The suspension was sonicated on ice 10 times with 20 sec on/off pulses 
using a Sanyo Soniprep 150 sonicator with amplitude of 6 microns and a microtip. 
The sonicated suspension was centrifuged at 20,000 x g for 20 min at 4 C and the 
resultant supernatant mixed with Ni2+-chelated Sepharose Fast Flow (Ni-resin; 
GE Healthcare) for 1–2 h at 4 C with end-over-end rotation. Ni-resin was 
centrifuged at 1,000 x g for 2 min, washed at least 5 times in 5B-LB-II containing 
50 mM imidazole before protein elution in 5B-LB-II containing 250 mM imidazole. 
Eluted protein was quantified using Bradford’s reagent and stored at -80 C. An 
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NS5B ΔC21 [GND] expression plasmid was expressed and purified in parallel as 
described above. 
3.4.3     RNA-dependent RNA polymerase in vitro  activity assay 
150 nM purified NS5B ΔC21 or NS5B ΔC21 [GND] was incubated in RNA 
dependent RNA polymerase (RdRp) reaction buffer (20 mM Tris-HCl [pH 7.6], 
5 mM MgCl2, 1 mM dithiothreitol (DTT), 25 mM KCl, 1 mM EDTA, 20 Units RNasin 
(Promega) with 0.5 μg in vitro transcribed full length JFH1 [GND] RNA for 30 min at 
25 C. In vitro transcribed RNA was re-folded before addition to RdRp reaction 
buffer by denaturation at 95 C for 3 min, cooling on ice for 2 min and incubation in 
refolding buffer (100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) [pH 8.0], 100 mM NaCl, 6.6 mM MgCl2) for 20 min at 37 C. RdRp 
reactions were initiated by the addition of NTP mix (10 μCi [α-32P]-CTP [Perkin 
Elmer], 10 μM cold CTP, 1 mM ATP, 1 mM UTP, 5 mM GTP) and incubated for 1 h 
at 25 C. Products from transcription reactions were purified using RNeasy Mini Kit 
(QIAGEN) and diluted into Emulsifier-Safe™ liquid scintillation cocktail (Perkin 
Elmer) and read on a Tri-Card® 2100 TR liquid scintillation counter. 
3.4.4     Generation of Adhirons 
Purified NS5B ΔC21, 12.4 μM, was surface biotinylated by incubation with 20-fold 
Molar excess EZ-Link NHS-SS-biotin (Pierce) for 1 h at room temperature before 
removal of excess biotin using Zeba spin 7K MWCO Desalting column (Thermo 
Fisher Scientific) by centrifugation at 1500 x g for 2 min. Biotinylated protein was 
provided to the Leeds Adhiron BioScreening group for the generation of adhirons 
specific to the HCV polymerase (Tiede et al., 2014). In summary, biotinylated NS5B 
ΔC21 was bound to streptavidin-coated wells (Pierce) for 1 h before 1012 colony 
forming units of phage were added for 2.5 h with shaking. Phage were initially 
pre-screened against biotinylated BL21 DE3 cell lysate from NS5B ΔC21 plasmid 
naïve cells. Naïve bacterial cell lysate from 5B-LB-II supernatant was biotinylated 
as described for NS5B. Panning wells containing phage were washed 10 times 
before elution of bound phage with 50 mM glycine-HCl [pH 2.2] and neutralisation 
with 1 M Tris-HCl [pH 9.1], followed by an additional elution with 100 mM 
trimethylamine for 6 min and neutralisation with 1 M Tris-HCl [pH 7.0]. ER2738 cells 
were infected with eluted phage by incubation for 1 h at 37 ºC and 90 rpm before 
plating on agar with 100 μg/ml carbenicillin and culturing overnight at 37 ºC. Single 
colonies were picked, grown in 30 mL LB containing 100 μg/ml carbenicillin and 
infected with 1 x 109 M13K07 helper phage. After 1 h at 90 rpm, kanamycin was 
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added to 25 μg/ml and incubated at 25 °C for 16 h at 170 rpm. Phage were 
precipitated using 4% (w/v) polyethylene glycol 8000, 0.3 M NaCl and 
re-suspended in 1 ml TE buffer (10 mL Tris [pH 8.0], 1 mM EDTA). For the second 
round of selection, 2 μl of phage suspension was incubated for 1 h with NS5B 
labelled streptavidin beads (Invitrogen). Beads were then washed five times and 
phage eluted and amplified as above. A third panning round used neutravidin high 
binding capacity plates (Pierce) as described for panning round 1 with phage eluted 
using 100 μl of 100 mM DTT. 
3.4.5     Phage ELISA 
Individual colonies of ER2738 cells (Section 3.4.4) were grown in 100 μl of LB with 
100 μg/ml carbenicillin in a 96 well plate at 37 °C for 6 h at 900 rpm. A 25 μl aliquot 
of culture was inoculated into 200 μl of LB with carbenicillin and grown at 37 °C for 
1 h at 900 rpm. 10 μl of 1011/ml helper phage were added with 25 μg/ml kanamycin 
and incubated overnight at 25 °C (450 rpm). Streptavidin-coated plates (Pierce) 
were blocked with 2X casein blocking buffer (Sigma) overnight at 37 °C followed by 
incubation with biotinylated NS5B ΔC21 or biotinylated plasmid-deficient BL21 
(DE3) cell lysate for 1 h. 45 μl of overnight growth medium containing phage were 
then added and incubated for 1 h. After washing, phage were detected using 
horseradish peroxidase-conjugated anti-phage antibody (1:1000; Seramun) for 1 h 
and visualised with 3,3’,5,5’-tetramethylbenzidine (Seramun) at 610 nm. 
3.4.6     Adhiron purification 
Plasmids coding for adhirons were grown in BL21 (DE3) cells (Section 3.4.1) and 
lysed in Adhiron lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 20 mM 
imidazole, 10% (v/v) glycerol, BugBuster [Novagen], Halt Protease Inhibitor 
cocktail – EDTA free [ThermoFisher Scientific], 10 Units/ml Benzonase [Sigma]) 
(Ad-LB) supplemented with 1 mM DTT for 20 min with end-over-end rotation. Lysis 
and subsequent buffers were pH 7.4 for adhirons, 21 and 28; pH 8.4 for adhirons 
10 and 16. Bacterial lysate was centrifuged at 5,000 x g for 20 min before 
incubation with Ni-resin for 1–2 h with end-over-end rotation. Ni-resin was 
centrifuged at 1,000 x g for 2 min, washed at least 5 times in Ad-LB containing 
100 mM imidazole before elution in Ad-LB containing 300 mM imidazole. Pure 
protein was quantified using 280 nm absorbance and frozen at -80 C for long term 
storage. 
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3.4.7     Adhiron labelling 
Purified Adhiron, 18.75 μg, was incubated with tris(2-carboxyethyl)phosphine 
(TCEP) resin (ThermoScientific) pre-equilibrated in phosphate buffered saline 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 [pH 7.4]) (PBS) 
containing 1 mM EDTA for 1 h with end-over-end rotation. Reduced Adhiron was 
recovered from TCEP resin by centrifugation at 1,000 x g for 60 sec and 
immediately incubated with 80 μM Alexa Fluor 647 C2 Maleimide (Life 
Technologies) for 16 h at RT whilst protected from light. Excess Alexa Fluor label 
was removed from labelled Adhiron using Zeba spin 7K MWCO Desalting Column 
by centrifugation at 1500 x g for 2 min. 647-labelled Adhiron was mixed with an 
equal volume of 80% (v/v) glycerol and stored at -20 C. 
3.4.8     NS5B dot blot 
Purified NS5B ΔC21 was dotted onto methanol activated PVDF transfer 
membranes for 1 h before blocking in 50% (v/v) Odyssey Blocking buffer for 
15 min. adhirons or antibodies were incubated with transfer membranes at 4 C 
overnight or 1 h at RT in 25% Odyssey Blocking buffer. Membranes were washed 
3 times in PBS to remove excess adhirons/antibodies before drying and imaging on 
either an FLA-5000 fluorescent (Fujifilm) or Odyssey (LI-COR) imager. 
3.5     Tissue culture 
3.5.1     Passaging of cells 
Mammalian cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma) supplemented with 10% (v/v) foetal bovine serum (FBS), 100 IU/ml 
penicillin, 100 μg/ml streptomycin and 1% (v/v) non-essential amino acids (Lonza) 
in a humidified incubator at 37 C with 5% CO2. Cells were passaged at 80–90% 
confluence by washing in PBS prior to incubation with 0.5 mg/ml trypsin-EDTA 
(Sigma) to detach cells. Once detached, trypsin was inactivated by addition of 
excess complete media and cells seeded into culture flasks or plates for further 
passage or experimentation. 
3.5.2     RNA electroporation of mammalian cells 
Trypsinised cells were counted after dilution 1 : 1 into HyClone Trypan Blue 
solution (Fisher Scientific) to identify live cells. Cells were pelleted at 700 x g for 
5 min then washed twice in ice cold DEPC-treated PBS. Pelleted cells were 
re-suspended in RNase free PBS to a final concentration of 1 x 107 cells/ml for SGR 
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assays and 2 x 107 for infectious virus. RNA, 5 μg for SGR and 10 μg for virus, was 
mixed with 0.4 ml of cell suspension in a chilled electroporation cuvette (Geneflow) 
before electroporation at 950 μF, 260 V for 25 msec (BioRad Gene Pulser). Cells 
were immediately recovered in complete media and seeded into culture plates. 
Media was replaced with fresh complete media at 4 h post electroporation (h.p.e.) 
to remove cell debris. 
3.5.3     Stable cell selection 
Cells electroporated with SGRs were cultured in complete media containing 
500 μg/ml G418 (Sigma) at 24 h.p.e. Cell death was monitored daily with media 
replacement as required but at least every 2–3 days. Polyclonal populations of 
G418 resistant cell colonies were propagated and maintained in the presence of 
500 μg/ml G418. 
3.5.4     Transient luciferase assays 
Six well plates seeded with 1 x 105 cells from SGR electroporations were harvested 
for luciferase activity at 4, 24, 48 and 72 h.p.e. by washing in PBS and lysis in 
0.2 ml Passive Lysis Buffer (PLB; Promega). Samples were stored at -20 C until 
analysis by the addition of 30 μl Luciferase Assay Reagent (Promega) to 20 μl of 
cell lysate. Light emission was monitored on a BMG plate reader. 
3.5.5     DNA transfection 
Cells were seeded the day before DNA transfection into 24 well culture plates with 
glass coverslips and media exchanged for Opti-MEM (Life Technologies) 30 min 
prior to transfection. 250 ng DNA was diluted into 0.1 ml Opti-MEM before addition 
of 0.5 μl FuGENE6 transfection reagent (Promega) and incubation at RT for 15–
30 min. Transfection complex was subsequently added to cells dropwise and 
incubated in a humidified incubator for 8 h before complex-media replacement with 
fresh complete DMEM. 
3.5.6     Infectious virus propagation 
Cells electroporated with infectious HCV RNA were transferred to BSL3 
containment 4 h.p.e. and media replaced with complete media supplemented with 
25 mM HEPES (Lonza). Cell culture supernatant was collected and replaced every 
24 h and stored at 4 C or -80 C. Naïve cells were infected with virus by incubation 
with supernatant derived from electroporations for the indicated time points 
between 0.1–1 multiplicity of infection (m.o.i.). 
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3.5.7     Virus titration 
Virus preparations were titred against HuH7 cells as described in (Stewart et al., 
2015). Briefly, 8 x 103 cells were seeded 8 h before titration. Either a 1 in 2 or 1 in 
10 dilution series of virus was prepared in complete media and incubated with cells 
for 48 h. Infected cells were washed in PBS and fixed in 4% (w/v) 
paraformaldehyde (PFA) in PBS for 20 min. Cells were then washed in PBS and 
permeabilised in 0.2% (v/v) Triton X-100 in PBS for 15 min before incubation with 
αNS5A primary and 594-fluorescent secondary antibodies sequentially in PBS for 
2 h at RT. Cells were washed in PBS between each antibody incubation. Red 
fluorescent positive cells were imaged using an IncuCyte ZOOM and virus 
concentration determined as infectious units/ml (IU/ml). Alternatively, labelled plates 
of titrated virus were imaged by eye and titre recorded as focus forming units/ml 
(f.f.u/ml). 
3.6     Fluorescence microscopy 
3.6.1     Sample preparation 
Cells seeded onto glass coverslips were manipulated for experimentation as 
required before fixation in 4% (w/v) PFA in PBS or 2% (w/v) PFA in complete 
media, at RT for 10 min. Samples were washed in PBS three times before 
permeabilisation in 0.2% (v/v) Triton X-100 in PBS for 10 min. Primary and 
secondary antibodies against targets were incubated sequentially in PBS at RT for 
one hour with PBS washes after each incubation. Coverslips were mounted in 
ProLong Gold or Diamond (Life Technologies), after 5 min incubation with 300 nM 
4’,6-diamidino-2-phenylindole (DAPI) in PBS, and cured overnight in the dark. 
3.6.2     Click Chemistry 
Cells were labelled with 5-ethynyl uridine (5EU) by addition of 1 mM 5EU to 
complete DMEM under normal growth conditions for the indicated times. Samples 
were then fixed and permeabilised as described in Section 3.6.1. Prior to antibody 
labelling, 5EU was detected using the Click-iT RNA labelling kit (Life Technologies) 
with 5 μM Alexa Fluor® 488 azide for 30 min at RT. 
3.6.3     Wide-field Microscopy 
Cured coverslips from Section 3.6.1 were imaged on a DeltaVision Deconvolution 
microscope; a wide-field Olympus IX70 inverted microscope with either an Olympus 
PlanApo 60X or 100X 1.4 NA oil immersion objective. Images were captured on a 
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CoolSNAP HQ CCD camera (Photometrics) with 1X gain at -30 ºC. Typically 
camera binning was 1 x 1 or 2 x 2 with an image size of 512 x 512. To prevent light 
reaching the camera, filters for DAPI, fluorescein, tetramethylrhodamine, or 
Cyanine 5 (Cy5) were used prior to the CCD camera. Image acquisition and 
deconvolution were controlled by softWoRx® software. 
3.6.4     Primary antibody labelling 
Primary antibodies for super-resolution microscopy were labelled directly. For 
dSTORM an ~1:1 ratio of fluorescent dye per antibody molecule was routinely 
achieved. Alexa Fluor® 647 NHS ester (Life Technologies) and Cy3B NHS ester 
(GE Healthcare) were lyophilised from DMSO into 20 µg aliquots and stored 
at -20 C in the dark. Fluorescent dyes were re-suspended in DMSO fresh for 
labelling reactions. For single fluorescent dye labelling, 0.1 µg Alexa Fluor® 647 
and 1 µg Cy3B were incubated with 3 µl of primary antibody (1 mg/ml) and 125 mM 
NaHCO3 in PBS for 30 min in the dark. Labelled antibodies were then purified from 
excess unreacted fluorescent dye using 40K MWCO Zeba Spin Desalting columns 
(Thermo Fisher Scientific). Labelled antibodies were stored at 4 C in the dark for 
up to three days. 
3.6.5     PALM/dSTORM sample preparation 
25 mm diameter high tolerance, #1.5 thickness (0.17 ± 0.01 mm), round glass 
coverslips (Cat #: 64-0735 [Model #: CS-25R17]; Warner Instruments) were 
cleaned with a 1:1:5 solution of ammonium hydroxide : hydrogen peroxide : ddH2O 
at 80 C for 16 h in the fume hood. Coverslips were then washed in copious 
amounts of ddH2O before dipping in methanol and, under sterile conditions, 
air-dried and stored in tissue culture plates. Cells were seeded onto sterile 25 mm 
coverslips and fixed in 4% (w/v) PFA in PBS or 2% (w/v) PFA in complete media. 
For dSTORM, cells were permeabilised in 0.2% (v/v) Triton X-100 in PBS for 
10 min and blocked in 1% (v/v) normal donkey serum (Sigma) in PBS for one hour. 
Samples were washed in PBS three times before labelling with the freshly prepared 
directly labelled primary antibody (Section 3.6.4) at RT for one hour. Labelled 
αNS5A and αNS3 were used at dilutions of 1:2,000 and 1:1,000 respectively. 
Excess, unbound antibody was removed with three PBS washes. Once labelled, 
samples were imaged within three days. 
3.6.6     PALM/dSTORM microscopy 
Super-resolution imaging was performed on a custom built microscope (Figure 3.1) 
comprising a wide-field Olympus IX81 inverted microscope using a water immersion 
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Olympus UPlanSApo 60X 1.2 NA objective. Prior to image capture on an Andor 
iXon Ultra EMCCD camera two additional magnifiers of 1.6x and 1.2x were used 
before a cylindrical lens with a focal length of 150 mm. Laser wavelengths of 405, 
488, 561 and 647 nm were supplied by an Omicron Laserage Light Hub. To prevent 
light reaching the camera a filter cube (Chroma) was used prior to the EMCCD 
camera. Samples were mounted in an ASI MS-2000 (XYZ) stage with drift 
mitigation using stage position control by a C-focus (Mad City Labs Inc.).  
Before imaging, samples were incubated in 0.01% (v/v) poly-L-Lysine (Sigma) for 
10 min before addition of fiducial markers, either 100 nm or 150 nm gold 
nanoparticles (Cat #: 742031 or 743058; Sigma) diluted in PBS. A calibration file of 
z positions were acquired from the PSF of fiducials from 50 nm steps in the z axis. 
Calibration files were acquired for each wavelength used in PALM or dSTORM 
imaging. PBS or dSTORM imaging buffer (glucose oxidase (10 Units), catalase 
(50 Units), 12.5 mg/ml glucose, 1 mM 2-mercaptoethylamine (MEA) in PBS 
[pH 8.0]) was then added to samples for PALM and dSTORM imaging, respectively. 
dSTORM imaging buffer was replaced with freshly prepared buffer every hour at 
the end of image acquisitions. 
Images were acquired under wide-field illumination with 561 nm at 30–50 mW for 
PALM and 642 nm at 50 mW for dSTORM. 0–1.6 µW 405 nm illumination was used 
to encourage photo-switching of fluorescence molecules. Multiple data sets of 
11,000 frames were acquired at a frame rate of 20 Hz with an EMCCD camera gain 
of 100. Typically this was 50 repetitions of 200 frames followed by 20 frames of the 
fiducial position. 
3.6.7     Computational methods 
To reconstruct super-resolution images, individual fluorescent event localisation 
and sample drift correction were conducted using the palm3d software (York et al., 
2011). The same software was then used to generate histogram representations of 
the microscopy data. Additional processing, image analysis and visualisation was 
subsequently conducted in either R (R Core Team, 2013), python (Oliphant, 2007) 
or ImageJ (NIH) (Schindelin et al., 2015; Schneider et al., 2012). A more detailed 
description of the methods are provided in Chapter 4 Section 4.2.1) with the 
processing scripts provided in Appendix 3-5. Colocalisation analysis of fluorescence 
images were conducted in ImageJ with the JACoP plugin (Bolte and Cordelieres, 
2006). Graphical representations and statistical tests were conducted in GraphPad 
Prism. 
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Figure 3.1: Ray diagram and PALM/STORM microscope layout. 
A: Ray diagram of the PALM/STORM microscope. Individual components are 
labelled with grey arrows. B: Images of the PALM/STORM microscope 
corresponding to labelled boxes in A. Individual components are labelled with red 
arrows. Blue, purple and green arrows indicate the direction of light through the 
system.   
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microscopy studies of the HCV 
replication complex 
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4.1     Introduction 
The HCV replication complex (RC), like other positive strand RNA viruses, is 
closely associated with cellular membranes (Romero-Brey and Bartenschlager, 
2014). For HCV, these membrane rearrangements are termed replication factories 
and consist of vesicles compacted into a membranous matrix (Egger et al., 2002). 
These structures are derived from the ER and autophagy pathways (see Chapter 5) 
and provide a specialised environment for productive infection (Paul and 
Bartenschlager, 2015).  
The current ultrastructural knowledge of HCV RCs derive from electron microscopy 
(EM) and soft X-ray microscopy studies of the membranous rearrangements during 
HCV infection (Figure 4.1) (Ferraris et al., 2010; Pérez-Berná et al., 2016; Romero-
Brey et al., 2012). The production of double membrane vesicles (DMV) correlated 
with the kinetics of HCV RNA replication, and were typically between 100–1000 nm 
in diameter (Ferraris et al., 2010; Romero-Brey et al., 2012).  
DMV were identified as sites of HCV replication by immunogold labelling with 
antibodies to the non-structural proteins and dsRNA (Ferraris et al., 2010; Gosert et 
al., 2003). Additionally, purified DMV contain active viral replicases capable of de 
novo synthesis of HCV RNA (Paul et al., 2013). However, a major limitation of the 
immunogold staining was the inefficient labelling of HCV RC components. Although 
these studies identified the presence of HCV proteins on DMV, a detailed 
description of their organisation about HCV-induced membrane structures was not 
revealed. 
Correlative light and electron microscopy studies have aimed to address this deficit 
in knowledge by characterising NS5A fluorescent puncta at the ultrastructural level 
using EM (Figure 4.1) (Romero-Brey et al., 2012). These studies identified 
NS5A-GFP fluorescence signal corresponded to accumulations of DMV in close 
proximity to LDs and the ER. However, light microscopy is fundamentally limited to 
~200 nm resolution in the visible light range by the diffraction of light (Section 1.5.2, 
Equation 1) (Abbe, 1873; Rayleigh, 1896). Consequently, at the light microscopy 
level NS3 and NS5A staining appears as diffraction limited spots by conventional 
light microscopy (El-Hage and Luo, 2003; Gosert et al., 2003; Mottola et al., 2002; 
Shi et al., 2003). Therefore, the precise organisation of HCV components within 
these membranous structures remains elusive. 
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Figure 4.1: Correlative light-electron micrographs of cells harbouring a GFP-tagged 
SGR.  
A: Overlay of whole cell fluorescence and 60 nm ultrathin electron micrograph from 
correlative light and electron microscopy of NS5A-GFP replicon harbouring cells. 
Areas marked with green dotted line indicate regions of intense fluorescence. B and 
C: Higher magnification of regions 1 and 2 respectively. Areas marked in white 
boxes are magnified in corresponding right panels. LD, lipid droplet; ER, 
endoplasmic reticulum; DMV, double membrane vesicle; m, mitochondrion; if, 
intermediate filaments. Adapted from (Romero-Brey et al., 2012). 
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Recent developments in light microscopy now allow observations of structures 
below the diffraction limit revealing previously unknown protein organisations 
(Schermelleh et al., 2010). Single molecule localisation microscopy (SMLM) using 
both fluorescent proteins (Betzig et al., 2006; Hess et al., 2006), and antibodies 
(Rust et al., 2006), has achieved image resolutions of 10–20 nm using fluorescence 
microscopy. This ~10-fold improvement in resolution has resolved structures with 
significantly improved spatial resolution compared to wide-field microscopy (Figure 
4.2) (Kanchanawong et al., 2010; Lambacher et al., 2016; Löschberger et al., 2012; 
Shroff et al., 2013; Szymborska et al., 2013). A recent report of SMLM provided 
insights into the organisation of HCV structural proteins around the viral assembly 
site at lipid droplets (Figure 4.2F and G) (Eggert et al., 2014). The organisation of 
core and E2 around lipid droplets indicated a lower level of colocalisation than 
previously documented by conventional light microscopy (Eggert et al., 2014). 
Understanding the protein architecture within HCV RCs is now achievable with the 
improved resolving power of SMLM over wide-field microscopy. 
An important component of the HCV replication complex is NS5A, a multifunctional 
phosphoprotein (Ross-Thriepland and Harris, 2015). It interacts with other 
non-structural proteins (Shirota et al., 2002), HCV RNA (Foster et al., 2010) and 
lipid droplets (Miyanari et al., 2007), along with cellular proteins (Hamamoto et al., 
2005). As such, it is regularly used as a marker for replication complexes. The 
protein is regulated by phosphorylation, although the precise mechanisms by which 
it does so remain elusive (Ross-Thriepland and Harris, 2015). Recently, our lab has 
reported a complex multi-phosphorylation process in the regulation of NS5A 
function (Section 1.3.7.4) (Ross-Thriepland et al., 2015; Ross-Thriepland and 
Harris, 2014). 
The critical functions NS5A plays during HCV genome replication are also 
highlighted by the development of the potent NS5A inhibitor daclatasvir (DCV), 
recently approved by the FDA for HCV therapy. Currently the mechanism of action 
is unknown as NS5A does not have any known enzymatic activity. Therefore 
multiple models for DCVs binding to NS5A have been proposed (Barakat et al., 
2015; Kazmierski et al., 2014; Lambert et al., 2014; Nettles et al., 2014; O’Boyle Ii 
et al., 2013) although the exact site of binding is still unknown.  
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Figure 4.2: STORM microscopy of clathrin coated pits and HCV structural proteins. 
A: Conventional direct immunofluorescence image of clathrin. B: Z-projection of 
3D-STORM image from A. C: 50 nm thick x-y cross-section from B. D: Magnified 
Z-projection of two clathrin coated pits from B. E: Corresponding 100 nm thick x-y 
cross-section from D. F: Image stacks from 3D-STORM of HCV infected cells. Core 
protein (green), E2 protein (red), lipid droplet (blue). G: Corresponding 3D volume 
reconstruction from stacks in F. From left to right, all three channels, core and lipid 
droplet, E2 and lipid droplet then core-E2 colocalisation volume (yellow) and lipid 
droplet. Ruler hatch marks in 3D image correspond to 100 nm. A-E adapted from 
(Huang et al., 2008b). F-G adapted from (Eggert et al., 2014). 
.  
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Cell based studies monitoring NS5A-GFP localisation from the NS3–5B polyprotein 
and SGR systems have revealed no accumulation of DMV or other virus-induced 
membrane structures in subcellular regions containing NS5A-GFP fluorescence 
(Berger et al., 2014; Reghellin et al., 2014). These studies indicated that DCV 
inhibits the formation of the membranous web without interfering with NS5A 
localisation, or its interactions with PI4KIIIα (Berger et al., 2014). Although 
confusingly, DCV was found in a separate study to have no effect on preformed 
replication factories (McGivern et al., 2014).  
Taking advantage of the improved resolution SMLM microscopy offers, this chapter 
was focussed on elucidating the NS5A and NS3 protein organisation within HCV 
replication complexes. By inhibiting NS5A functions through DCV treatment, or 
manipulating NS5A phosphorylation, this study aimed to better understand the roles 
of NS5A within the replication complex. 
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4.2     Localisation microscopy methods 
4.2.1     Workflow for localisation microscopy 
4.2.1.1     SMLM image acquisition 
Localisation microscopy studies were carried out on a custom built super-resolution 
microscope at Leeds (Section 3.6.6). Preparation of samples followed the same 
protocol as immunofluorescence studies with additional coverslip cleaning (Section 
3.6.5). Additionally, once samples were fixed and labelled they were imaged within 
three days, after which the quality of labelled antibodies deteriorated. Antibodies 
used in dSTORM imaging were directly labelled with an ~1:1 ratio of Alexa Fluor 
647 (Section 3.6.4).  
Prior to image acquisition, fiducials markers (gold nanoparticles of 100 nm or 
150 nm (Section 3.6.6) for PALM and dSTORM, respectively) were applied to 
coverslips. Imaging of fiducials under the required excitation wavelength was 
performed to generate a calibration stack of the PSF distortion in x-y from the 
cylindrical lens using 50 nm steps in z (Figure 1.15). By performing a cross 
correlation (Guizar-Sicairos et al., 2008) between sample and bead PSFs, the 
molecular localisation of fluorescent events in z were obtained. These gold 
nanoparticles embedded in the sample were then used as fiducial markers to track 
drift during image acquisition.  
Image acquisitions collected for each sample typically consisted of 11,000 frames 
(22,000 for 3D-PALM imaging). These were composed of 50 repeating sequences 
of 200 frames followed by 20 frames (Section 3.6.6). The 20 frame data sets were 
for monitoring image drift between acquisition of the 200 frame image sequences. 
Laser illumination powers were typically 30 mW or 50 mW for 561 nm and 647 nm 
wavelengths, respectively. To encourage blinking of either fluorescent proteins or 
dyes, 0–3 µW 405 nm illumination was used as required. 
 
 
 
 
 
 
 
  86 
 
Figure 4.3: Flowchart of localisation microscopy image acquisition and processing. 
Black arrows indicate direction of workflow, grey arrows correspond to processes 
carried out during the current step, and green arrows represent output. 
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4.2.1.2     SMLM image processing 
Fluorescent event localisation and drift correction were conducted in the palm3d 
software (https://github.com/AndrewGYork/palm3d) which uses the Python 
programming language (Oliphant, 2007; York et al., 2011). Image acquisition runs 
were loaded into the palm3d software and selection parameters determined 
empirically for each image collection to reduce false positive and false negative 
localisations. A Gaussian-Laplace filter (σ = 4) was applied to each data frame as a 
band-pass filter to remove slowly-varying background and quick-varying noise. The 
Laplacian is a 2D measure of the second spatial derivative of an image 
(Abramowitz and Stegun, 1964). It identifies regions of rapid intensity change, in 
this case the appearance of a single fluorescent event. Gaussian smoothing of the 
image beforehand reduces the sensitivity of the Laplacian to noise. Pixels in the 
filtered image were then selected according to intensity, typically 3–5 standard 
deviations above the mean. Candidate particles are then compared to the 
calibration stack to estimate the sub-pixel position in x, y and z. Routinely, 20 nm 
localisation precision was obtained in x-y and 30 nm in z. Localisation precision was 
measured from the standard deviation of the full width at half maximum from a 
source of multiple emitters, in this case gold fiducials (Hendrik Deschout et al., 
2014). 
After candidate selection and localisation, sample drift during acquisition was 
corrected. A single fiducial from the field of view was selected by filtering all 
localisations to a specified x-y-z position and minimum correlation strength between 
subsequent frames. Piecewise linear interpolation and Gaussian smoothing are 
then used to estimate drift over time. 
4.2.1.3     SMLM image reconstruction 
Once all fluorescent events have been localised and drift corrected, the molecular 
coordinates were plotted in a 3D histogram. The entire field of view was 
reconstructed with 100 nm pixel bins, within ± 1.5 µm of the imaging focus, from 
localisations with a cross-correlation strength above 0.4 to the calibration stack. 
Correction of the x and y coordinates with pre-determined correction factors, 
typically x=106 nm and y=133 nm, were applied before image reconstruction. 
These correction factors remove the distortion caused by the cylindrical lens and 
were determined from gold nanoparticles in the same microscope set-up as 
samples. Cropping and re-binning of histogram images is then used to inspect 
regions of interest.  
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To visualise localisations with Gaussian smoothing, kernel density estimation was 
conducted in R (R Core Team, 2013). The molecular coordinates were extracted 
from the palm3d output files (Appendix 3) and smoothed using a 3D Gaussian 
kernel (σ of 20 nm in x-y and 30 nm in z) on a regular grid. The Gaussian kernel 
bandwidth corresponds to the average localisation precision obtained. Grid spacing 
was chosen as 501 x 501 for the x and y dimensions to produce 10 nm pixels in the 
final image.  
4.2.1.4     Analysis of protein clusters 
The coordinate positions of localisations in x-y-z were extracted directly from 
palm3d output files into a Python NumPy array. Protein clusters were analysed 
using density-based spatial clustering of applications with noise (DBSCAN) analysis 
in Python (Appendix 4 and Appendix 5) (Figure 4.4). DBSCAN requires two 
parameters, the first is the minimum number of localisations within a cluster 
(minimum points), and the second is the size of the search radius (ε) (Figure 4.4). 
Localisations were assigned to clusters or noise based on their local density (Ester 
et al., 1996). DBSCAN identifies localisations as either a core, border or noise point 
(Figure 4.4). Core points contain the minimum number of localisations within the 
search radius, and are therefore in a cluster. Border points contain a core point 
within the search radius but do not have the minimum number of localisations to be 
a core point. Therefore these points are on the borders of clusters. Lastly, 
localisations which do not satisfy either DBSCAN parameter are termed noise. 
The choice of DBSCAN parameters were carefully selected and optimised 
empirically according to some considerations. First, the choice of minimum points 
was selected as 20 for PALM and 30 for dSTORM. This ensured several protein 
molecules had to be within a cluster, and also accounted for each protein molecule 
being represented more than once, e.g. for blinking in dSTORM. Second, the 
search radius was informed from current knowledge on the size of replication 
factories (Ferraris et al., 2010; Romero-Brey et al., 2012). Therefore, the search 
radius (ε) was set to 150 nm, the size of smaller membranous structures produced 
by HCV infection. This was much higher than the average localisation precision of 
~20 nm and ensured multiple, spatially separate localisations within the search 
radius. Visual inspection of DBSCAN clustering was conducted to ensure the 
minimum selection of false positives. 
 
 
  89 
 
Figure 4.4: Schematic illustrating DBSCAN clustering of localisations. 
Points are clustered based on local density. Two parameters are required for 
DBSCAN clustering. First, the number of points (min points) needed within a search 
radius, and secondly the size of the search radius (ε). DBSCAN scores points as 
either core points, which satisfy min points and ε; border points, which have a core 
point within their search radius but do not have min points; or noise points, which 
fail both criteria. Core, border and noise points are shown in purple, yellow and 
blue, respectively. 
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Multiple characteristics were measured from clusters identified by DBSCAN 
analysis, such as the number of localisations per cluster, cluster size, and distance 
of localisations from the cluster centroid (Appendix 5). The measurements provided 
information about cluster size and the internal organisation of localisations. The 
cluster centroid is the geometric centre of localisations within a cluster. For each 
localisation within a cluster, the Euclidean distance to the centroid position of its 
cluster was calculated. The cluster size is reported as the mean pairwise Euclidean 
distance in x-y between localisations within a cluster. Graphical and statistical 
analysis was then conducted using GraphPad Prism. 
4.2.2     NS5A-mEos3.2 cloning strategy 
To undertake PALM imaging studies on the HCV replication complex, the 
photoswitchable fluorescent protein mEos3.2 (McKinney et al., 2009; Zhang et al., 
2012) was engineered into domain III of NS5A (Figure 4.5). mEos3.2 was chosen 
because of its monomeric nature and superior photophysical properties over other 
fluorescent proteins. The coding sequence for mEos3.2 was PCR amplified 
(Appendix 1) introducing unique BamHI and BclI restriction enzyme sites, at the N- 
and C-terminus respectively. PCR amplified mEos3.2 was ligated into NS5A using 
the unique restriction enzyme site BclI in pmSUB (Mair Hughes Thesis). BamHI and 
BclI have compatible ligations sites. Colony PCR was used to screen constructs 
with the correct orientation of mEos3.2. To assess the replication kinetics of the 
NS5A-mEos3.2 fusion protein, the BamHI and HpaI restriction digestion fragment 
from pmSUB [NS5A-mEos3.2] was ligated into pmSGR-Feo-JFH1 creating 
pSGR-Feo-JFH1 [NS5A-mEos3.2]. All constructs were confirmed by restriction 
digestion and Sanger sequencing. 
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Figure 4.5: Illustration of NS5A-mEos3.2 cloning strategy. 
A: mEos3.2 sequence was PCR amplified, introducing unique restriction enzyme 
sites at the N- and C-terminus. The PCR product was cloned into pmSUB using the 
unique BclI restriction enzyme site within domain III of NS5A. B: NS5A-mEos3.2 
fusion protein was ligated into pmSGR-Feo-JFH1 using BamHI and HpaI creating 
pSGR-Feo-JFH1 [NS5A-mEos3.2]. Coding sequences for NS3, NS4B, NS5A, 
NS5B and mEos3.2 in yellow, green, light blue, dark blue and red, respectively. 
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4.3     Results 
4.3.1     Characterisation of NS5A-mEos3.2 fusion protein 
Introduction of the mEos3.2 fluorescent protein into domain III of NS5A did not 
affect HCV replication (Figure 4.6A). Luciferase signal increased for 
SGR-Feo-JFH1 [NS5A-mEos3.2] by ~2log10 up to 72 hours post infection (h.p.e) 
(Figure 4.6). The increase in luciferase signal, as a measure of replication, was the 
same as unaltered control RNA. In contrast there was no increase in luciferase 
signal for the replication deficient SGR-Feo-JFH1 [GND].  
mEos3.2 maintains the ability to correctly fold when expressed as an internal 
insertion in domain III of NS5A (Figure 4.6B). This correlates with previous reports 
of fluorescent protein insertion (e.g. GFP) internally into NS5A (Eyre et al., 2014; D. 
M. Jones et al., 2007). The localisation of mEos3.2 fluorescent puncta is 
characteristic of NS5A, and colocalisation with antibody staining for NS5A was also 
observed. Both the luciferase kinetics and immunofluorescence data validate the 
SGR-Feo-JFH1 [NS5A-mEos3.2] construct for super-resolution imaging. A 
population of cells stably harbouring SGR-Feo-JFH1 [NS5A-mEos3.2] were 
selected and taken forward for super-resolution microscopy analysis. 
4.3.2     Visualising NS5A-mEos3.2 by 3D-PALM 
PALM imaging of NS5A-mEos3.2 showed clusters of molecules that were 
equivalent to the diffraction limited puncta observed by wide-field (Figure 4.7). 
Diffraction limited NS5A puncta in wide-field images were resolved as regions of 
dense localisations clustered into discrete structures. (Figure 4.7D and E arrows). 
These protein clusters were observed in the cytoplasm of SGR harbouring cells, 
amid a diffuse background of single molecule localisations. NS5A-mEos3.2 protein 
clusters were observed distributed throughout the cytoplasm at random.  
NS5A-mEos3.2 protein clusters were identified from the diffuse single molecule 
background by DBSCAN analysis (Figure 4.8). Protein clusters identified from 
areas of dense NS5A-mEos3.2 localisations were typically between 90–140 nm in 
size, with a mean size of 123 ± 1.6 nm (Figure 4.8C and D). This size range 
correlated with the smaller DMV structures measured by electron microscopy 
during HCV infection (Romero-Brey et al., 2012). Image reconstruction and analysis 
of two independent cells identified >1,000 NS5A-mEos3.2 protein clusters, which 
contained around 59 localisations on average. From all the localisations in the 
reconstructed image, around 25% were classified as part of a cluster by DBSCAN 
analysis. 
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Figure 4.6: Characterisation of SGR-Feo-JFH1 [NS5A-mEos3.2]. 
A: Luciferase reporter values were measured up to 72 h.p.e. from transient 
electroporation of 5 μg RNA into HuH7 cells. Comparison of mEos3.2 tagged NS5A 
to wildtype and polymerase deficient (GND) SGR controls. Data represent the 
mean ± SD, n=3. B: Cells stably harbouring SGR-Feo-JFH1 or SGR-Feo-JFH1 
[NS5A-mEos3.2] were fixed and labelled with anti-NS5A antibody and DAPI. White 
boxes indicate zoomed in regions with 2 μm scale bars. 
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Figure 4.7: 3D-PALM imaging of SGR-Feo-JFH1 [NS5A-mEos3.2]. 
A: Sum of z slices, 3.9 μm thick, from a representative 3D-PALM image 
reconstruction from a stable SGR-Feo-JFH1 [NS5A-mEos3.2] cell line. Image was 
reconstructed from 348,829 localisations using 100 nm 3D histogram pixel bins. 
B: Bright-field image of cell in A. C: Wide-field image of cell in A. D and E: 5 μm2 
regions of interest from the cell cytoplasm after kernel density estimation 
(σ = 20 nm in x-y, 30 nm in z) using 4 nm pixels. Sum of z slices, 850 nm thick. 
Arrows illustrate protein clusters. Scale bars are indicated. 
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Figure 4.8: DBSCAN analysis of SGR-Feo-JFH1 [NS5A-mEos3.2] protein clusters. 
A: Maximum z projection of representative region of interest from 3D-PALM image 
reconstruction of SGR-Feo-JFH1 [NS5A-mEos3.2] containing 7,968 localisations. 
B: Clusters identified from DBSCAN analysis of A (min points = 20, ε = 150 nm). 42 
clusters containing 2,115 localisations are coloured according to their cluster 
identity. C: Cumulative percentage of cluster size from two independent cells. 
Median and percentile values are indicated. D: Summary of clusters from DBSCAN 
analysis, derived from 28 regions of interest from 2 independent cells. Data 
represent the mean ± SEM. 
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4.3.3     Super-resolution imaging of untagged NS5A by dSTORM 
NS5A produced during HCV infection was readily detected under a number of 
permeabilisation conditions (Figure 4.9). Discrete punctate structures were 
observed distributed throughout the cytoplasm of infected cells. Fluorescence 
intensity appeared greatest with Triton X-100 permeabilisation indicating a greater 
accessibility of antibodies to NS5A epitopes. This is likely a consequence of the 
non-selective extraction of lipids by Triton X-100, whereas saponin and digitonin 
preferentially form pores in the plasma membrane by binding cholesterol (Jamur 
and Oliver, 2010). All future antibody staining was conducted using Triton X-100 
permeabilisation for NS protein detection. 
Image reconstructions from dSTORM of antibody labelled NS5A resolved a greater 
number of clustered structures over 3D-PALM with a reduced single molecule 
population (Figure 4.10). NS5A protein clusters were more clearly defined as 
regions of dense localisations. The distribution of NS5A proteins clusters 
throughout the cytoplasm was comparable to NS5A-mEos3.2. However, over twice 
as many fluorescence events were localised from 3D-dSTORM imaging compared 
to 3D-PALM. Additionally, these were obtained from a single data collection series 
compared to the two required to reconstruct a 3D-PALM image. 
In contrast to 3D-PALM imaging, NS5A protein clusters were typically smaller in 
size, between 64–140 nm, with a mean of 113.8 ±1.7 nm (Figure 4.11 and Figure 
4.12). Although around 10 nm smaller in size, 3D-dSTORM protein clusters 
contained around 5-fold more localisations within each cluster than 3D-PALM (269 
compared to 59). This discrepancy may be attributed to the greater number of 
localisations identified from antibody labelling, likely a result of multiple localisations 
from a single dye due to fluorescence blinking (Endesfelder et al., 2014). After 
fluorescence emission, fluorophores under dSTORM conditions may enter a “dark” 
state before a second excitation at a later time. This results in multiple localisations, 
and therefore multiple positions, being recorded for the same fluorophore (Dave et 
al., 2009). The differences in position of the detected fluorophore between PALM 
and dSTORM, genetic tag in domain III of NS5A vs antibody staining respectively, 
may alter the apparent cluster size (Huang et al., 2008b). The improved labelling 
density revealed that 65% of all observed localisations were identified as part of a 
cluster structure, compared to only 25% for 3D-PALM (Figure 4.12B). 
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Figure 4.9: Optimisation of different permeabilisation conditions for antibody 
labelling of NS5A. 
HuH7 cells were infected with JFHcc for 48 before permeabilisation with the 
indicated detergent and antibody detection of NS5A. Scale bars are indicated. 
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Figure 4.10: 3D-dSTORM imaging of antibody labelled NS5A. 
Cells stably harbouring SGR-Neo-JFH1 were fixed and subjected to 
immunofluorescence staining for NS5A before 3D-dSTORM imaging. A: Sum of z 
slices, 3.9 μm thick, from a representative 3D-dSTORM image reconstruction. 
873,185 localisations were binned into 100 nm pixels in a 3D histogram. 
B: Bright-field image of cell in A. C: Wide-field image of cell in A. D and E: 5 μm2 
regions of interest after kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 
4 nm pixel bins. Sum of z slices, 800 nm thick. Arrows illustrate clusters. Scale bars 
are indicated. 
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Figure 4.11: DBSCAN analysis of SGR-Neo-JFH1 antibody labelled NS5A protein 
clusters. 
A: Maximum z projection of representative region of interest from 3D-dSTORM 
image reconstruction containing 15,721 localisations. B: Clusters identified from 
DBSCAN analysis of A (min points = 30, ε = 150 nm). 66 clusters containing 11,790 
localisations are coloured according to their cluster identity. C: Cumulative 
percentage of cluster size from three independent cells. Median and percentile 
values are indicated. D: Summary of clusters from DBSCAN analysis, derived from 
63 regions of interest from 3 independent cells. Data represent the mean ± SEM. 
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Figure 4.12: Comparison of cluster characteristics between PALM and dSTORM 
imaging. 
A: The mean number of localisations in each cluster from PALM or dSTORM image 
reconstructions. B: The percentage of localisations assigned to a cluster by 
DBSCAN analysis. Error bars represent the SEM. **** P <0.0001. 
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4.3.4     Comparison of NS5A protein clusters from different genotypes 
NS5A from different genotypes were clustered into discrete regions of dense 
localisations comparable to genotype 2a (SGR-Neo-JFH1) (Figure 4.13 and Figure 
4.14). Genotype 1b and 3a NS5A protein clusters were distributed throughout the 
cytoplasm (Figure 4.13D and Figure 4.14D).  
Genotype 1b and genotype 3a NS5A localisations were organised into smaller 
protein clusters of 85.1 ± 1.3 nm and 76.9 ± 1.2 nm respectively (Figure 4.15). 
Genotype 3a protein clusters were the smallest on average and, along with 
genotype 1b, contained significantly fewer localisations than genotype 2a (Figure 
4.15B). Although different to genotype 2a, there was no significant difference in the 
number of localisations per cluster, or the percentage of clustered localisations, 
between genotypes 1b and 3a (Figure 4.15B and C). 
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Figure 4.13: 3D-dSTORM image reconstruction of NS5A from genotype 1b. 
Cells stably harbouring SGR-Neo-Con1 were fixed and subjected to 
immunofluorescence staining for NS5A before 3D-dSTORM imaging. A: Sum of z 
slices, 1.95 μm thick, from a representative 3D-dSTORM image reconstruction. 
259,072 localisations were binned into 50 nm pixels in a 3D histogram. 
B: Bright-field image of cell in A. C: Wide-field image of cell in A. D: 5 μm2 region of 
interest after kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel 
bins. Sum of z slices, 850 nm thick. Arrows illustrate NS5A protein clusters. Scale 
bars are indicated. E: Cumulative percentage of cluster size from three independent 
cells. Median and percentile values are indicated. 
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Figure 4.14: 3D-dSTORM image reconstruction of NS5A from genotype 3a. 
Cells stably harbouring SGR-Neo-S52 were fixed and subjected to 
immunofluorescence staining for NS5A before 3D-dSTORM imaging. A: Sum of z 
slices, 1.7 μm thick, from a representative 3D-dSTORM image reconstruction. 
426,071 localisations were binned into 50 nm pixels in a 3D histogram. 
B: Bright-field image of cell in A. C: Wide-field image of cell in A. D: 5 μm2 region of 
interest after kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel 
bins. Sum of z slices, 650 nm thick. Arrows illustrate NS5A protein clusters. Scale 
bars are indicated. E: Cumulative percentage of cluster size from three independent 
cells. Median and percentile values are indicated. 
  105 
 
Figure 4.15: Comparison of NS5A protein clusters between genotypes. 
A: The mean distance in x-y between localisations within clusters. B: Mean number 
of localisations within each NS5A protein cluster. C: The percentage of localisations 
contained within clusters. Error bars represent the SEM. * P <0.05, **** P <0.0001. 
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4.3.5     dSTORM of HCV infection 
Clusters of NS5A localisations from HCV infected cells were resolved from 
diffraction limited NS5A foci in wide-field images (Figure 4.16). Consistent with SGR 
observations, NS5A protein clusters were distributed evenly throughout infected 
cells (Figure 4.16D).  
In contrast to SGR samples, NS5A protein clusters at 24 h.p.i. were smaller with a 
size range between 63–110 nm. Although with a mean size around 20 nm smaller 
at 95.5 ± 1.5 nm, these protein clusters were still larger than those observed for 
genotype 1b and 3a SGRs by 10–20 nm. At 24 h.p.i., an early time after HCV 
infection, NS5A protein clusters contained around a third fewer localisations within 
each cluster than those from SGR harbouring cells. This also correlated with the 
lower percentage of localisations contained within clusters (Figure 4.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  107 
 
Figure 4.16: 3D-dSTORM imaging of NS5A in HuH7 cells infected with JFHcc. 
HuH7 cell infected with JFHcc for 24 h before fixation and immunofluorescence 
labelling for NS5A. Samples were then imaged by 3D-dSTORM. A: Sum of z slices, 
3.9 μm thick, from a representative 3D-dSTORM image reconstruction with 100 nm 
pixel bins in a 3D histogram from 199,451 localisations. B: Bright-field of cell in A. 
C: Wide-field of cell in A. D: 5 μm2 region of interest after kernel density estimation 
(σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel bins. Sum of z slices, 650 nm thick. 
Arrows illustrate NS5A protein clusters. Scale bars are indicated. E: Cumulative 
percentage of cluster size from three independent cells. Median and percentile 
values are indicated. 
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Figure 4.17: Comparison of NS5A protein clusters between SGR and virus 
replication. 
A: The mean distance between localisations in x-y within clusters. B: Mean number 
of localisations within each NS5A protein cluster. C: The percentage of localisations 
contained within clusters. Error bars represent the SEM. ** P <0.01, **** P <0.0001. 
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4.3.6     Internal cluster organisation of NS5A 
NS5A localisations within clusters are ~95 ± 2.5 nm from the centroid position for 
virus infected cells (Figure 4.18). The centroid position is the geometric centre of an 
object, and corresponds to the mean position of all coordinates in all directions. The 
smaller clusters for virus infection produce a smaller distance from the centroid 
position than stable SGR harbouring cells. Distances were plotted as a frequency 
distribution with 5 nm bins (Figure 4.18). The peak of the skewed right distribution, 
the mode, corresponds to the most common distance of localisations from the 
centroid. This was calculated as 95 ± 2.5 nm and 125 ± 2.5 nm for virus and SGR 
NS5A protein clusters respectively. The lack of localisations within 100 nm of the 
centroid indicates a spherical cluster organisation with a hollow core. The following 
tail in the distribution corresponds to clusters of increasing size where the distance 
of localisations to the centroid increases. A closer inspection of individual clusters 
indicate that a number of elliptical clusters of differing sizes contain a hollow core 
(Figure 4.19). Additionally, some clusters were found to have a non-uniform shape 
(Figure 4.19, bottom panel arrows), and these were observed for both 
SGR-Neo-JFH1 harbouring and HCV infected cells. This subpopulation may be due 
to a specific membranous organisation during infections of due to undersampling of 
these clusters. From these observations, the internal diameter of NS5A protein 
clusters would be 190 nm and 250 nm for virus and SGR respectively. 
4.3.7     NS5A clusters around lipid droplets 
Fluorescence labelling of lipid droplets revealed an association with NS5A protein 
clusters (Figure 4.20). Observations with SGRs and HCV infected cells identified 
NS5A protein clusters surrounding regions in the reconstructed image absent of 
other NS5A localisations. Magnification of the corresponding bright-field region 
revealed light diffractive spherical structures that could be labelled with a lipid 
droplet dye (Figure 4.20A). Mapping of these putative lipid droplets onto the 
3D-dSTORM image revealed a number of NS5A protein clusters in close 
association, or in neighbouring locations to lipid droplets (Figure 4.20B, circles and 
arrows, respectively). The association of NS5A with lipid droplets is well 
documented during the HCV lifecycle (Appel et al., 2008; Masaki et al., 2008; Zayas 
et al., 2016). Interestingly, the 3D-dSTORM imaging presented here revealed that 
discrete protein clusters are associated with lipid droplets whereas NS5A was 
previously thought to coat lipid droplets similar to core (Miyanari et al., 2007).  
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Figure 4.18: Distance of localisations in clusters from cluster centroid position. 
A: Diagram illustrating Euclidean distance measurement of cluster localisation to 
centroid position. 1) Cluster centroid determined, red cross. 2) Euclidean distance 
(δ) between cluster localisation and centroid calculated, black arrow. 3) Euclidean 
measurement repeated for all localisations in every cluster. B: Euclidean distance 
histogram (5 nm bins) from localisation position to centroid. Data from 3 cells with 
2,062 and 1,266 clusters containing 554,079 and 218,040 localisations for 
SGR-Neo-JFH1 and JFHcc respectively. The peak of the skewed right distribution 
(δMODE) for each sample is indicated. 
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Figure 4.19: Architecture of individual protein clusters. 
Individual clusters isolated from 3D-dSTORM reconstructed images. A-C from 
SGR-Neo-JFH1 harbouring HuH7 cells. D-F from JFHcc infected cells. Left panel; z 
projection through entire volume. Right panel; 300 nm thick cross-section. Arrow 
heads indicate hollow core structures of NS5A proteins clusters. Arrows highlight 
clusters with a non-elliptical shape. Kernel density estimation (σ = 20 nm for x-y, 
30 nm for z) of localisation coordinates with a pixel size of 4 nm. Scale bar 100 nm. 
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Figure 4.20: Association of NS5A protein clusters with lipid droplets. 
A: Bright-field image of HuH7 cells infected with JFHcc for 24 h. Cells were labelled 
for lipid droplets. Box corresponds to panels on right of digitally enhanced 
bright-field and wide-field images. Arrows indicate positions of lipid droplets. 
B: 5 μm2 regions of interest from SGR-Neo-JFH1 harbouring and JFHcc infected 
HuH7 cells, top and bottom panels respectively. Left panels, reconstructed 
3D-dSTORM images after kernel density estimation (σ = 20 nm in x-y, 30 nm in z) 
with 4 nm pixel bins. Sum of z slices 800 nm and 650 nm thick for SGR-Neo-JFH1 
and JFHcc, respectively. Right panels, correspond to digitally magnified bright-field 
region. Circles indicate putative lipid droplet locations. Arrows indicate NS5A 
protein clusters around the periphery, or closely associated, with putative lipid 
droplets. Scale bars are indicated.  
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4.3.8     NS3 clusters during HCV infection differ from NS5A 
dSTORM imaging showed that NS3 protein clusters within cells infected with HCV 
are significantly smaller than NS5A protein clusters (Figure 4.21 and Figure 4.22). 
Both proteins are involved in the HCV replication complex and NS3 and NS5A 
puncta colocalise by wide-field microscopy with a Pearson correlation >0.85 (Ross-
Thriepland and Harris, 2015). Similar to observations with NS5A, NS3 proteins 
clusters were resolved from diffraction limited puncta throughout the cytoplasm of 
infected cells. NS3 protein clusters were detected as dense regions of localisations 
within a comparable cellular distribution to NS5A (Figure 4.21D).  
The mean size of NS3 protein clusters was 62.1 ± 1.0 nm with a size range from 
45–72 nm. Interestingly, these sizes are closer to the observations of protein 
clusters from genotype 1b and 3a SGR studies than all previous genotype 2a NS5A 
sizes. Additionally, the quantity of NS3 localisations within clusters and the 
percentage of clusters observed were significantly lower than NS5A (Figure 4.22). 
To understand the organisation of NS3 within protein clusters, the distance to the 
centroid position was calculated (Figure 4.23A). The distribution exhibited the same 
skewed right profile as NS5A but a minimum expected distance of ~55 nm was 
smaller than measured for NS5A. This smaller distance correlates with the 
measured size of NS3 clusters which are significantly smaller than NS5A (Figure 
4.22). Closer inspection of individual NS3 clusters also revealed a hollow core 
phenotype, comparable to previous observations with NS5A but with a smaller 
overall hollow core size (Figure 4.23). This finding indicates the internal diameter 
between NS3 localisations within clusters is ~110 nm, which shares a hollow core 
phenotype like NS5A. 
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Figure 4.21: 3D-dSTORM imaging of NS3 in HuH7 cells infected with JFHcc. 
HuH7 cell infected with JFHcc for 24 h before fixation and immunofluorescence 
labelling for NS3. Samples were then imaged by 3D-dSTORM. A: Sum of slices, 
3.9 μm thick, from a representative 3D-dSTORM image reconstruction with 100 nm 
pixel bins in a 3D histogram from 289,015 localisations. B: Bright-field of cell in A. 
C: Wide-field of cell in A. D: 5 μm2 region of interest after kernel density estimation 
(σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel bins. Sum of z slices, 800 nm thick. 
Arrows illustrate NS3 protein clusters. Scale bars are indicated. E: Cumulative 
percentage of cluster size from two independent cells. Median and percentile 
values are indicated. 
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Figure 4.22: Comparison of NS3 and NS5A protein clusters 24 h.p.i. of HuH7 cells 
with JFHcc. 
A: The mean distance between localisations in x-y within clusters. B: Mean number 
of localisations within each protein cluster. C: The percentage of localisations 
contained within clusters. Error bars represent the SEM. **** P <0.0001. 
  116 
 
Figure 4.23: Distance of localisations in NS3 protein clusters from centroid position. 
A: Euclidean distance histogram (5 nm bins) from localization position to cluster 
centroid. Data from 2 cells with 677 clusters containing 60,104 localisations. The 
peak of the skewed right distribution (δMODE) is indicated. B: Individual NS3 protein 
clusters isolated from 3D-dSTORM reconstructed images. Top panel, 150 nm cross 
section. Bottom panel, corresponding z projection. Arrow heads indicate hollow 
core structures of NS3 protein clusters. Scale bar 100 nm. 
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4.3.9     Effect of daclatasvir treatment 
Inhibition of HCV infection with daclatasvir (DCV) results in the gradual 
accumulation of NS5A puncta in a perinuclear region (Figure 4.24). Daclatasvir is a 
potent inhibitor of NS5A function with an unknown mechanism of action. Prior to 
treatment with DCV, NS5A puncta are observed distributed through the cytoplasm 
as observed previously (Figure 4.9). After 6–8 h treatment with 1 nM daclatasvir, 
condensation and an overall loss of fluorescent signal was observed (Figure 4.24). 
This phenotype in virus infected cells corroborates previous findings in NS3–5B 
expressing cells (Chukkapalli and Randall, 2014) and replicon harbouring cells 
(Reghellin et al., 2014). Treatment of HCV infected cells with DCV for 8 h was 
sufficient to induce a distinct phenotype observed by conventional microscopy and 
was thus taken forward for 3D-dSTORM imaging. 
Treatment of HCV infected cells with the NS5A inhibitor daclatasvir alters NS5A 
protein cluster morphology (Figure 4.25). Visual inspection of 3D-dSTORM images 
revealed little alteration in NS5A protein cluster morphology, but measurement of 
protein cluster size revealed a small but statistically significant reduction in cluster 
size (Figure 4.26A). In addition, , protein clusters contained a significant increase in 
the number of localisations contained within clusters indicating they contained a 
greater quantity of protein (Figure 4.26B). This finding correlated with a 
corresponding decrease in the single molecule localisation pool of NS5A with a 
higher percentage of localisations contained within clusters (Figure 4.26C). 
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Figure 4.24: Alterations in NS5A distribution during daclatasvir treatment. 
HuH7 cells were infected with JFHcc for 24 h before the addition of 1 nM DCV for 
the indicated time points. Cells were then fixed and processed for 
immunofluorescence staining with antibodies against NS5A. Scale bars are 
indicated.  
 
 
 
 
 
  119 
 
Figure 4.25: 3D-dSTORM imaging of NS5A in JFHcc infected cells treated with 
DCV. 
HuH7 cells 24 h.p.i. with JFHcc were treated with 1 nM DCV for 8 hour before 
fixation and immunofluorescence labelling of NS5A. A: Sum of z slices, 3.9 μm 
thick, from a representative 3D-dSTORM image reconstruction from 587,570 
localisations with 100 nm pixel bins in a 3D histogram. B: Bright-field image of cell 
in A. C: Wide-field image of cell in A. D: 5 μm2 region of interest after kernel density 
estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel bins. Sum of z slices, 
800 nm thick. Arrows illustrate NS5A protein clusters. Scale bars are indicated. 
E: Cumulative percentage of cluster size from two independent cells. Median and 
percentile values are indicated. 
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Figure 4.26: Comparison of NS5A protein clusters after treatment with DCV. 
A: The mean distance in x-y between localisations within clusters. B: Mean number 
of localisations within each protein cluster. C: The percentage of localisations 
contained within clusters. Error bars represent the SEM. * P <0.05, **** P <0.0001. 
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4.3.10     NS5A phosphorylation mutants 
Interference with NS5A phosphorylation alters the phenotype of NS5A protein 
clusters (Figure 4.27-3.30). NS5A is a multifunctional phosphoprotein that is 
regulated by phosphorylation with two species observed by SDS-PAGE, termed 
basal and hyperphosphorylated. The precise details of NS5A regulation by 
phosphorylation remain elusive and this section focused on characterising serine 
mutants previously described (Section 1.3.7.4) (Ross-Thriepland and Harris, 2014).  
Analysis of NS5A puncta from wide-field images reveals that S146A, S146D and 
S225D all retain the diffuse distribution of NS5A protein clusters throughout the 
cytoplasm. S225A on the other hand exhibits a markedly different phenotype that is 
restricted to a perinuclear region. This phenotype was previously reported for NS5A 
and is additionally characterised by an impairment in replication (Ross-Thriepland 
and Harris, 2014).  
The protein cluster size increased for both S146A and S146D mutations from 
113.8 ± 1.7 nm for SGR-Neo-JFH1 to 137.1 ± 2.1 nm and 135.3 ±1.7 nm for 
SGR-Neo-JFH1 [S146A] and SGR-Neo-JFH1 [S146D] respectively (Figure 4.31). 
The S146A mutant exhibits the biggest differences with ~30% more localisations in 
a cluster than wildtype, compared to ~15% more for S146D. Both mutants contain a 
greater number of clustered localisations than wildtype, although S146D has a 
larger single molecule population (Figure 4.31C).  
Larger irregular-shaped fluorescence structures observed for S225A in a 
peri-nuclear region by wide-field appear to be formed from collections of small 
clusters grouping together when imaged by 3D-dSTORM (Figure 4.29A and D 
arrowheads). The S225D protein cluster size is smaller (104.8 ± 1.7 nm) than 
wildtype whereas the S225A is larger (132.0 ± 2.9 nm). However, both populations 
have more localisations within clusters and a greater percentage of clusters 
compared to wildtype (Figure 4.31). 
 
 
 
 
 
  122 
 
Figure 4.27: 3D-dSTORM imaging of SGR-Neo-JFH1 with S146A phosphorylation 
mutation. 
Cells stably harbouring SGR-Neo-JFH1 [S146A] were fixed and processed for 
immunofluorescence. Cells were stained with NS5A antibody for 3D-dSTORM 
imaging. A: Sum of z slices, 3.9 μm thick, from a representative 3D-dSTORM image 
reconstruction with 100 nm pixel bins from 689,802 localisations in a 3D histogram. 
B: Bright-field image of cell in A. C: Wide-field image of cell in A. D: 5 μm2 region of 
interest after kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel 
bins. Sum of z slices, 800 nm thick. Arrows illustrate NS5A protein clusters. Scale 
bars are indicated. E: Cumulative percentage of cluster size from three independent 
cells. Median and percentile values are indicated. 
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Figure 4.28: 3D-dSTORM imaging of SGR-Neo-JFH1 with S146D phosphorylation 
mutation.  
Cells stably harbouring SGR-Neo-JFH1 [S146D] were fixed and processed for 
immunofluorescence. Cells were stained with NS5A antibody for 3D-dSTORM 
imaging. A: Sum of z slices, 3.9 μm thick, from a representative 3D-dSTORM image 
reconstruction with 100 nm pixel bins from 570,379 localisations in a 3D histogram. 
B: Bright-field image of cell in A. C: Wide-field image of cell in A. D: 5 μm2 region of 
interest after kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel 
bins. Sum of z slices, 650 nm thick. Arrows illustrate NS5A protein clusters. Scale 
bars are indicated. E: Cumulative percentage of cluster size from three independent 
cells. Median and percentile values are indicated. 
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Figure 4.29: 3D-dSTORM imaging of SGR-Neo-JFH1 with S225A phosphorylation 
mutation. 
Cells stably harbouring SGR-Neo-JFH1 [S225A] were fixed and processed for 
immunofluorescence. Cells were stained with NS5A antibody for 3D-dSTORM 
imaging. A: Sum of z slices, 3.9 μm thick, from a representative 3D-dSTORM image 
reconstruction with 100 nm pixel bins from 641,609 localisations in a 3D histogram. 
B: Bright-field of cell in A. C: Wide-field of cell in A. D: 5 μm2 region of interest after 
kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel bins. Sum of 
z slices, 800 nm thick. Arrows illustrate NS5A protein clusters. Scale bars are 
indicated. E: Cumulative percentage of cluster size from two independent cells. 
Median and percentile values are indicated. 
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Figure 4.30: 3D-dSTORM imaging of SGR-Neo-JFH1 with S225D phosphorylation 
mutation. 
Cells stably harbouring SGR-Neo-JFH1 [S225D] were fixed and processed for 
immunofluorescence. Cells were stained with NS5A antibody for 3D-dSTORM 
imaging. A: Sum of z slices, 3.9 μm thick, from a representative 3D-dSTORM image 
reconstruction with 100 nm pixel bins from 354,952 localisations in a 3D histogram. 
B: Bright-field of cell in A. C: Wide-field of cell in A. D: 5 μm2 region of interest after 
kernel density estimation (σ = 20 nm in x-y, 30 nm in z) with 4 nm pixel bins. Sum of 
z slices, 800 nm thick. Arrows illustrate NS5A protein clusters. Scale bars are 
indicated. E: Cumulative percentage of cluster size from three independent cells. 
Median and percentile values are indicated. 
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Figure 4.31: Comparison of NS5A phosphorylation mutation. 
A: The mean distance in x-y between localisations within clusters. B: Mean number 
of localisations within each protein cluster. C: The percentage of localisations 
contained within clusters. Error bars represent the SEM. * P <0.05, ** P <0.01, *** P 
<0.001, **** P <0.0001, all compared to wildtype. 
  127 
4.4     Discussion 
Within this chapter, I set out to characterise the hepatitis C virus replication complex 
organisation and architecture, using the localisation microscopy techniques of 
3D-PALM and 3D-dSTORM. A comparison between PALM and dSTORM 
demonstrated a reduced single molecule population and the observation of more 
protein cluster structures in dSTORM imaging (Figure 4.12). A key finding from this 
study was the clear difference in the organisation of NS5A and NS3 within clusters 
(Figure 4.18 and Figure 4.23), as well as the arrangement of protein clusters 
around lipid droplets (Figure 4.20). Additionally differences were seen between 
HCV genotypes; 2a was able to form larger and denser protein clusters than either 
1b or 3a (Figure 4.15). Finally, interference of NS5A protein function by 
pharmacological inhibition (Figure 4.24), or manipulation of protein phosphorylation, 
both produced distinct phenotypes compared to wildtype (Figure 4.31). 
4.4.1     DBSCAN analysis of clusters 
Single molecule localisation microscopy offers the ability to study biological 
molecules and processes in the native environment from fluorescence imaging at 
the nanometer scale. In contrast to conventional microscopy, the resultant data is a 
multidimensional array of coordinates that can be plotted to render images with 
much higher resolution (Baddeley et al., 2010). However, image rendering has the 
potential to lose or obscure important information about the sample or produce 
spurious structures (Baddeley et al., 2010). Instead, exploring the mathematical 
relationship of localisation positions provides information at the single-molecule 
level and avoids the need for image rendering (Nicovich et al., 2017). 
To identify clusters of localisations for further characterisation, the DBSCAN 
algorithm was used (Ester et al., 1996) (Figure 3.32D). DBSCAN identifies clusters 
by detecting density differences between clustered points and the background, 
making it particularly well-suited to SMLM (H. Deschout et al., 2014; Nicovich et al., 
2017). In this study, the algorithm was able to efficiently identify clusters of varying 
density and size, which allowed its application across different sample conditions. 
DBSCAN analysis of SMLM images have been documented by a number of groups 
and prove a robust method of cluster identification in SMLM (Bar-On et al., 2012; 
Endesfelder et al., 2013; Itano et al., 2014; Nan et al., 2013; Pertsinidis et al., 
2013). However, a drawback to DBSCAN is the requirement of user selected 
variables for the size of the search query (ε) and the number of points (min points). 
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A number of other clustering algorithms are available which have been applied to 
the study of SMLM and all define clusters differently. K-means clustering partitions 
data into a user defined number of clusters by classifying each point into the cluster 
with the nearest centroid (Lloyd, 1982). However, the number of potential clusters 
are often unknown in advance with SMLM and there is no theoretical way to find the 
optimum number (Lloyd, 1982). Additionally, K-means is a partitioning algorithm, 
therefore noise is incorporated into clusters. The mean shift is another 
centroid-based algorithm which locates the maxima of a density function (Fukunaga 
and Hostetler, 1975). A kernel function, typically Gaussian, is used to determine the 
weight of nearby points for re-estimation of the mean in an iterative process until 
convergence. This process can detect arbitrary shaped clusters like DBSCAN, 
however as an iterative process it is typically much slower and relies on a high data 
density that exhibits a well-defined gradient to the cluster center (Fukunaga and 
Hostetler, 1975). 
Ripley’s K and pair correlation functions (PCF) (Figure 3.32A–B) have been 
explored for SMLM clustering and provide information on the length-scale of 
clusters (Owen et al., 2010; Ripley, 1977; Sengupta et al., 2011; Sengupta and 
Lippincott-Schwartz, 2012). These measure the average number of extra 
localisations within a given radius of each point, providing a measure of the overall 
clustering and average cluster size in a sample or region of interest.  
However, analysing the ensemble average undermines the benefits of SMLM when 
information about individual clusters provides information about the distribution of 
the underlying biology. Segmentation of individual clusters by Ripley’s H function 
followed by interpolation to a regular grid and thresholding allows conventional 
image-analysis methods to be performed on SMLM data (Getis and Franklin, 1987; 
Owen et al., 2010). Adaptation using Bayesian inference produces optimal radius 
selection and threshold values after evaluating cluster segmentation against a 
model (Griffié et al., 2016; Rubin-Delanchy et al., 2015). However, this approach 
does require a high density of points across the image and suffers from the 
drawbacks of image rendering (Baddeley et al., 2010). 
Another approach for image visualization, and more recently cluster segmentation, 
uses Voronoi and Delaunay diagrams (Figure 3.32E) (Andronov et al., 2016; 
Baddeley et al., 2010; Levet et al., 2015). These are formed of polygons with edges 
that are equidistant between neighbouring points. The area of polygons is inversely 
proportional to the local density and can be thresholded to identify clusters 
(Andronov et al., 2016; Levet et al., 2015). 
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Figure 4.32: Diagrams illustrating different clustering algorithms. 
A: Nearest-Neighbour measures pairwise distances (red lines, inset) between the 
closest neighbour points (Clark and Evans, 1954). The histogram of the measured 
data (orange) indicates shorter nearest-neighbour distances than a random 
distribution of points with the same density (purple). B: Ripley’s K measures the 
point density for each point as a function of circle radius (green circle, inset) (Ripley, 
1977). The peak at 170 nm indicates clustering at this length scale. C: The 
pair-correlation approach is similar to Ripley’s K but the circles are replaced by 
concentric tori with width δr (inset, blue) (Sengupta et al., 2011). D: DBSCAN 
groups points together in a defined neighbourhood ε that have at least min points 
(Ester et al., 1996). Clustered points are coloured according to their cluster identity, 
noise points are grey. E: A mesh representation with Voronoi polygons (blue lines) 
and the Delaunay triangulation (orange lines, inset) (Andronov et al., 2016; 
Baddeley et al., 2010; Levet et al., 2015). Clusters can then be segmented based 
on the inverse relationship of density with polygon size (green). Reproduced from 
Nicovich et al., 2017. 
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A limitation to all the above approaches is the input of parameters or thresholds 
with which to segment images for analysis at some stage during the process. 
DBSCAN is also sensitive to parameter selection and choices should be made 
using domain knowledge. In this study the search radius was set to 150 nm, the 
size of smaller membrane structures produced by HCV. Adaptations to DBSCAN 
have been developed such as OPTICS (ordering points to identify clustering 
structure) (Ankerst et al., 1999) and DeLi-Clu (density-link clustering) (Achtert et al., 
2006). These are designed to perform like DBSCAN but aim to eliminate the need 
to specify min points and ε. Continued investigations into clustering the SMLM 
produced here for HCV will explore these algorithms in the future to reduce user 
bias and characterise the data using different approaches. 
4.4.2     The internal architecture of HCV replication complexes 
A major aim of this investigation was to characterise the internal architecture of 
HCV replication complexes. The distance of localisations within clusters to the 
cluster centroid revealed two distinct distributions for NS5A and NS3. In both cases 
a defined minimum distance was observed which tailed off at increasing distance 
from the centroid; the minimum diameter was 110 ± 5 nm for NS3 and 190 ± 5 nm 
for NS5A. 
All HCV proteins are known to be membrane associated (Moradpour et al., 2003), 
and this distribution of protein molecules likely corresponds to membrane 
associated NS3 and NS5A molecules around either the interior or exterior of DMV. 
Although the orientation of proteins with respect to membranes cannot be explicitly 
determined from these images, the sizes correlate well with the known size range of 
HCV DMV produced during infection (Ferraris et al., 2010; Romero-Brey et al., 
2012). The identification of purified DMV containing HCV polymerase activity, which 
is resistant to protease and nuclease treatment before disruption of the membrane, 
suggests that HCV non-structural proteins are sequestered inside (Paul et al., 
2013).  
One explanation for the observed size differences between NS3 and NS5A are that 
each protein is associated with different DMV sizes. Although this is unlikely as the 
full complement of NS3–5B constitutes the replication complex and is required for 
genome replication (Lohmann et al., 1999), a high degree of colocalisation between 
NS3 and NS5A is observed by wide-field (Gosert et al., 2003; Ross-Thriepland and 
Harris, 2014), and specific interactions have been observed between the non-
structural proteins (David et al., 2015; Paredes and Blight, 2008; Shimakami et al., 
2004; Zhang et al., 2005).  
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A second explanation suggests that each protein is associated with the same DMV 
although some of the protein is localised to different sides of the membrane (Figure 
4.34). In the model proposed, NS5A is localised to the exterior of DMV on the 
cytosolic side (Figure 4.34B). The theoretical distance of NS5A from the cluster 
centroid is approximately 102.1 nm. This is calculated from the measured distances 
of NS3 and the expected displacement distance of NS5A if antibody labelled and 
oriented on the opposite side of the membrane (Figure 4.34A). This theoretical 
distance is in good agreement with the measurements made by dSTORM of 
95 nm ± 2.5 nm.  
The association of NS5A on this side of the membrane has a number of 
consequences for HCV infection. Domain III of NS5A is reported to interact with 
core on lipid droplets (Appel et al., 2008; Masaki et al., 2008; Miyanari et al., 2007; 
Zayas et al., 2016). Accordingly, DMV are known to be in close association with 
lipid droplets (Romero-Brey et al., 2012), and protein clusters observed by 
dSTORM were also observed in close association (Section 4.3.7). The presentation 
of NS5A on the surface of DMV may facilitate the localisation of replication factories 
to sites of HCV assembly through interactions with core. In comparison, the 
remaining non-structural proteins inside the DMV are protected from cellular innate 
immune detection of replication intermediates such as double stranded RNA (Paul 
and Bartenschlager, 2015).  
To experimentally validate this model a number of key experiments need to be 
explored. Firstly, multi-colour dSTORM imaging (Erdelyi et al., 2013; Lampe et al., 
2012; Zhao et al., 2015) of NS5A and NS3 is required to confirm whether the 
protein clusters observed individually in this study are associated structures or 
independent from each other. Secondly, biochemical studies such as selective 
permeabilisation of the host cell membrane followed by either, immunofluorescence 
imaging, or protease digestion, would identify cytosolic exposed NS proteins in 
HCV infected cells.  
Proteinase K protection assays have been reported for HCV sub-genomic replicon 
harbouring or infected cells (Miyanari et al., 2003; Paul et al., 2013; Quinkert et al., 
2005). These studies identified that a small proportion, <5%, of each NS protein 
remains protease resistant before membrane disruption with detergents, yet 
accounts for the full replicase activity (Quinkert et al., 2005). Therefore, the HCV 
NS proteins are proposed to reside on both cytosolic exposed and cytosolic 
protected membranes. However, careful examination of the reported results 
indicate that NS5A is more susceptible to proteinase K digestion, and therefore 
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more exposed, than the other NS proteins when lower concentrations of proteinase 
K are used (Figure 4.33).  
Immunogold labelling experiments of DMV in ultrathin sections, or purified from 
HCV infected cells, have previously been exploited to confirm the association of 
HCV NS proteins with virus induced membrane structures (Ferraris et al., 2010; 
Paul et al., 2013). However, the relative orientation of proteins about the purified 
membranes was not investigated extensively in these studies. Labelling of NS5A 
was observed on both the internal and external membrane faces, whereas NS3 and 
the majority of dsRNA was observed internally (Ferraris et al., 2010; Paul et al., 
2013). Reproduction of both proteinase K and immunogold labelling experiments 
with a quantitative approach to determine the relative orientations of each NS 
protein should be investigated in the future to rigorously test the proposed model. 
Along with 3D-dSTORM data presented here, the proteinase K and immunogold 
studies previously reported provide evidence in support of the model (Figure 4.34). 
The data indicate that the small proportion of each NS protein in a detergent 
sensitive environment provides replicase activity, explaining the requirement of 
NS3–5B for genome replication (Lohmann et al., 1999). The remaining NS5A, 
which is more susceptible to proteinase K digestion, is then oriented on the exterior 
of DMV in a cytosolic exposed environment facilitating interactions between NS5A 
and core for HCV assembly (Appel et al., 2008; Masaki et al., 2008; Miyanari et al., 
2007; Zayas et al., 2016), or between other cellular proteins (Tripathi et al., 2013).  
4.4.3     Association of protein clusters with lipid droplets 
A second finding from dSTORM imaging was the identification of HCV NS5A 
protein clusters surrounding putative lipid droplets in SGR harbouring and virus 
infected cells (Figure 4.20). Although the location of lipid droplets were inferred from 
bright-field images, a number of protein clusters were observed in close proximity, 
either associated around the surface, or in the vicinity of proposed lipid droplets 
(Figure 4.20). This contrasts with previous reports by conventional light microscopy 
that show NS5A covering lipid droplets in a localisation similar to core (Miyanari et 
al., 2007). 
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Figure 4.33: Susceptibility of NS proteins to proteinase K digestion. Digitonin 
permeabilised cells were incubated with proteinase K at varying concentrations 
(0 μg/ml lane 1, 1 μg/ml lane 2, 5 μg/ml lane 3, 10 μg/ml lane 4, 50 μg/ml lane 5 
and 100 μg/ml lane 6). Asterisk denotes the position of calnexin NH2-terminal 
segment located in the ER lumen. BiP/Grp78 which is located in the ER lumen was 
used as a negative control for proteinase K digestion. Reproduced from (Miyanari et 
al., 2003). 
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It is well documented that HCV requires the lipid droplet as a scaffold for virion 
assembly (Ogawa et al., 2009; Paul et al., 2014). Light and electron microscopy 
studies have identified that DMV are closely associated with the ER and lipid 
droplets in the membranous web (Egger et al., 2002; Romero-Brey et al., 2012; 
Targett-Adams et al., 2008a). Future studies exploiting multi-colour dSTORM with 
specific labelling of lipid droplets are required to confirm the association of HCV NS 
proteins. Three-colour super-resolution imaging of the HCV assembly site around 
lipid droplets have already been investigated with core and E2 labelling (Eggert et 
al., 2014). 
These results from 3D-dSTORM in this study fit with the proposed model of HCV 
replication complexes in close association with lipid droplets, thereby allowing tight 
regulation of HCV replication and assembly (Masaki et al., 2008; Romero-Brey et 
al., 2012; Zayas et al., 2016). 
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Figure 4.34: Revised model of HCV replication complex formation. 
A: Illustration of non-structural protein organisation on different sides of DMV 
membrane with detection of proteins by labelled primary antibodies in dSTORM. 
The diameter of non-structural proteins was measured as the minimum diameter of 
a sphere occupied by the protein volume (Erickson, 2009), 5.5 nm for NS3 and 
3.6 nm for NS5A domain I. Antibody (red) displacement of 10 nm (Huang et al., 
2008b), and average localisation precision (yellow) of 20 nm are indicated. The 
fluorescent dye is assumed to be centrally located on the antibody during random 
labelling of amines. Double membrane vesicle diameter of 8 nm corresponds to two 
4 nm thick ER membranes (Mitra et al., 2004). The measured and theoretical 
distances to the cluster centroid are indicated. B: Left, original model of HCV 
non-structural proteins in a macromolecular protein assembly inside DMV. Right, 
revised model of non-structural protein organisation around DMV as informed from 
dSTORM imaging. Images are drawn to scale. 
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4.4.4     HCV replication complexes are organised differently between 
genotypes 
An investigation of NS5A protein clusters from different genotypes revealed distinct 
differences. Both genotype 1b and 3a were observed in protein clusters smaller 
than the previously characterised genotype 2a, which also contained more NS5A 
localisations.  
The epitope for the 9E10 antibody has been localised to residues 414–428 of NS5A 
domain III which are 100% conserved between the genotypes used in this study 
(Galli et al., 2013; Scheel et al., 2012). Therefore, the differences in protein cluster 
size observed are likely not due to changes in antibody affinity but represent 
phenotypic differences in the organisation of NS5A between different genotypes. 
The genotype 2a isolate, JFH1, is currently the only isolate which undergoes the full 
replication cycle in cell culture without the addition of cell culture adaptive mutations 
(Wakita et al., 2005). Both genotype 1b and 3a SGRs require selective pressure to 
obtain cell populations harbouring SGRs for each genotype (Lohmann et al., 1999; 
Saeed et al., 2012). Therefore, JFH1 is much more efficient in establishing 
replication in cell culture than other genotypes. The precise mechanisms for this are 
not understood but the identification of larger and denser NS5A protein clusters for 
genotype 2a compared to 1b or 3a, in stable SGR harbouring cells, indicate a more 
efficient and robust establishment of replication complexes (Figure 4.15). 
Additionally, this efficiency of DMV formation may be an attribute associated with 
NS5A alone. Expression of NS5A in cells is reported to induce formation of DMV in 
the absence of other non-structural proteins (Paul et al., 2013; Romero-Brey et al., 
2012). 
This hypothesis is also supported by the increased NS5A cluster sizes observed in 
replicon compared to virus infection. Cells stably harbouring replicons have an 
average protein cluster diameter of 250 ± 5 nm. Accordingly, at later times post 
infection larger (~300 nm) multi-membrane vesicles were observed within infected 
cells (Romero-Brey et al., 2012). 
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4.4.5    Effect of daclatasvir treatment 
The extremely potent NS5A inhibitor DCV currently has an unknown mechanism of 
action as NS5A does not have a known enzymatic activity. Current models propose 
that DCV binding to NS5A alters its dimerisation state, ultimately disrupting HCV 
RC formation (Berger et al., 2014; McGivern et al., 2014) or RNA binding (Ascher et 
al., 2014). A number of NS5A dimer conformations have been proposed based on 
the X-ray crystallographic structures of domain I (Lambert et al., 2014; Love et al., 
2009; Tellinghuisen et al., 2005), and the symmetrical structures of daclatasvir and 
related inhibitors. Molecular dynamic simulation studies indicate that this interaction 
may occur at the dimer interface in close association with the cell membrane 
(Lambert et al., 2014). However, which, if any, dimer conformations are functional 
during HCV infection remains to be experimentally determined.  
The increased quantity of NS5A localisations observed within protein clusters after 
DCV treatment fit the current hypothesis that DCV binding stabilises a dimer of 
NS5A, thereby trapping and/or immobilising NS5A in an inactive replication 
complex (Berger et al., 2014; Gao et al., 2010). 72 h treatments with DCV result in 
a condensed and immobile phenotype of NS5A puncta suggesting stalling of 
replication assembly at an early step (Chukkapalli and Randall, 2014).  
Expansion of the studies presented here for virus infection and daclatasvir 
treatment are required to monitor how protein cluster size changes during the 
course of infection, and how NS5A is altered during the earlier hours following 
daclatasvir treatment, for example at 2 or 4 h. Correspondingly, HCV virion 
production is inhibited as early as 2 h after treatment of cells with DCV (McGivern et 
al., 2014). This has been proposed to occur through some displacement of NS5A 
from lipid droplets, or inhibition of RNA binding which uncouple transfer of HCV 
RNA from replication complexes to core (Ascher et al., 2014) A precise description 
of lipid droplet positions was beyond the scope of this investigation but two-colour 
imaging approaches using NS5A and lipid droplet staining are under investigation 
to address how the organisation of NS5A in protein clusters around lipid droplets is 
altered upon inhibition with DCV.  
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4.4.6    Roles of phosphorylation during HCV infection 
Manipulation of NS5A phosphorylation resulted in a number of phenotypic 
differences in NS5A proteins cluster organisation by 3D-dSTORM. Mutations of 
S146 to either ablate phosphorylation at the site with an alanine, or mimic with an 
aspartate resulted in increased NS5A cluster sizes which contained more 
localisations that wildtype. In transient replication assays both S146 mutants are 
capable of wildtype replication, but a reduction in the hyperphosphorylated species 
is observed (Ross-Thriepland and Harris, 2014). The molecular details and purpose 
of hyperphosphorylation within cells remain elusive. Genotype 1b appears to be 
dependent on hyperphosphorylation for efficient replication, whereas this is not the 
case for genotype 2a (Appel et al., 2005; Neddermann et al., 2004). Intriguingly, in 
all genotypes except 2a and 1a, S146 is an alanine (Ross-Thriepland and Harris, 
2014). Therefore, this phosphorylatable serine may provide an additional level of 
replication control such as the regulation of NS5A dimer formation (Ross-Thriepland 
and Harris, 2014).  
Mutation of S225 had a more pronounced impact on NS5A, with an accumulation of 
NS5A in a perinuclear region (Figure 4.29) (Ross-Thriepland et al., 2015). These 
were observed as groups of clusters localised in a similar region. The absence of 
S225A distributed throughout the cytoplasm indicates a deficient trafficking and 
mobility function of NS5A. Accordingly, the association of replication complexes 
with actin filaments and microtubules are reported to depend on NS3 and NS5A 
(Lai et al., 2008). The impaired but competent replication kinetics for this mutant 
indicate that S225A retains the ability to form active replication complexes (Ross-
Thriepland and Harris, 2014). The deficiency of this mutant may be associated with 
a reduced re-localisation and interaction with lipid droplets. Accordingly, the 
quantity of lipid droplets in S225A replicating cells was significantly lower than 
wildtype and the corresponding S225D (Ross-Thriepland et al., 2015). To quantify 
the association of S225A with lipid droplets, 2-colour dSTORM imaging methods 
are currently under investigation to simultaneously visualise both NS5A and lipid 
droplet in SMLM. 
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4.4.7    Model of HCV replication complexes 
The data reported in this chapter from localisation microscopy analysis of SGR 
harbouring and HCV infected cells has provided additional information on the 
organisation and architecture of the HCV replication complex. From our findings a 
revised model of HCV replication complex organisation is proposed (Figure 4.35).  
dSTORM imaging indicates that NS3 may be associated on the membrane on the 
interior of DMV, whereas NS5A is localised on the exterior (Figure 4.34; Figure 
4.35, step 2). Inhibition of NS5A with DCV may arrest replication complex assembly 
(Figure 4.35, step 2) (Berger et al., 2014). The observed close association of 
replication complexes with lipid droplets may be instigated by interactions of NS5A 
with core (Appel et al., 2008; Masaki et al., 2008; Miyanari et al., 2007; Zayas et al., 
2016). Thus positioning replication complexes spatially adjacent to sites of HCV 
virion assembly (Figure 4.35, steps 3–4). Close association of replication factories 
with lipid droplets facilitates the transport of HCV RNA into sites of virion assembly. 
The precise mechanism of this step remains elusive but is proposed to involve the 
RNA binding properties of NS5A (Foster et al., 2010), along with its known 
interactions with other non-structural proteins (David et al., 2015; Shimakami et al., 
2004) and core (Masaki et al., 2008; Miyanari et al., 2007; Zayas et al., 2016), 
thereby bridging the space between replication complexes and sites of assembly. 
Alteration of the NS5A conformation and reduction of RNA binding by DCV (Ascher 
et al., 2014), reduces the transport of RNA from replication complexes to sites of 
assembly thus producing a rapid arrest in virion production (McGivern et al., 2014). 
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Figure 4.35: Model of HCV replication. 
Step 1: HCV polyprotein is translated and cleaved into individual proteins on the 
ER. Step 2: Formation of HCV replication factories with NS5A on exterior and 
NS3/4A, NS4B and NS5B on the interior.  Step 3–4: NS5A interactions with core 
mediate close association of replication factories with sites of virus assembly.  
Step 5: NS5A mediated transport of RNA to core at sites of HCV assembly.  
Step 6: Budding of HCV virions into the ER and trafficking through endosome-Golgi 
pathway releasing progeny virions. 
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Chapter 5 - The PI3P binding protein 
DFCP1 is required for HCV replication 
complex formation 
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5.1     Aims and Objectives 
The manipulation and repurposing of cellular membranes for virus propagation is 
common amongst all positive strand RNA viruses studied to date (Romero-Brey 
and Bartenschlager, 2014). However, the origin of HCV replication factories and the 
corresponding cellular interaction partners remain poorly defined.  
The autophagosome biogenesis pathway has the potential to supply the DMVs 
required for HCV replication. However, the precise mechanisms with which HCV 
interacts with the autophagy machinery remain poorly defined.  
To address this, a combination of pharmacological inhibition, genetic ablation and 
fluorescence imaging were used. The data presented here correspond to the 
imaging studies undertaken in the investigation, excluding the live cell imaging. All 
other experimentation was carried out by Bjorn-Patrick Mohl and is reported 
alongside this microscopy analysis in Mohl et al. 2016. 
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5.2     Introduction 
The production of double and multi-membrane vesicles is a well-documented 
phenotype of HCV infection both in cell culture and patients (Ait-Goughoulte et al., 
2008; Dreux et al., 2009; Rautou et al., 2011; Sir et al., 2008). The large quantities 
of vesicles produced during infection have commonly been referred to as the 
“membranous web”, a convoluted system of vesicles in a perinuclear region of 
infected cells (Figure 1.10, Figure 4.1) (Egger et al., 2002). This clustering of 
vesicles, mainly double-membraned vesicles (DMVs), is proposed to be the site of 
HCV genome replication (Gosert et al., 2003; Miyanari et al., 2003). Recent studies, 
along with work presented here in Chapter 3, have sought to characterise these 
structures in molecular detail to better understand their role during the HCV lifecycle 
(Paul et al., 2013; Pérez-Berná et al., 2016; Romero-Brey et al., 2012).  
The double membranous architecture of these vesicles has led to the hypothesis 
that these structures are derived from the cellular process of autophagy. Importantly 
this process, which is normally involved in maintaining cell homeostasis, is 
characterised by the formation of DMVs, termed autophagosomes (Tanida, 2011). 
During times of nutrient starvation or stress these DMVs subsequently fuse with 
lysosomes facilitating the degradation and re-cycling of the vesicular contents. In 
higher eukaryotes, autophagy can also be utilised by the cell for development, 
immunity and eliminating intracellular microorganisms (Choi et al., 2013; Deretic et 
al., 2013).  
The unfolded protein response (UPR) is one method of autophagy induction 
whereby ER stress results in DMV formation which sequester misfolded proteins 
(Ding et al., 2007; Ron and Walter, 2007). HCV has been shown to induce the UPR 
(Chan and Egan, 2005; Ke and Chen, 2011; S. Li et al., 2009; Shinohara et al., 
2013), and this process was proposed as the subsequent induction of autophagy by 
HCV as inhibition of the UPR results in a decrease of HCV RNA levels (Sir et al., 
2008). However, more recent work in the lab identified the induction of autophagy at 
4 h post infection with the UPR not observed until 48 h (Mohl et al., 2012). Critically, 
although autophagy is induced by HCV, the fusion of autophagosomes with 
lysosomes is inhibited (Sir et al., 2008). 
A growing body of evidence points to autophagy as an important process in HCV 
replication. This parallels with observations for other positive strand RNA viruses 
where subversion of autophagy facilitates viral propagation (Romero-Brey and 
Bartenschlager, 2014), a notable example is poliovirus (Taylor and Kirkegaard, 
2007). Downregulation or chemical inhibition of proteins involved in autophagosome 
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formation such as Atg5, Atg7, Atg4B, LC3 and Beclin1 all result in reduced HCV 
replication (Dreux et al., 2009; Mizui et al., 2010; Sir et al., 2008). Additional reports 
also suggest that HCV may upregulate autophagy proteins during its lifecycle, 
specifically Beclin1 by NS5A (Shrivastava et al., 2012). Sucrose gradient 
fractionation experiments have identified autophagosome-like membranes 
co-purifying with NS3 and NS5A, and immunogold labelling of EM sections 
revealed the presence of NS5A and dsRNA within LC3 positive DMVs (Ferraris et 
al., 2010).  
Other precipitation studies have isolated LC3 containing vesicles and shown they 
contain NS5A, NS5B and remain productive for HCV RNA generation (Sir et al., 
2012). Direct interactions between proteins have been observed biochemically 
through immunoprecipitation of NS4B and p7 (Aweya et al., 2013; Su et al., 2011) 
and yeast two-hybrid studies of NS5B (Guévin et al., 2010) which identified Vps34, 
Beclin1 and Atg5 interaction partners, respectively.  
Although strong biochemical evidence exists for direct protein interactions, 
conflicting data exists for colocalisation of proteins in microscopy studies. Studies 
using the GFP-LC3 fusion protein have provided evidence to support (Guévin et al., 
2010; Sir et al., 2012) or contest (Ait-Goughoulte et al., 2008; Dreux et al., 2009) 
the idea that HCV replication complexes are found on autophagosomes. However, 
the analysis of studies using transient expression of LC3 should be interpreted with 
caution as overexpression can cause re-localisation of LC3 into protein aggregates 
(Kuma et al., 2007). Data from our lab using endogenous staining of LC3 and NS5A 
suggest that replication complexes are not on autophagosomes (Mohl et al., 2012). 
This data agreed with previous findings that identified the Atg4B and Beclin1 
proteins as important for initial HCV RNA translation, however they were no longer 
required once infection is established (Dreux et al., 2009). 
Despite the current understanding about the “membranous web” and the interplay 
between HCV and autophagy, the biogenesis of the HCV replication complex 
remains to be fully elucidated. The expression of NS4B or NS5A alone within cells 
results in the production of DMVs, however no single protein is sufficient and the full 
complement of NS proteins are required for complete “membranous web” formation 
(Egger et al., 2002; Paul et al., 2013; Reiss et al., 2011; Romero-Brey et al., 2012; 
Su et al., 2011). It is currently thought that the DMVs are derived from ER 
membranes as EM studies have observed a close association between these two 
structures (Romero-Brey et al., 2012). This parallels with autophagy where the 
maturation of autophagosomes is reported to stem from specialised domains of the 
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ER (Axe et al., 2008; Bernales et al., 2006). In particular the recruitment of the class 
III phosphatidylinositol 3-kinase (PI3K) complex to mitochondrial-associated ER 
membranes (MAM) produces phosphatidylinositol 3-phosphate (PI3P) (Hamasaki et 
al., 2013). The PI3K complex subsequently generates a PI3P-rich region for 
recruitment of additional effector proteins, such as the double-FYVE-containing 
protein 1 (DFCP1) and WD-repeat protein-interacting phosphoinositide (WIPI) 
(Karanasios et al., 2013; Koyama-Honda et al., 2013; Polson et al., 2010; Ridley et 
al., 2001). Binding of these proteins gives rise to cup-like protrusions from the ER, 
called omegasomes, which provide the scaffold for expansion of the isolation 
membrane (phagophore); the membrane domain from which autophagosomes are 
produced (Axe et al., 2008; Polson et al., 2010). Recently the link between these 
effector proteins and the lipidation of LC3 (microtubule-associated protein light 
chain 3) with phosphatidylethanolamine (PE), a key process for the expansion and 
closure of the phagophore, has been elucidated (Dooley et al., 2014). 
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5.4     Results 
It was shown previously that HCV enhances the activity of class I PI3K by our lab 
(Street et al., 2004) and others (He et al., 2002). However, the importance of this 
has yet to be elucidated during HCV infection. The first step during autophagosome 
formation is the local production of PI3P on the ER membrane by the class III PI3K 
Vps34 (vacuolar protein sorting 34). Treatment of cells stably expressing a 
sub-genomic replicon with the well-known inhibitor of PI3K, wortmannin, resulted in 
a progressive loss of LC3-II over time, indicative of Vps34 inhibition, and a 
concurrent loss in NS5A protein and luciferase reporter levels (Mohl et al., 2016). 
These findings confirmed the requirement of HCV for autophagy, specifically the 
production of PI3P by Vps34, during infection.  
DFCP1 (double-FYVE-containing protein 1), and other PI3P binding proteins are 
then recruited to the local PI3P pool produced by Vps34 (Karanasios et al., 2013; 
Koyama-Honda et al., 2013; Polson et al., 2010; Ridley et al., 2001). These proteins 
provide the scaffold for expansion and closure of the ER membrane into 
autophagosomes (Axe et al., 2008; Dooley et al., 2014; Polson et al., 2010). 
Therefore, the role of these autophagosome biogenesis proteins during the HCV 
lifecycle was investigated by siRNA-mediated silencing in stable cell lines and 
during virus infection. Efficient silencing of either protein resulted in a loss of HCV 
replication in genotype 1b and 2a comparable to the HCV inhibitors cyclosporin A 
and daclatasvir (Mohl et al., 2016). These observations suggest that HCV 
replication is dependent on a functional autophagosome biogenesis pathway 
involving Vps34 and DFCP1. 
5.4.1     Validation of an mCherry-DFCP1 expression construct 
To address whether the HCV replication complex associates with DFCP1, an 
mCherry-DFCP1 expression construct was constructed by B.-P. Mohl (Mohl et al., 
2016) from an existing EGFP-DFCP1 expression plasmid (Axe et al., 2008), and its 
functionality validated (Figure 5.1). 
After induction of autophagy by thapsigargin, an increase in the appearance of LC3 
puncta was observed which exhibited overlapping fluorescence signals with the 
mCherry-DFCP1 (Figure 5.1). In comparison, both the LC3 and mCherry-DFCP1 
staining from DMSO or wortmannin treated cells were more diffuse and exhibited 
minimal colocalisation. Wortmannin is a well-known inhibitor of autophagy (Mohl et 
al., 2012), whereas thapsigargin is an inhibitor of the ER Ca2+-ATPase which 
induces ER stress and the induction of autophagy (Ogata et al., 2006). 
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Figure 5.1: Validation of an mCherry-DFCP1 construct as a marker for 
autophagosome formation. 
HuH7 cells were transfected with an mCherry-DFCP1 expression plasmid for 
forty-eight hours. Cells were then treated with vehicle (DMSO), thapsigargin (3 µM) 
or wortmannin (1 µM) for 3 h before fixation and autophagosome and nuclear 
staining with an LC3 antibody and DAPI. Scale bars, 5 µm. White boxes indicate 
magnified regions.  
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Figure 5.2: Colocalisation analysis from mCherry-DFCP1 expression plasmid 
validation.  
The mean Pearson correlation coefficient was determined from vehicle, 
thapsigargin and wortmannin treatment, from 6, 8 and 8 cells, respectively. Data 
represent the mean ± SD. Statistical significance measured by Welch’s unpaired 
t-test, *** P<0.0005, **** P<0.0001. 
 
The quantification confirmed the observations that there was a significant difference 
in fluorescence signal overlap between LC3 and mCherry-DFCP1 in autophagy 
stimulated and inhibited cells (Figure 5.2). The observation that mCherry-DFCP1 
localises to cytoplasmic puncta and colocalises with LC3 after the induction of 
autophagy, validate this construct for future microscopy studies. 
5.4.2     HCV replication complexes do not stably associate with 
DFCP1 during infection 
To address whether HCV replication complexes are associated with DFCP1 during 
infection, the localisation of NS5A (as a marker for replication complexes) and 
DFCP1 was investigated. There was no observable colocalisation of NS5A puncta 
with DFCP1 in cells replicating HCV (Figure 5.3). The absence of colocalisation 
was also observed in cells treated with the alternative PI3K inhibitor 
3-methyladenine (3MA). Intriguingly, the inhibition of PI3K in these cells did not 
block the process of virus-induced autophagy previously shown with wortmannin 
(Mohl et al., 2016).  
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The observation of NS5A puncta distributed throughout the cell is characteristic of 
NS5A localisation and confirmed HCV positive cells. Consistent with the induction 
of autophagy by HCV following infection, mCherry-DFCP1 localised to cytoplasmic 
puncta similar to uninfected cells treated with thapsigargin (Figure 5.1).  
The absence of any colocalisation between DFCP1 and HCV replication complexes 
suggest no direct interaction occurs between these two partners. This is supported 
in part by the inability to successfully pull-down either protein by 
co-immunoprecipitation (data not shown). However, an alternative hypothesis is 
that the interaction between DFCP1 and replication complexes are only required 
during the establishment of infection, therefore any interaction might be transient 
and short-lived. Accordingly, omegasomes are transient structures early in the 
process of autophagosome formation (Axe et al., 2008). This idea is supported by 
previously published work indicating that autophagy is required for the translation of 
incoming HCV genomes (Dreux et al., 2009). It was later shown that HCV 
translation requires active HCV RNA synthesis (Liu et al., 2012), which in turn 
requires a functional autophagosome biogenesis pathway (Mohl et al., 2016).  
To investigate the potential transient interaction between DFCP1 and NS5A, live 
cell imaging was carried out on mCherry-DFCP1 transfected cells ((Mohl et al., 
2016); Figures 6 and 7), subsequently infected with a HCV derivative containing an 
NS5A-GFP fusion at 24 hours post infection (Mohl et al., 2016; Schaller et al., 
2007). This analysis revealed a sub-population of puncta containing both NS5A and 
DFCP1. Over a period of 8 min there was the progressive accumulation of NS5A 
and DFCP1 into a distinct structure containing both proteins, followed by their 
eventual dissociation into two distinct structures (Mohl et al., 2016). These 
observations were comparable to the previously reported transient interaction of 
DFCP1 with LC3 in the formation of autophagosomes (Axe et al., 2008) and provide 
strong evidence to support the hypothesis that a short-lived interaction between 
replication complexes (NS5A) and omegasomes (DFCP1) are required in 
autophagosome formation. 
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Figure 5.3: HCV replication complexes do not stably colocalise with 
mCherry-DFCP1. 
HuH7 cells were transfected with mCherry-DFCP1 for 48 h prior to infection with 
Jc1 (Pietschmann et al., 2006) (0.5 f.f.u/cell) for 24 h. Before fixation, cells were 
treated with or without 0.1 mM 3-methyladenine (3MA) and subsequently stained 
for HCV replication complexes (NS5A) and nuclei (DAPI). Scale bars in insets 
2 µm. White boxes indicate magnified regions. 
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5.4.3     Incomplete colocalisation is observed between DFCP1 with 
NS5A or NS4B expression constructs 
This observed association between replication complexes and omegasomes might 
be a core function of one of the non-structural proteins. To investigate which HCV 
proteins contribute to the interaction, cells were transfected with different 
non-structural expression plasmids in combination with mCherry-DFCP1 (Figure 
5.4).  
All proteins were localised in bright punctate structures with a diffuse background 
staining throughout the cell. NS5A puncta were distributed evenly throughout the 
cytoplasm while NS4B-GFP was constrained to a more perinuclear region (Figure 
5.4). In all cases there was limited or incomplete colocalisation between the 
non-structural protein and DFCP1. The degree of colocalisation for each expression 
plasmid combination was subsequently derived using Mander’s overlap coefficients 
(Figure 5.5) NS3/5A colocalisation from cells stably expressing a SGR and 
target/DAPI overlap were used as positive and negative controls respectively. 
The expression construct data from at least 10 individual cells indicate that around 
15–20% of NS5A puncta colocalise with DFCP1 and up to 40% of DFCP1 overlaps 
with NS5A staining (Figure 5.5). For NS4B, ~20–30% of protein overlapped with 
DFCP1 and vice versa. During this analysis, differences were also observed 
between NS5A and NS4B. More NS4B signal overlapped with DFCP1 than NS5A, 
however DFCP1 colocalised more with NS5A (Figure 5.5). The known interaction 
between NS3 and NS5A results in at least 75% signal overlap for each protein with 
the other, whilst <5% of any target overlaps with DAPI staining (Figure 5.5). 
This quantitative data indicate that, albeit at low levels, there is a significant 
colocalisation of either N55A or NS4B with DFCP1, compared to the negative 
control, when expressed together within cells. 
5.4.4     Expression of WIPI2b, another PI3P effector protein in 
autophagosome formation 
Investigations so far have looked exclusively at DFCP1, but the formation of 
autophagosomes involves multiple proteins, and protein complex interactions. In 
order to investigate if HCV replication complexes also interact with WIPI2b, a 
GFP-WIPI2b fusion protein expression construct was obtained  (Dooley et al., 
2014) and transfected into HuH7 cells (Figure 5.6). WIPI2b has been reported to 
link LC3 conjugation, a key step in the maturation of autophagosomes, with PI3P 
synthesis at sites of autophagosome formation, by recruiting the LC3-conjugating 
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Atg12-5-16L1 complex (Dooley et al., 2014). Comparable to the reported 
phenotype, GFP-WIPI2b was distributed throughout the cytoplasm of transfected 
cells with an apparent ER localisation (Figure 5.6). After the stimulation of 
starvation-induced autophagy by Earle’s balanced salt solution (EBSS), discrete 
punctate structures could be observed within cells in a perinuclear region that were 
absent from wortmannin treated cells (white arrows in Figure 5.6).  
These initial experiments confirmed the ability of WIPI2b to be recruited to, punctate 
structures in HuH7 cells during starvation-induced autophagy. However, a major 
drawback from these experiments was the high expression levels of this protein in 
transfected cells. This made analysis challenging as only a limited number of 
discrete puncta where discernible above the background in stimulated cells. 
Additionally, a high GFP signal was still observed in a perinuclear region of cells 
treated with the PI3K inhibitor wortmannin. Considering the distribution of NS5A in 
HCV infected cells, an interpretation of colocalisation between these two proteins 
would be complicated by the high expression and background signal of 
GFP-WIPI2b. To address this, a cell line which stably expresses GFP-WIPI2b at 
low levels is currently under investigation. Unfortunately due to time constraints in 
this project a stable cell population for further investigation has not yet been 
established. 
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Figure 5.4: Incomplete colocalisation between NS5A or NS4B with DFCP1, either 
expressed alone or in the context of NS3–5B. 
HuH7 cells were transfected with expression plasmids for mCherry-DFCP1 and 
JFH-1 NS3-5B or NS5A or NS4B-GFP for 48 h. Cells were fixed and NS5A 
detected by indirect immunofluorescence. Scale bar in inset 2 µm. White boxes 
indicate magnified regions. Arrows highlight regions of fluorescence overlap 
between the two channels. 
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Figure 5.5: Colocalisation analysis of DFCP1 and non-structural protein expression 
constructs. 
Mander’s overlap coefficients were determined from >10 cells for each expression 
construct combination. Data represent the mean ± SD. Statistical significance 
measured by Welch’s unpaired t-test, * P <0.05, ** P <0.005, *** P <0.0005, 
**** P <0.0001. 
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Figure 5.6: Transient expression of GFP-WIPI2b. 
HuH7 cells were transfected with GFP-WIP2b for 48 h before vehicle, 
starvation-induced stimulation or pharmacological inhibition of autophagy with 
DMSO, EBSS or wortmannin, respectively. Scale bar in insets 3 µm. White boxes 
indicate digitally magnified region. White arrows highlight discrete GFP-WIPI2b 
puncta. 
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5.5     Discussion 
The results from this study provide strong evidence to support that an intact 
autophagosome biogenesis pathway is required in the formation of HCV replication 
complexes. The characteristic membranous web produced upon HCV infection was 
shown in an elegant EM study (Romero-Brey et al., 2012) to be mostly composed 
of DMVs derived from, or closely associated with, the ER. The similarities between 
HCV DMVs and autophagosomes strongly indicate they arise via a common 
biogenesis pathway. In agreement with this hypothesis, both pharmacological 
inhibition and siRNA mediated gene silencing revealed that the class III PI3K 
Vps34, and PI3P effector DFCP1, are key requirements for HCV replication (Mohl 
et al., 2016).  
The role of DFCP1 in HCV replication is previously undocumented, and the findings 
reported here confirm a previously reported role of Vps34 (Su et al., 2011). Taken 
together with the observation that HCV upregulates Beclin1 expression 
(Shrivastava et al., 2012) and that the corresponding inhibition studies reduce HCV 
replication (Dreux et al., 2009), the formation of the class III PI3K complex 
(Vps34-Vps15-Beclin1-Atg14L) appears to be critical for the establishment of HCV 
infection. It is worth noting however that a separate study found no effect of Vps34 
inhibition or silencing (Sir et al., 2012). Considering the diverse ways of autophagy 
induction and the stimulation of the UPR by HCV, the redundancy in 
autophagosome biogenesis may explain this observation. 
The mCherry-DFCP1 expression plasmid constructed for this study was 
comparable to a previously reported EGFP-DFCP1 expression construct (Axe et al., 
2008), and therefore a powerful tool for understanding the roles of omegasomes 
within cells using fluorescence microscopy. The investigation of both fixed and live 
cell imaging strongly suggest that DFCP1 is involved in the early stages of HCV 
replication, however it is not stably associated with HCV structures and therefore is 
only required for replication complex formation. A finding corroborated by previously 
documented studies showing an involvement of Atg4B and Beclin1 in initial HCV 
RNA translation (Dreux et al., 2009). The transient colocalisation of HCV replication 
complexes (NS5A) with DFCP1 is reminiscent of the LC3-DFCP1 interaction 
previously reported (Axe et al., 2008). In both cases fluorescent puncta association 
and dissociation occurs over a 10 min period. 
This study’s findings also agree with previously published literature regarding the 
involvement of NS5A and NS4B in DMV generation (Paul et al., 2013; Romero-Brey 
et al., 2012) as both proteins partially colocalise with DFCP1 when expressed within 
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cells. The colocalisation patterns, which at first were confusing, can be explained by 
the expression levels and localisation patterns of each protein. NS5A was localised 
throughout the cytoplasm whilst NS4B is constrained to a perinuclear region, a 
distribution most similar to DFCP1. Therefore a significant portion of NS5A 
occupies cytoplasmic space that DFCP1 does not. 
Previous reports have shown a direct interaction between HCV non-structural 
proteins and the autophagic machinery, in particular NS4B with Vps34 (Su et al., 
2011) and NS5B with Atg5 (Guévin et al., 2010). Unfortunately, previous attempts 
within the lab (co-immunoprecipitation studies conducted by Bjorn-Patrick Mohl) 
have failed to provide any biochemical evidence in support of a direct interaction 
between HCV proteins and DFCP1. Nonetheless, the live cell imaging would 
suggest that any interaction or association between the HCV non-structural proteins 
and DFCP1 would be short-lived. Therefore, biochemical investigations that enable 
detection of transient interactions, such as protein crosslinking (Yakovlev, 2009; 
Yang et al., 2010) and label transfer approaches (Horney et al., 2001; Lapinsky and 
Johnson, 2015), are better suited to addressing if there is a direct interaction 
between HCV and DFCP1. 
Finally, the roles of another PI3P effector downstream of PI3K in autophagosome 
formation, WIPI2b were investigated. Of particular note is the recent report of a 
direct association between WIPI2b and Atg16L1 (Dooley et al., 2014) therein linking 
the production of PI3P with the lipidation of LC3, a key step in the formation of 
autophagosomes. The results so far suggest that although viable, the expression 
levels of the GFP-WIPI2b from the expression construct require fine tuning to 
reproducibly observe omegasomes by fluorescence microscopy. Unfortunately due 
to time restrictions of this project work into this area is ongoing, with efforts towards 
selecting a stable cell line expressing GFP-WIPI2b at levels suitable for future 
experimentation. 
The manipulation and subversion of autophagy is a well-documented phenotype for 
multiple viral infections. A noteworthy example is that of poliovirus which produces 
autophagosome-like vesicles to serve as a scaffold for RNA replication (Taylor and 
Kirkegaard, 2007). Additionally a more recent study identified the nsp6 protein from 
coronaviruses and the nsp5-7 protein from arterivirus recruiting Vps34 and DFCP1 
to the ER resulting in omegasome formation (Cottam et al., 2011). Furthermore, a 
closely related virus to HCV, Dengue virus, has been shown to replicate and 
translate on amphisomes which arise from the fusion of autophagosomes with 
endosomes (Lee et al., 2008; Panyasrivanit et al., 2009). However, the final 
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membrane architecture of these structures is distinct from HCV (Welsch et al., 
2009).  
All together these results are in agreement with a model of the HCV replication 
complex formation requiring and utilising the cellular process of autophagy. The 
HCV non-structural proteins, shortly after translation on the ER, likely associate with 
the omegasome nucleation machinery, in particular the class III PI3K Vps34 (Figure 
5.7). The subsequent production of PI3P recruits DFCP1, possibly WIPI2b — 
although not confirmed, leading to LC3 lipidation and phagophore expansion. 
During this process the non-structural proteins form replication complexes in the 
developing DMV, eventually resulting in full autophagosome production. By a yet 
unknown method, autophagosomes containing HCV non-structural proteins are 
diverted away from degradation by lysosome fusion, lose their lipidated LC3 (Sir et 
al. 2012 observe colocalisation of NS5A and NS5B with LC3, whereas no such 
colocalisation has been observed previously by our lab Mohl et al. 2012), and 
become dedicated HCV DMVs within the membranous web. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  162 
 
Figure 5.7: Model of HCV replication complex formation using the autophagosome 
biogenesis pathway. 
A: autophagosome biogenesis within cells. 1) ULK1 and PI3K complexes recruited 
to curved mitochondrial-associated ER membranes (MAM). 2) DFCP1 and WIPI2b 
recruitment to PI3P-rich membrane. 3) Recruitment of Atg5-Atg12-Atg16L1 
complex and Atg3-LC3-I. 4) Lipidation of LC3-I onto phosphatidyethanolamine 
producing LC3-II. 5) Phagophore membrane expansion from Atg9 containing 
vesicles. 6) Engulfment of cytoplasmic contents and autophagosome closure. 
7) Fusion with lysosomes for degradation. 
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Chapter 6 - Developing fluorescence 
microscopy tools to study HCV 
infection 
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6.1     Aims and Objectives 
Fluorescence microscopy has become a powerful and widely used technique in the 
study of biological processes. The development of strategies to fluorescently label 
particular targets, typically with antibodies or fluorescent proteins, has enabled a 
direct visualisation of cellular processes (Stadler et al., 2013). This ultimately leads 
to a better understanding of target localisation, interaction partners, signalling 
pathways and more.  
Several strategies exist to label proteins and RNA in cells, as discussed below. The 
main goal of the research in this chapter was to develop a range of novel tools to 
visualise HCV protein and RNA in cells.  
Part I focusses on methods to label HCV non-structural proteins through either 
genetic incorporation of fusion proteins as reporters, or the selection of 
non-antibody binding proteins to the HCV polymerase. 
Part II discusses the incorporation of a modified nucleotide into HCV RNA to 
monitor the localisation of actively replicating HCV RNA in cells. 
 
 
  
  166 
  
  167 
6.3     Part I – Detection of HCV non-structural proteins 
6.3.1     Fusion proteins as reporters on protein localisation 
The genetic incorporation of fluorescent proteins (FPs) and epitope tags into target 
proteins has become a routine approach for protein detection, particularly in the 
study of proteins in living cells or when antibodies to the endogenous protein are 
unavailable. This was first demonstrated using the green fluorescent protein (GFP) 
derived from the jellyfish Aequorea victoria (Chalfie et al., 1994). However, because 
of its size (238 amino acids) this can result in aberrant or defective protein function 
and localisation within cells (Margolin, 2012). In addition, viruses have compressed 
genomes which can encode multi-functional proteins or overlapping open reading 
frames (Belshaw et al., 2007). Alternatively, small epitope tags, such as the FLAG 
tag (Hopp et al., 1988), require less sequence space to encode, but require 
subsequent detection with antibodies. The use of larger tags such as FPs (e.g. GFP 
~27 kDa) are more problematic as the size and shape may interfere with the native 
protein structure or function (Snapp, 2005).  
More recently, the tetracysteine (TC) tag, a six residue natural amino acid 
sequence was developed (Griffin et al., 1998). Tetracysteine tags are small peptide 
sequences that fold into a hairpin structure and bind fluorescent arsenical 
derivatives (Griffin et al., 1998). Since its first description, additional modifications 
have been made to improve its binding properties, and its size has increased to 12 
amino acids (Adams et al., 2002; Martin et al., 2005). The tetracysteine tag has 
been reported functional in a number of proteins at the N or C terminus and as an 
internal protein tag (Andresen et al., 2004; Counihan et al., 2011; Eyre et al., 2014). 
Protein in live cells can be labelled by adding the dye to cells, which is taken up and 
binds to the TC tag, allowing the labelled protein to be imaged. The small size of 
the tag also makes it attractive for super-resolution microscopy (Lelek et al., 2012). 
An additional benefit is the absence of fluorescence from the arsenical derivative 
until it binds to the TC tag (Griffin et al., 1998). 
The study of many important virus infections has been facilitated by the TC tag. 
These include the investigation of HCV core and NS5A protein trafficking in cells 
during infection (Coller et al., 2012; Counihan et al., 2011; Eyre et al., 2014). 
Epitope tag incorporation has proven successful for other HCV proteins, including 
E2 (Eggert et al., 2014), p7 (Vieyres et al., 2013), NS2 (Stapleford and Lindenbach, 
2011) and NS4B (Paul et al., 2013). However, there is a distinct lack of functional 
fusion proteins for NS3 and NS5B. Protein expression constructs for NS3 and 
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NS5B with GFP or FLAG tags are reported (Chatel-Chaix et al., 2011; Wu et al., 
2008), however these are expressed outside the natural NS3–5B polyprotein. 
Transposon mutagenesis studies can probe the ability of protein domains to 
tolerate tag insertions. Recent reports of transposon insertions into the HCV 
genome have revealed areas considered non-essential for protein function, defined 
by their ability to tolerate small 15 nucleotide insertions (Arumugaswami et al., 
2008; Remenyi et al., 2014). The findings from these studies indicate that epitope 
tags may be tolerated at insertion sites between amino acids 1023–1035 
(N-terminus of NS3), and 3010–3016 (before the C-terminal transmembrane 
domain of NS5B) (Figure 6.1); amino acid numbering corresponds to the JFH-1 
genome sequence.  
Thus it should be possible to use this information to generate and characterise NS3 
and NS5B TC tagged constructs (Sections 6.4.1 and 6.5.1). 
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Figure 6.1: Tetracysteine tag cloning sites identified from transposon mutagenesis 
studies. 
A: Transposon insertion sites in sub-region of NS2–3 coding sequence. 
B: Transposon insertion sites in sub-region of NS5B coding sequence. Schematic 
of HCV region is shown below each graph with amino acid sequence. Lethal, 
attenuated and tolerated phenotypes are shown as red, blue and green bars 
respectively. Adapted from (Arumugaswami et al., 2008). 
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6.3.2     Non-antibody binding reagents 
Antibodies are the most widely used binding proteins, with applications in research, 
diagnosis and therapy. Nonetheless, they have a number of limitations. They 
require inoculation of animals with a target protein for their generation and are large 
multimeric proteins (~150 kDa) that require disulphide bonds for stability. With 
regard to super-resolution microscopy, the size of antibodies is another 
consideration as they position the detected fluorophore around 10 nm away from 
the intended target. In comparison, other labelling methods such as nanobodies 
(Ries et al., 2012), aptamers (de Castro et al., 2016), or non-antibody binding 
proteins (Tiede et al., 2014), are attractive alternatives due to their small size and 
alternative selection procedures.  
Nanobodies are a variable single-domain antibody, composed of homodimeric 
heavy-chains without light chains (Muyldermans, 2013). As such they have 
comparable binding properties to conventional antibodies but are much smaller in 
size, ~15 kDa (Figure 6.2). This makes them attractive candidates for 
super-resolution imaging, over antibodies, due to the closer positioning of the 
detected fluorophore to the target (Platonova et al., 2015; Pleiner et al., 2015; Ries 
et al., 2012). However, they still require the inoculation of animals for their 
generation. In particular, nanobodies are only produced by a small number of 
animals, namely Tylopoda (camels, dromedaries and llamas) and sharks (Flajnik et 
al., 2011). 
Aptamers are short oligonucleotide sequences that are engineered to bind a target 
ligand. They are identified from a library of sequences using the systematic 
evolution of ligands by exponential enrichment (SELEX), an in vitro selection 
technique (Ellington and Szostak, 1990; Oliphant et al., 1989; Tuerk and Gold, 
1990). Aptamers are much smaller than antibodies (~15 kDa; Figure 6.2) (Lupold et 
al., 2002; Wilner et al., 2012) and therefore have been exploited for 
super-resolution imaging studies (de Castro et al., 2016; Opazo et al., 2012). 
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Figure 6.2: Size comparison between protein binding molecules. 
Crystal structures of an antibody (orange), nanobody (pink), aptamer (blue) and 
Adhiron (grey). PDB ID no.’s: 1HZH, 3K1K, 3QLP, 4N6T respectively. Images are 
displayed to scale. 
 
The selection of aptamers to HCV is well documented with targets including core 
(Shi et al., 2014; Stewart et al., 2016), both envelope proteins (Chen et al., 2015; 
Yang et al., 2013), the non-structural proteins NS2 (Gao et al., 2014), NS3 (Fukuda 
et al., 2000), NS5A (X. Yu et al., 2014), NS5B (Lee et al., 2013), and the HCV IRES 
(Kikuchi et al., 2003). Although these studies were focused on the applications of 
aptamers as therapeutic agents, they exemplify the ability of selection techniques to 
identify unique and specific binders to particular targets. However, to our 
knowledge, no selection of non-antibody binding proteins has been conducted 
towards HCV proteins. 
Non-antibody binding proteins have been generated from a range of different 
scaffolds, and inserted variable peptide sequences within these proteins are 
designed to recognise specific ligands. Some of these include designed ankyrin 
repeat proteins (Binz et al., 2003), repebodies (Lee et al., 2012), anticalins 
(Schlehuber and Skerra, 2005), fibronectins (Koide et al., 1998), affibodies (Nord et 
al., 1995) and engineered Kunitz domains (Nixon and Wood, 2006). Recently, a 
novel scaffold, termed the Adhiron (or affimer), has been characterised at the 
University of Leeds (Tiede et al., 2014).  
The Adhiron scaffold is derived from plant cysteine protease inhibitors called 
phytocystatins (Kondo et al., 1991), which are small (~100 amino acid), monomeric 
proteins with high solubility and stability. In place of the inhibitory sequences, two 
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variable 9 amino acid loops have been inserted resulting in a library of potential 
non-antibody binding proteins from 1.3 x 1010 clones (Tiede et al., 2014). Specific 
and high affinity binders to a target protein can be selected by screening the 
Adhiron library against an immobilised target (Figure 6.3). Once identified, binders 
can be expressed and purified to high levels in bacteria and specifically labelled by 
modification of unique cysteines engineered into the scaffold backbone — for 
example, fluorophore conjugation using a maleimide derivative. Therefore Adhirons 
provide an excellent alternative to antibodies for protein detection. 
Given the various potential approaches to derive novel binders to NS5B, and the 
expertise at Leeds, we have therefore attempted to raise Adhirons to NS5B 
(Section 6.5.4) for use in fluorescent labelling. Although our lab has previously 
produced a polyclonal antiserum against NS5B, this serum recognises non-specific 
cellular proteins by western blot and immunofluorescence. Thus, the generation of 
Adhirons to NS5B would be a useful tool to investigate the localisation of this 
protein in cells. 
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Figure 6.3: Adhiron scaffold and phage display procedure. 
A: Crystal structure (PDB ID no. 4N6T) of Adhiron scaffold in grey. Variable loops 1 
and 2 are coloured red and blue respectively. Residues in scaffold modified to 
cysteines for site specific labelling in orange. B: Phage display screening 
procedure. 1) Phage library incubated with target protein. 2) Unbound phage 
washed away 3) Elution of Adhiron binders. 4) Eluted phage amplified and 
re-incubated with target in further panning rounds. 5) After 3–5 selection rounds, 
eluted phage isolated and sequenced. 
  174 
  
  175 
6.4     Part I – Cloning strategies 
6.4.1     Tetracysteine tag cloning into NS3 and NS5B 
To facilitate our investigations on the structure and architecture of the HCV 
replication complex, the TC tag was engineered into both NS3 and NS5B. In each 
case a sub-clone containing either the NS3 or NS5B coding region was generated, 
termed pSUB-NS3 and pSUB-NS5B respectively (Figure 6.4A). pSUB-NS3 
contains a single copy of the NcoI restriction enzyme site at the N-terminus of NS3. 
Using site-directed mutagenesis, a unique restriction site was introduced into the 
NS5B coding region within pSUB-NS5B. The single nucleotide mutation, C to A, 
created an NruI restriction enzyme site within NS5B without altering the protein 
coding sequence, termed NS5B [NruI]. This internal restriction enzyme site is 
immediately prior to the C-terminal transmembrane domain of NS5B. 
To introduce the TC tag into either NS3 or NS5B, each target gene was amplified 
by PCR with primers containing the optimised TC tag (FLNCCPGCCMEP; 
Appendix 1) (Figure 6.4B). PCR products were then cloned into pSUB-NS3 or 
pSUB-NS5B using the unique restriction enzyme sites. To characterise the fitness 
of these TC-tagged proteins during HCV replication, each was cloned into 
SGR-Feo-JFH1 to monitor luciferase expression as an indirect measure of 
sub-genomic replicon replication; SGR-Feo-JFH1 [NS3-TC] and SGR-Feo-JFH1 
[NS5B-TC] respectively. The introduction of NruI into NS5B did not alter the protein 
coding sequence; however it is possible that RNA interactions required for HCV 
replication are altered by this modification. Therefore an NS5B SGR containing NruI 
was created to determine the consequence of this RNA modification, termed 
SGR-Feo-JFH1 [NruI]. 
All constructs were confirmed by analytical digest and Sanger sequencing. 
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Figure 6.4: NS3 and NS5B tetracysteine tag cloning strategies. 
A: Generation of sub-clones containing unique restriction sites from NS3–4B and 
NS5A–5B regions. pmSGR was digested with either KpnI and BamHI or BamHI and 
XbaI before ligation into pLITMUS28i with the corresponding restriction sites to 
generate pSUB-NS3 and pSUB-NS5B respectively. pSUB-NS3 contains the unique 
restriction site NcoI for TC tag insertion into NS3. pSUB-NS5B was modified by 
site-directed mutagenesis to introduce the unique restriction site NruI into NS5B, 
without altering the protein coding sequence. B: Introduction of the TC tag into NS3 
and NS5B. Optimised TC tag sequence, including flexible linker regions on either 
end (pink), was introduced into NS3 and NS5B sequences using PCR (Appendix 1). 
The resultant PCR fragments were cloned into pSUB-NS3 or pSUB-NS5B using 
NcoI and NheI or NruI and XbaI respectively. Tagged protein constructs were then 
cloned into pmSGR using KpnI and SpeI or HpaI and XbaI for NS3 and NS5B 
respectively. Coding sequences for NS3, NS4B, NS5A and NS5B in yellow, green, 
light blue and dark blue, respectively. 
 
6.4.2     NS5B ΔC21 expression construct 
In order to select Adhirons against NS5B, a C-terminal hexa-histidine affinity tagged 
expression construct was purified from E. coli (Simister et al., 2009) (Section 3.4.2). 
A corresponding expression construct, containing a defective polymerase active 
site (GDD to GND), was engineered by replacing the NcoI and AscI gene fragment 
from the expression construct with the corresponding fragment from 
SGR-Feo-JFH1 [GND]. 
6.4.3     Cloning of Adhiron expression constructs 
To express, purify and fluorescently label Adhirons, sequences were PCR amplified 
and cloned into pET11b with a C-terminal hexa-histidine tag (Figure 6.5). A 
two-step PCR process was conducted with Adhiron primers 1–4 (Appendix 1), 
generating 2 PCR products. This introduced two cysteines into the Adhiron 
backbone, first a substitution of leucine 26, and secondly the addition of a cysteine 
prior to the hexa-histidine tag at the C-terminus. The two PCR fragments were then 
combined and amplified using SOE PCR, before ligation into pET11b. All constructs 
were confirmed by restriction digestion and Sanger sequencing. 
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Figure 6.5: Adhiron cloning strategy. 
Adhiron sequences were amplified by PCR in two fragments (F1 and F2), 
simultaneously introducing cysteines (orange) into Adhiron backbone (Appendix 1). 
PCR products were then combined by splice overlap extension PCR to yield full 
Adhiron sequence containing unique restriction sites and modified cysteine 
residues. Final PCR product was subsequently cloned into pET11b using NheI and 
NotI restriction sites. 
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6.5     Part I – Results 
6.5.1     Replicative fitness of TC-tagged SGRs 
Introducing the TC-tag affected the replication fitness of HCV SGR (Figure 6.6). 
Luciferase expression levels from SGRs correlate with HCV RNA copy numbers, 
and therefore provide a measure of HCV replication fitness (Krieger et al., 2001). 
While luciferase signal was observed 4 h.p.e. of the RNA for the control 
SGR-Feo-JFH1, neither SGR-Feo-JFH1 [NS3-TC] nor SGR-Feo-JFH1 [NS5B-TC] 
showed any increase in luciferase signal for up to 72 h.p.e. Their replication kinetics 
were thus similar to the polymerase deficient control SGR-Feo-JFH1 [GND] for 
which no increase in luciferase was observed at 48 and 72 h.p.e. 
The selection of HuH7 cells stably expressing TC-tagged SGRs also proved 
unsuccessful (data not shown). Due to the limited number of viable insertion sites 
identified by transposon mutagenesis studies, no additional investigations exploiting 
the introduction of reporters were conducted. Instead the selection of Adhirons to 
NS5B was explored. 
6.5.2     Expression and purification of NS5B ΔC21 
To screen the Adhiron library against the HCV polymerase, NS5B was expressed 
and purified from E. coli using an expression construct containing a 21 amino acid 
deletion at the C-terminus, termed NS5B ΔC21 (Simister et al., 2009). The 
polymerase fold of NS5B was shown previously to be unaffected by the 
transmembrane domain deletion by crystallography and in vitro polymerase activity 
assays (Simister et al., 2009). 
Fractions collected from NS5B ΔC21 expression and purification were analysed by 
SDS-PAGE (Figure 6.7A and B). Lysates from IPTG induced bacteria contained an 
abundant protein band with an apparent molecular weight around 58 kDa (ExPASy 
Protparam predicted molecular weight of 64.2 kDa), which was insoluble under 
initial lysis conditions (Figure 6.7A and B, lanes 1–3), consistent with previous 
studies (Simister et al., 2009). Resuspension and sonication of the lysate pellet 
yielded soluble NS5B (lane 4) which was then bound to Ni2+-charged Sepharose. 
However, a significant portion of expressed NS5B remained insoluble after this step 
(lane 5). After washing of immobilised NS5B, protein was eluted (lane 11). 
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Figure 6.6: Replication of TC-tagged SGR constructs. 
Luciferase reporter values were measured up to 72 h.p.e. from transient 
electroporation (Section 3.5.2) of 5 μg SGR RNA into HuH7 cells. Comparison of 
TC tagged constructs to wildtype and polymerase deficient (GND) SGR controls. 
Data represent the mean ± SD, n=3. 
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Figure 6.7: NS5B ΔC21 protein purification. 
A: Coomassie stain of SDS-PAGE analysis from Ni2+-affinity purification of NS5B 
ΔC21 (Section 3.4.2). Induced cell pellets were lysed (lane 1) and insoluble material 
pelleted (lanes 2–3). Insoluble pellet was re-suspended and sonicated to solubilise 
NS5B ΔC21 (lanes 4–5). Soluble NS5B ΔC21 was loaded onto Ni2+ charged resin 
(lane 6). Bound NS5B ΔC21 was washed in buffer containing 50 mM imidazole 
(lanes 7–10) before elution in buffer containing 250 mM imidazole (lane 11). 
B: NS5B ΔC21 GND was purified as in A. Molecular weight markers in kDa are 
indicated. 
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6.5.3     Purified NS5B ΔC21 exhibits polymerase activity 
The identity of purified NS5B ΔC21 was confirmed by western blotting using the in 
house anti-NS5B polyclonal serum (Figure 6.8A). Protein bands were detected by 
NS5B serum and control antibody (anti-hexa-histidine tag) at the predicted 
molecular weight. 
NS5B ΔC21 purified from E. coli displayed polymerase activity confirming the 
purification of correctly folded and functional protein (Figure 6.8B). The polymerase 
activity was measured by incorporation of [α-32p]-CTP into HCV transcripts from de 
novo initiation by NS5B ΔC21. An approximately 20-fold increase in radioactivity 
was observed from transcripts derived from NS5B ΔC21 reactions over the 
polymerase deficient control. The low levels of radioactivity observed for NS5B 
ΔC21 [GND] represent background signal from transcript purification. 
The selection of Adhirons that bind to and recognise NS5B in HCV infected cells 
requires a correctly folded target protein that displays native epitopes. Purified 
protein can often be incorrectly folded or inactive when expressed using E. coli 
(Khow and Suntrarachun, 2012). Fractions of purified, active polymerase were 
taken forward for screening against the Adhiron library to identify novel and specific 
high affinity binding proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  183 
 
Figure 6.8: Purified NS5B ΔC21 is correctly folded and functional. 
A: western blot analysis from SDS-PAGE of purified NS5B ΔC21. Quantity of pure 
protein per lane and antibody identity is indicated. B: Liquid scintillation counting of 
in vitro polymerase assay products. 150 nM of pure NS5B ΔC21, or GND mutant, 
were incubated with JFH1 [GND] template RNA in the presence of [α-32P]-CTP. 
Incorporation of 32P into HCV transcripts, after 1 h incubation, was measured from 
purified transcripts by liquid scintillation counting. Data represent mean ± SD, n=3. 
** P <0.005. 
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6.5.4     Five Adhirons were identified from NS5B ΔC21 screening 
After three selection rounds of the Adhiron library against ΝS5B ΔC21, seven 
Adhiron-phage were identified as potential binders from 32 colonies (Figure 6.9A). 
An arbitrary cut-off of 0.2 absorbance units was used to identify Adhiron binders, 
this corresponds to an approximately 4-fold increase in absorbance over the 
negative control. The increase in absorbance at 620 nm from the horseradish 
peroxidase reaction product indicates binding of Adhiron-phage to NS5B ΔC21.  
Sequencing of the variable loops from the seven adhiron-phage identified five 
unique binders (Figure 6.9B). In two pairs of Adhirons, Adhirons 10 and 27 and 
Adhirons 16 and 17, the sequence of the variable loops were identical. Each of the 
five remaining Adhirons had unique variable loops with no apparent consensus 
sequence or common amino acid properties observed from the primary amino acid 
sequence.  
Adhiron 28 had 11 amino acids in variable loop 1 compared to 9 in the remaining 
Adhirons (Figure 6.9B). The Adhiron library was constructed by splice overlap 
extension (SOE) of two PCR products (Horton et al., 1990; Tiede et al., 2014), 
creating two variable loops containing nine random amino acids. The longer loop in 
Adhiron 28 is most likely a result of miss-matched PCR product overlap or 
polymerase error during the Adhiron library construction and suggests that the 
phage library may be larger than first predicted, although how much larger is 
currently unknown (Tiede et al., 2014). Protein BLAST (Altschul et al., 1990) 
alignments were conducted using the adhiron variable loops against human and 
HCV proteins to identify potential NS5B interaction partners based on the Adhiron 
protein sequence (Espadaler et al., 2005), however no complete alignments were 
observed (data not shown). 
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Figure 6.9: Adhirons identified from phage display screening against NS5B ΔC21. 
A: Horseradish peroxidase based phage-ELISA. Isolated Adhiron-phage from the 
third selection round were incubated with target protein in a phage-ELISA. 
Horseradish peroxidase activity was measured by 620 nm absorbance of reaction 
product. Biotinylated, NS5B ΔC21 plasmid-deficient, BL21 (DE3) cell lysate was 
used as a negative control. Dashed red line indicates arbitrary cut-off of 0.2 
absorbance units used in Adhiron selection. B: Amino acid sequence of variable 
loops from Adhirons identified as NS5B ΔC21 binders. Adhirons were screened and 
identified by the Leeds Adhiron BioScreening group (Section 3.4.4) (Tiede et al., 
2014). 
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6.5.5     Expression and purification of Adhirons 
Each of the five Adhirons identified from screening were expressed to high levels 
from E. coli (Figure 6.10). An abundant protein band with apparent molecular 
weight around 11 kDa, matching the expected molecular weight (Table 6.1), was 
observed from bacterial expression trials after IPTG induction.  
Four of the five Adhirons were successfully purified using Ni2+-affinity purification 
(Figure 6.11 lanes 8–10). Purified Adhirons in elution fractions (lanes 8–10) 
contained little or no contaminants consistent with previous reports (Tiede et al., 
2014). During the purification procedure, Adhiron 21 precipitated from solution after 
elution from the Ni2+-resin indicating protein aggregation or insolubility. The 
introduction of nine amino acid variable loops into a scaffold may cause 
self-interaction or destabilise the scaffold (Tiede, personal communication), 
therefore Adhiron 21 was no longer investigated and is discussed no further. The 
other four Adhirons had no observable precipitation and were taken forward for 
cysteine labelling. 
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Adhiron Molecular 
weight (kDa) 
Extinction 
coefficient 
(M
-1
 cm
-1
) 
Isoelectric 
point 
A10 12.26 22585 7.13 
A16 12.50 17085 6.75 
A21 12.63 13075 8.53 
A28 12.78 18575 8.53 
A30 12.48 20065 7.16 
Table 6.1: Properties of Adhirons as computed by the ExPASy ProtParam 
bioinformatics tool. Extinction coefficients presented are for Adhirons with reduced 
cysteines. 
 
 
 
 
Figure 6.10: Expression of Adhirons from pET11b in BL21(DE3) cells. 
Cells were grown to an OD600 of 0.6–0.8 at 37 °C before induction of expression 
using 0.1 mM IPTG for 4 h at RT. Pellets from uninduced (- lanes) or induced 
(+ lanes) cells were lysed and analysed by Coomassie stain of SDS-PAGE. 
Molecular weight markers in kDa are indicated. 
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Figure 6.11: Adhiron purification fractions analysed by Coomassie stain of 
SDS-PAGE. 
Adhirons expressed from BL21 DE3 cells were lysed (lane 1) and loaded onto 
Ni2+-charged resin collecting flow through (FT; lane 2). Bound Adhirons were 
washed in buffer containing 100 mM imidazole (lanes 3–7) before elution in buffer 
containing 300 mM imidazole (lanes 8–10). Fractions from Ni2+-affinity purification 
were analysed by SDS-PAGE. Molecular weight markers in kDa are indicated. 
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6.5.6     Adhirons were labelled with Alexa Fluor 647 
Fluorescence imaging of Alexa 647-labelled Adhirons run on an SDS-PAGE gel 
confirmed that Alexa Fluor 647 had been conjugated to cysteines on the Adhiron 
scaffold (Figure 6.12). Western blot analysis with an antibody to the Adhiron 
hexa-histidine tag confirmed the identity of the Adhiron band. In some cases two 
closely resolved bands were observed, and is due to incomplete denaturation of the 
Adhiron stable protein fold before SDS-PAGE analysis (Christian Tiede, personal 
communication). Regardless, the presence of  647 nm fluorescent protein bands 
demonstrate successful labelling of purified Adhirons. Labelled Adhirons were taken 
forward to assess their binding and detection of NS5B in cells. 
6.5.7     Purified Adhirons do not bind native NS5B 
No fluorescence signal corresponding to NS5B was observed in cells stably 
harbouring SGR-Feo-JFH1 (Figure 6.13A). No observable 647 nm fluorescence 
signal was observed for Adhiron 28 or 30, in any cell which had high levels of NS5A 
expression (Figure 6.13A). In contrast a weak fluorescence signal was observed for 
Adhiron 10 and 16 in cells.  
For Adhiron 10, this was mostly confined to the nucleus, a cellular compartment not 
occupied by HCV, and therefore likely represents cross-reactivity with cellular 
polymerases. This is supported by the observation that there is an identical weak 
fluorescence signal in replicon and virus naïve cells (Figure 6.13B). Additionally, in 
both replicon harbouring and naïve cells, a weak and diffuse signal was observed 
throughout the cytoplasm. However, this was significantly lower than signal 
observed with NS5A staining. 
Adhiron 16 exhibited a similar weak fluorescence signal in the nucleus as found for 
Adhiron 10. However, it also stained discrete puncta or ring-like structures in the 
cytoplasm (Figure 6.13A). Ring structures are a reported phenotype for HCV core 
(Miyanari et al., 2007) and suggested that Adhiron 16 might be specifically 
detecting NS5B. However, comparable fluorescence structures were observed in 
the cytoplasm of naïve HuH7 cells (Figure 6.13B). Therefore, this is not a real 
phenotype and corresponds to non-specific binding of Adhiron 16 to a cellular 
structure, possibly proteins on, or the surface of lipid droplets directly. 
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Figure 6.12: Alexa Fluor 647 labelling of Adhiron cysteines. 
Adhiron cysteines were labelled by incubation with Alexa Fluor 647 C2 maleimide 
for 16 h at RT in the dark following reduction of Adhiron cysteines using TCEP 
resin. SDS-PAGE analysis of labelled Adhirons was imaged for 647 nm 
fluorescence or by western blot using anti-hexa-histidine antibody. 
 
Despite the observed binding of Adhirons to NS5B ΔC21 in the phage-ELISA 
(Figure 6.9), no fluorescence signal was detected by microscopy to native NS5B. 
SGR-Feo-JFH1 harbouring cells were analysed as they constitutively express 
NS5B to high levels as part of the NS3–5B polyprotein (Wyles et al., 2009). 
Expression of SGRs within cells was confirmed by immunofluorescence staining for 
NS5A, a marker for replication complexes. 
Labelled Adhirons were also unable to detect purified NS5B ΔC21 blotted onto 
PVDF membranes (Figure 6.14A). For each membrane containing NS5B ΔC21, no 
fluorescence signal was detected when incubated with labelled Adhirons. The 
presence of NS5B was confirmed using the anti-NS5B polyclonal serum, and the 
quantity of Adhiron applied to detect NS5B was readily detected when applied 
directly to membranes (Figure 6.14B). Combined with the immunofluorescence, 
these experiments strongly indicate that none of the identified Adhirons from 
Section 6.5.4 are able to bind native NS5B. 
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Figure 6.13: Validation of Adhirons as non-antibody binding proteins for 
fluorescence microscopy detection of NS5B. 
A: HuH7.5 cells stably harbouring SGR-Feo-JFH1 were fixed and labelled with 
anti-NS5A antibody, 647-labelled Adhiron and DAPI. B: Naïve HuH7 cells were 
fixed and labelled as in A. Scale bars are indicated. 
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Figure 6.14: In vitro binding of 647-labelled Adhirons to purified NS5B ΔC21. 
A: Purified NS5B ΔC21 was blotted onto PVDF membranes in 10-fold dilutions 
before the membrane was incubated with 647-labelled Adhirons (5 µg) or 
anti-NS5B antibody. Membranes were imaged for 647 nm fluorescence or by 
western blot for primary antibody detection. B: 5 µg of 647-labelled Adhirons were 
dotted onto PVDF membranes prior to 647 nm fluorescence detection. 
 
 
  193 
6.6     Part I – Discussion 
In part I of this chapter I attempted to develop multiple different approaches to 
visualise HCV non-structural proteins that would then be suitable for 
super-resolution imaging. These included engineering TC-tagged fusion proteins of 
NS3 and NS5B, and identifying specific and high affinity non-antibody binding 
proteins to the HCV polymerase. Unfortunately, none of these approaches gave 
reliable detection of the specific target and could not be taken forward for 
super-resolution imaging. 
6.6.1     Characterisation of TC-tagged NS3 and NS5B proteins 
To the best of our knowledge, there are currently no reported fusion proteins for the 
detection of NS3 or NS5B during active HCV replication. Fusion protein expression 
constructs are reported for each protein (Chatel-Chaix et al., 2011; Wu et al., 2008) 
which provide methods to visualise the localisation of both proteins in cells. 
However these would be supplied outside the native NS3-5B context during virus 
replication and may not fully represent the entire process accurately.  
The TC tagged constructs generated in this study were unable to replicate, with no 
detectable luciferase signal from transient electroporation. The absence of 
luciferase activity for NS3-TC or NS5B-TC indicates that the TC tag is somehow 
interfering with protein function during HCV replication. The N-terminal helix of NS3 
and the C-terminal transmembrane domain of NS5B are both reported to be critical 
for membrane association (He et al., 2012; Lee et al., 2004). Accordingly, the TC 
tag is inserted directly upstream from each of these protein domains.  
Although the transposon mutagenesis studies indicated these regions were able to 
tolerate small 5 amino acid insertions (Figure 6.1), the TC tag is bigger at 18 amino 
acids and may be sufficiently large to impair protein function. This is corroborated in 
part by the inability of G418 selection, using the neomycin 
phosphotransferase-luciferase reporter fusion protein expressed by 
SGR-Feo-JFH1, to select for a population of cells capable of HCV replication (data 
not shown). 
In comparison, the NS5A protein of HCV is well documented to tolerate epitope tag 
insertions (Amako et al., 2009; D. M. Jones et al., 2007; Masaki et al., 2008; 
McCormick et al., 2006; Moradpour et al., 2004) including the tetracysteine tag 
(Eyre et al., 2014). The inability of NS3 or NS5B to tolerate small peptide insertions 
reiterate the critical roles these proteins have in the virus lifecycle, with limited or no 
genetic flexibility. 
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Future studies will investigate if other epitope tags, such as the FLAG, HA or myc 
tag, can be inserted at the sites used in this study to produce functional NS3 and 
NS5B constructs. Alternatively, the direct insertion of the desired epitope tag into 
the protein coding sequence, for example by using Tn7-transposon mutagenesis 
(Zordan et al., 2015), subverts the need to independently verify each epitope tag.  
6.6.2     Selection of Adhirons targeted towards NS5B 
Without functional NS5B fusion proteins, there is currently no method available at 
the University of Leeds, to detect the HCV polymerase by fluorescence microscopy. 
Monoclonal antibodies to NS5B are reported for genotype 1 (Nikonov et al., 2008), 
however they were unsuccessful in our hands for the detection of genotype 2 NS5B 
(data not shown). Previously, an anti-NS5B polyclonal serum was raised in house 
to genotype 2 NS5B; however the quality of the raised serum was insufficient for 
fluorescence and super-resolution microscopy. Therefore, a library of Adhirons, 
were screened against purified NS5B to identify specific and high-affinity binding 
proteins. 
The attempt to find Adhirons that specifically bound to and recognised NS5B, was 
unsuccessful in this investigation. A number of potential binders were identified by 
Adhiron screening (Figure 6.9), however these failed to detect native NS5B 
expressed during active HCV replication (Figure 6.13), or purified, unbiotinylated, 
NS5B from E. coli (Figure 6.14).  
Adhirons have been successfully raised to numerous targets typically with high 
affinities, indicating their broad application to multiple target proteins (Kyle et al., 
2015; Rawlings et al., 2015; Tiede et al., 2014). During this investigation, only 32 
potential binders were selected for analysis from the final panning round which 
identified 5 unique binders for characterisation. A repeat of the final selection step 
with characterisation of many more binders may identify novel Adhiron binders to 
NS5B.  
It is possible that the Adhirons raised recognise an epitope on NS5B that does not 
exist on native protein. To screen for Adhirons, NS5B was surface biotinylated and 
immobilised, therefore a surface biotin may occlude or block an epitope. 
Alternatively, the presence of small quantities of contaminants in the original 
preparation may be the Adhiron target. However, no contaminants were 
unobserved by SDS-PAGE analysis and pre-screening of the Adhiron library with 
naïve bacterial lysate was conducted to reduce this possibility. 
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Another possibility is the orientation or presentation of the Adhiron on the phage 
capsid may display the variable binding loops in a unique conformation not adopted 
in the Adhiron scaffold alone. Additionally, part of the phage capsid protein itself 
may, in combination with the Adhiron variable loops, bind an epitope of NS5B. 
Lastly, there is always a chance that Adhirons will never be raised successfully 
against a target. Some proteins are poorly immunogenic and present limited 
epitopes, although the generation of antibodies to NS5B, both in house and against 
different HCV genotypes (Nikonov et al., 2008), and aptamers (Lee et al., 2013), 
suggest NS5B displays detectable epitopes. 
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6.7     Part II – Metabolically labelling HCV RNA 
6.7.1     Visualising RNA transcription within cells 
The HCV non-structural proteins are a critical component of replication complexes, 
directly involved in replication of the viral genome. However, viral proteins are often 
multifunctional, as is the case of NS5A (Ross-Thriepland and Harris, 2015), and 
therefore not all protein is involved in HCV genome replication. The visualisation of 
HCV RNA localisation therefore provides an alternative marker for replication 
complexes. 
Historically, the detection of RNA in cells uses fluorescence in situ hybridisation 
(FISH) (Langer-Safer et al., 1982). A fluorescently labelled complementary 
nucleotide probe binds to the target sequence, enabling visualisation of RNA 
localisation (Li et al., 2013).  
Another approach reported recently uses the RNA aptamer Spinach, which binds a 
fluorophore resembling the fluorophore in GFP (Paige et al., 2011). This 
RNA-fluorophore complex emits green fluorescence comparable to enhanced GFP. 
The genetic incorporation of Spinach into target RNA sequences allows live cell 
imaging of RNA localisation (Paige et al., 2011). Another genetic approach was 
described recently for HCV using the MS2 bacteriophage stem loop engineered into 
the HCV untranslated region (Fiches et al., 2016). HCV RNA was then observed 
indirectly by subsequent recruitment of an MS2-Coat-mCherry fusion protein to the 
MS2 RNA stem loop.  
The major drawback to these approaches is their detection of total RNA containing 
the relevant sequence. In the case of HCV, and other virus infections, a 
subpopulation of these may be exhausted or inactive replication complexes. 
The incorporation of modified nucleotides into newly synthesised RNA is an 
alternative to the above described techniques and offers an approach to visualise 
sites of active RNA transcription. Original methods to label new RNA transcripts 
were described through the incorporation of 5-bromouridine 5’-triphosphate 
(BrUTP) (Haukenes et al., 1997). In the presence of the host cell RNA synthesis 
inhibitor actinomycin D (AD), BrUTP incorporation into viral transcripts has been 
demonstrated for a number of virus infections, including HCV (El-Hage and Luo, 
2003; Sir et al., 2012). AD binds to RNA transcription initiation sites and prevents 
cellular RNA polymerase elongation, without affecting viral polymerases (Sobell, 
1985). However, cells are impermeable to BrUTP and therefore require methods to 
provide BrUTP into the cell cytoplasm, either by transfection (Haukenes et al., 
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1997), permeabilisation (Wei et al., 1999) or microinjection (Wansink et al., 1993). 
Additionally, BrUTP itself is non-fluorescent; therefore antibody detection is required 
for visualisation. 
Bio-orthogonal chemistry, defined as reactions that can occur without interfering 
with biological processes, have provided new methodologies to functionalise target 
molecules within the complex environment of cells (Sletten and Bertozzi, 2009). An 
investigation of RNA transcription in vivo illustrates how this can be applied to RNA 
labelling by a Sharpless-Meldal copper (I)-catalysed Huisgen cycloaddition reaction, 
often referred to as a “click” reaction (Jao and Salic, 2008). This was subsequently 
applied to the study of virus infections comparable to original methodology using 
BrUTP (Hagemeijer et al., 2012; Kalveram et al., 2011; Reid et al., 2015).  
A key advantage of this approach over BrUTP labelling is the direct conjugation of 
an azide-modified fluorophore onto the substrate 5-ethynyl uridine (5EU). 
Additionally, eukaryotic cells are able to uptake the substrate directly from growth 
medium eliminating the need for transfection. Therefore, the goal of part II in this 
chapter was to develop tools for fluorescence detection of actively replicating HCV 
genomes through incorporation of 5EU (Section 6.8). 
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6.8     Part II – Results 
6.8.1     HCV replication is unaffected by actinomycin D or 5-ethynyl 
uridine treatment of cells 
HCV replication was unaffected by cellular RNA transcription inhibition (Figure 
6.15A). No reduction in luciferase activity was detected, compared to control cells, 
up to 8 h after treatment with actinomycin D (AD). At 24 h, a reduction in luciferase 
compared to the control was observed with a concurrent increase in luciferase of 
control cells over earlier time-points (Figure 6.15A). The discrepancy between 
untreated and treated after 24 h treatment is a consequence of cell number and 
viability (data not shown). Therefore, an 8 h time period exists within which to 
incorporate 5EU into viral transcripts before deleterious effects on cell viability. 
Additionally, no effect on HCV replication was observed with 5-ethynyl uridine 
treatment of cells stably harbouring SGR-Feo-JFH1 (Figure 6.15B). After 24 h 
treatment with 5EU, no decrease in luciferase signal was observed compared to 
untreated cells. Therefore, HCV replication and cell growth are unaffected by the 
incorporation of 5EU into RNA transcripts. 
6.8.2     5-ethynyl uridine is incorporated into cellular RNA transcripts 
The localisation of 5EU incorporated into cellular RNA transcripts in HuH7 cells was 
visualised using click chemistry with an azide-modified fluorophore (Figure 6.16A). 
RNA was localised to the nucleus of labelled cells, in particular to bright nuclear 
sub-regions. These bright sub-regions were absent for histone 3 staining and 
contained the nucleolar protein fibrillarin. The presence of 5EU within these 
fibrillarin-positive structures is consistent with the nucleolus, a site of high RNA 
transcription within eukaryotic cells (Tollervey et al., 1991).  
Cells grown in the absence of 5EU exhibited no fluorescence signal in the nucleus, 
confirming the successful incorporation of, and specificity of azides for, 5EU (Figure 
6.16B). Additionally, inhibition of cells with AD produced a phenotype comparable to 
cells grown in the absence of 5EU. Therefore, AD treatment is sufficient to 
shut-down cell transcription and no 5EU was incorporated into cellular transcripts. 
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Figure 6.15: SGR-Feo-JFH1 replication in the presence of actinomycin D or 5EU. 
A: HuH7.5 cells stably harbouring SGR-Feo-JFH1 were incubated with or without 
10 μg/ml actinomycin D for the indicated times. Cells were subsequently lysed and 
luciferase activity measured. B: Cells stably harbouring SGR-Feo-JFH1 were 
incubated with or without 5EU for 24 h before cell lysis and measurement of 
luciferase activity. Data represent the mean ± SD, n= ≥3. *** P < 0.0005. 
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Figure 6.16: Localisation of 5EU incorporated into cellular transcripts. 
A: HuH7 cells were treated with 1 mM 5EU for 2 h and incorporation into RNA 
transcripts visualised with Alexa Fluor 488-azide using click chemistry. Nuclear 
compartments were labelled with either histone 3 or fibrillarin antibodies. B: HuH7 
cells were grown in the absence of 5EU or in the presence of 1 mM 5EU and 
10 µg/ml AD. 5EU incorporated into RNA transcripts was visualised as in A. White 
boxes indicate magnified regions. Scale bars are indicated. 
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6.8.3     5EU was not incorporated into HCV RNA 
No fluorescence signal was observed for 5EU incorporation into newly transcribed 
HCV genomes in cells stably harbouring SGR-Feo-JFH1 (Figure 6.17). Previous 
reports using BrUTP identified cytoplasmic puncta within infected cells (El-Hage 
and Luo, 2003; Shi et al., 2003; Sir et al., 2012). However, no such phenotype was 
observed for cells stably expressing replicons at high levels, confirmed by 
cytoplasmic NS5A staining. After 6 and 8 h 5EU incorporation, some weak 
fluorescence was observed as small nuclear speckles within cells (Figure 6.17). 
Therefore, despite AD mediated inhibition of transcription a small amount of 5EU is 
still incorporated into cellular transcripts. These nuclear speckles confirm that 5EU 
was still processed and incorporated by the cell under these conditions; however it 
was not incorporated into HCV RNA.  
Additionally, in cells transiently expressing SGR-Feo-JFH1, no cytoplasmic 
fluorescence signal was observed at 24 or 48 h.p.e., after incubation of cells with 
5EU (Figure 6.18). However, the nuclear speckles of 5EU were observed 
comparable to the stable cells. Transiently replicating SGRs undergo high levels of 
translation and replication in order to establish replication (Krieger et al., 2001). In 
comparison, cells stably harbouring SGRs may only undergo sufficient replication to 
be maintained within the cell population.  
Lastly, no fluorescence signal for 5EU was detected in cells infected with HCV 
(Figure 6.19). NS5A positive cells displayed no cytoplasmic 5EU fluorescence after 
8 h 5EU incorporation at either 24 or 48 h.p.i. HCV positive cells were confirmed by 
immunofluorescence staining for NS5A as a marker for the replication complex. 
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Figure 6.17: 5EU labelling of HCV RNA in cells stably harbouring SGRs. 
HuH7 cells stably harbouring SGR-Feo-JFH1 were treated with 10 µg/ml AD for 
30 min prior to incubation with 1 mM 5EU in the presence of AD. At the indicated 
times cells were fixed and 5EU detected by click chemistry before 
immunofluorescence labelling of NS5A. White boxes indicate magnified regions 
with 2 μm scale bars. 
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Figure 6.18: 5EU incorporation into transiently replicating SGR-Feo-JFH1 RNA. 
HuH7 cells were electroporated with 5 µg of SGR-Feo-JFH1 RNA and grown for 
either 24 or 48 h. Cells were then incubated with growth medium containing 1 mM 
5EU and 10 µg/ml AD for the indicated times after a 30 min pre-treatment with AD. 
Cells were then fixed and processed for immunofluorescence. 5EU incorporation 
and SGR-Feo-JFH1 positive cells were detected with fluorophore azide and NS5A 
staining respectively. White boxes indicate magnified regions with 2 μm scale bars. 
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Figure 6.19: 5EU incorporation into HCV genomes during virus infection. 
HuH7 cells were infected with JFHcc for 24 or 48 h. 1 mM 5EU and 10 µg/ml AD 
were then added to the culture medium for 8 h after a 30 min pre-treatment with 
AD. Cells were processed for immunofluorescence with 5EU detected by 
fluorophore azide and HCV positive cells identified by NS5A staining. White boxes 
indicate magnified regions with 2 μm scale bars. 
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6.9     Part II – Discussion 
In the second part of this chapter I attempted to visualise the localisation of HCV 
RNA in cells. Incorporating 5-ethynyl uridine into HCV transcripts was unfortunately 
unsuccessful with no detectable fluorescence puncta in HCV harbouring cells under 
all experimental conditions tested. The incorporation and detection of 5EU into HCV 
RNA has been recently reported using RNA isolation and qPCR analysis of whole 
cell lysates (Masaki et al., 2015). In comparison to fluorescence microscopy, qPCR 
analysis amplifies RNA to enable detection. Consequently, in these studies HCV 
RNA may have incorporated 5EU however the signal was below a useful threshold. 
Actively replicating HCV RNA localisation has been reported before using BrUTP 
with the SGR system (El-Hage and Luo, 2003; Shi et al., 2003; Sir et al., 2012). 
However, other groups, Romero-Brey et al (2012), have reported the detection of 
HCV RNA using BrUTP, 5EU or antibody labelling was not achievable. Of note, 
BrUTP is detected with primary and secondary antibodies. Therefore 
antibody-mediated signal amplification with BrUTP may bring fluorescence signal 
above a detectable threshold.  
A recent study has demonstrated total HCV RNA localisation and trafficking within 
cells through the recruitment of mCherry-capsid protein to MS2 stem loops encoded 
in the HCV genome (Fiches et al., 2016). However, a major limitation of this 
approach was the substantial fitness cost. Studies from our lab have corroborated 
this finding with replication deficient Spinach tagged HCV constructs (data not 
shown). 
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Chapter 7 - Conclusions and future 
perspectives 
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The subversion of cellular membranes by HCV has been well documented for over 
10 years. The viral determinants responsible are individually well characterized but 
the precise arrangement of non-structural proteins within the membranous web 
remains elusive. This study set out to gain a detailed understanding of viral protein 
organisation with replication factories, using advances in light microscopy to resolve 
structures previously obscured by the diffraction of light. 
A major finding from this investigation was the difference in NS3 and NS5A 
organisation within protein clusters, and the association of HCV replication factories 
with lipid droplets. From these findings a model of HCV protein arrangement within 
DMV was proposed (Figure 4.34). The HCV non-structural proteins NS3/4A, NS4B 
and NS5B are membrane associated and contained inside DMV where HCV 
genome replication occurs. NS5A is proposed to face the cytosol, arranged on the 
outside of DMV, allowing interactions with core located on lipid droplets. This brings 
replication factories into close association with sites of virus assembly.  
Currently, 2-colour imaging has not been achieved at Leeds due to additional 
technical requirements in image processing. However, this is an important next step 
in confirming or disputing the proposed model. Two colour imaging has been 
reported using dSTORM (van den Dries et al., 2013), and image processing to 
correct chromatic aberration of different channels provide methods for complete 
correction and image reconstruction (Erdelyi et al., 2013). 
Another important component of HCV replication factories not investigated in this 
study is the lipid species that compose the HCV DMV. DMV undergo 
virus-mediated alteration to form membrane structures that have an altered PI4P, 
cholesterol and sphingolipids composition (Berger et al., 2009; Paul et al., 2013). 
Approaches to fluorescently label lipids have been reported using GFP-tagged PI4P 
binding proteins (Balla et al., 2005), PI4P antibodies (Ross-Thriepland and Harris, 
2015), fluorescent cholesterol analogues (Maxfield and Wüstner, 2012), and lipid 
droplet dyes (Eggert et al., 2014). Future studies should look to exploit these 
approaches in 2-colour SMLM. 
Additionally, the HCV RNA is an important component of replication factories that 
warrants additional investigation. Efforts to fluorescently label HCV RNA with 
modified nucleotides have so far proved unsuccessful, although similar 
methodology using BrUTP is reported (Shi et al., 2003). Alternatively, in situ 
hybridisation for the detection of total RNA and has been successfully 
demonstrated for HCV (Li et al., 2013; Shiogama et al., 2013).  
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Although the mechanism of action for DCV inhibition remains undefined, temporal 
associations with NS5A appear to be important. Early inhibition of virus release 
after DCV treatment was observed before replication factory disruption (Berger et 
al., 2014; McGivern et al., 2014). Monitoring the different populations of NS5A 
should be investigated in the future. The SNAP/CLIP tags are an enzymatic 
labelling strategy compatible with pulse chase fluorescence experiments. These 
have been incorporated into functional NS5A SGR to monitor temporal and 
trafficking functions (Eyre et al., 2014; Ross-Thriepland et al., 2015). Additionally 
the application of SNAP/CLIP tagging strategy has been demonstrated for super 
resolution imaging (Stagge et al., 2013).  
Analysis of different genotypes also identified differences in NS5A protein cluster 
organisation. However, differences were also observed between SGR and virus 
infection in genotype 2a. Therefore an investigation of NS5A protein cluster 
organisation in genotype 1 infections is required. Culture adaptation of HCV isolates 
has produced genotype 1a infectious clones which should be explored in future 
studies (Li et al., 2015, 2012; Yi et al., 2006). 
Analysis of SMLM images was performed using a clustering algorithm which 
identifies regions of high local density amid background noise (Ester et al., 1996). 
This gave superior results over other clustering algorithms such as hierarchical 
DBSCAN which grouped clusters together (data not shown) (Campello et al., 2013). 
DBSCAN is limited in its application when there is a large amount of varying density 
in a sample (Section 4.4.1). Although carefully controlled by parameter selection in 
this study, improvements of DBSCAN should be explored in the future. For 
example, OPTICS (ordering points to identify the clustering structure) (Ankerst et 
al., 1999) overcomes this weakness by describing how densely packed clusters are 
and thus accounts for varying density. 
Along with the advances in SMLM, a number of developments have occurred in 
correlative imaging approaches. The power of correlative light and electron 
microscopy was demonstrated for HCV to identify HCV proteins within DMV 
(Romero-Brey et al., 2012). Techniques are now becoming available which 
combine SMLM with EM (Johnson et al., 2015; Watanabe et al., 2011). The 
advantage of these approaches are the ability to localise proteins at the nanoscale 
by SMLM with subsequent correlation to the cellular ultrastructure observed by EM. 
Currently methods have used resin embedding (Johnson et al., 2015; Watanabe et 
al., 2011), although applications with cryoelectron microscopy are under 
investigation (Wolff et al., 2016). An alternative to EM is soft X-ray microscopy 
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which can image cell architecture in intact, whole cells. Correlative approaches with 
conventional light microscopy will likely lead the way for correlative super-resolution 
approaches (Carzaniga et al., 2014; Hagen et al., 2012). 
The organisation of non-structural proteins in HCV replication factories have been 
further defined in this study, however the biogenesis of HCV DMV remains elusive. 
The identification of DFCP1 as a cellular factor essential for HCV replication 
indicates the requirement of the autophagosome biogenesis machinery. However, 
additional questions have been raised form this study, for example, what 
interactions dictate the association with autophagy? How does HCV inhibit 
autophagosome lysosome fusion? Future methodologies should explore earlier 
steps in the autophagy biogenesis pathway to determine the cellular interactions 
required by HCV. 
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Name Tm (°C) %GC Sequence (5’ – 3’) 
NS5A mEos3.2 FW 70.3 52.6 CTGTCACGTGATCACGGAAGTAGCGGGTCATCGATGAGTGCGATTAAGCCAGACAT
G 
NS5A mEos3.2 RV 69.7 50.0 CTGTCACGTGATCAGATGAAGAACCTGAAGATCCTCGTCTGGCATTGTCAGGCAAT
CC 
NS3 TC FW 72.4 51.5 CTGTCATACCATGGGATCCTCCTTTCTCAACTGTTGTCCAGGGTGTTGTATGGAACC
TG GTAGCTCTGCTCCCATCACTGCTTATGCCCAGCAAACACG 
NS3 TC RV 64.7 55.1 GACCTCAAGGTCAGCTTGCATGCATGTGG 
NS5B NruI FW 73.6 75.8 CACAGCGTGTCGCGAGCCCGACCCCGCTC 
NS5B NruI RV 73.6 75.8 GAGCGGGGTCGGGCTCGCGACACGCTGTG 
NS5B TC FW 72.6 54.1 CTGTCATATCGCGAGGATCCTCTTTTCTCAACTGTTGTCCAGGGTGTTGTATGGAAC
CT GGTAGCTCTGCCCGACCCCGCTCATTACTCTTCGGCC 
NS5B TC RV 58.6 50.0 GTACCAGAGCTCACCTAGGTATCTAGAC 
Adhiron P1 69.3 50.0 ATGGCTAGCAACTCCCTGGAAATCGAAG 
Adhiron P2 78.2 39.5 CAACACGAACGAATTCCAGACAAGCGTTTTCTTTTTTGTTGTG 
Adhiron P3 78.2 39.5 CACAACAAAAAAGAAAACGCTTGTCTGGAATTCGTTCGTGTTG 
Adhiron P4 83.1 55.3 TTACTAATGCGGCCGCACAAGCGTCACCAACCGGTTTG 
Appendix 1: List of cloning primers 
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Name Tm (°C) %GC Sequence (5’ – 3’) 
Luciferase Start FW 71.3 73.7 GCAGTTGCGCCCGCGAACG 
Luciferase Mid FW 65.7 52.4 GCTCACTGAGACTACATCAGC 
Neomycin Start FW 73.5 75.0 CGGCTGCTCTGATGCCGCCG 
NS3 Mid FW 62.7 52.6 ACTGGCAGTGGAAAGAGCA 
NS3 End 63.0 61.1 CTGGACCCCACCTTCACT 
NS4 FW 60.2 47.4 TAAGGAGGTCCTGTATGAG 
NS5A Start FW 75.5 65.0 GGATGCGTCGCAGCGTGTGA 
NS5A Mid FW 73.4 79.0 CACGGCGGAGACTGCGGCG 
NS5A End FW 71.3 73.7 GGGTAGCTCCCGGTTCGGG 
NS5A End RV 63.0 50.0 GTTATGGTATCGCAACAGCG 
NS5B Mid FW 60.2 47.4 AACGGGTGGAGTATCTCTT 
NS5B End FW 62.7 52.6 TGGGTTCGCATGGTCCTAA 
mEos3.2 FW 55.1 47.6 ATGAGTGCGATTAAGCCAGAC 
mEos3.2 RV 59.8 52.1 TCGTCTGGCATTGTCAGGCAATC 
DFCP1 Start FW 51.0 60.0 ATGAGTGCCCAGACTTCCCC 
DFCP1 Mid FW 54.0 54.2 GGGGATGCCTCAGAAGCTTATCTG 
DFCP1 End FW 50.0 63.2 GCTTAGCCTTGGACCCACC 
mCherry Start FW 50.0 63.1 ATGGTGAGCAAGGGCGAGG 
mCherry End RV 51.0 57.1 CTTGTACAGCTCGTCCATGCC 
Appendix 2: List of sequencing primers 
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## getpalm3ddata.R 
library(rPython) 
# Extract data from palm3d generated files  
# A pickle (.pkl) contains the drift information for each image 
# A .py in the image data folder contains the localisations from one acquisition 
getpalm3ddata <- function() { 
cat("Where is the pickle?\n\n") 
flush.console() 
pklfile <- file.choose() 
cat("Where is the localisations file?\n\n") 
flush.console() 
locsfile <- file.choose() 
pyfile <- "getpalm3ddata.py" 
# Load my Python function(s) with rPython package 
python.load(pyfile) 
# Run my Python function with rPython 
# This returns a lists of x, y, z, correl, with one item for each localisation 
# correl is lists of correlations: one member-list for each image 
palmdata <- python.call("getpalm3ddata", pklfile, locsfile) 
# Convert to data frame 
palmdata <- data.frame(palmdata) 
# Add region column to work with nearest neighbour calculations from tiled 
histograms 
palmdata <- cbind(region = 1, palmdata) 
palmdata } 
ConvertNm <- function(xyzdata) { 
 # Add x,y,z columns in nm to pixel data 
 # User input of pixel to distance conversion 
nm.ppx.x <- as.numeric(readline("nm per pixel (if unbinned) or bin (if via histogram) 
in x? ")) 
nm.ppx.y <- as.numeric(readline("nm per pixel (if unbinned) or bin (if via histogram) 
in y? ")) 
nm.ppx.z <- as.numeric(readline("nm per pixel (if unbinned) or bin (if via histogram) 
in z? "))  
 # Append coordinates in nm 
 xyzdata$x.nm <- xyzdata$x * nm.ppx.x 
 xyzdata$y.nm <- xyzdata$y * nm.ppx.y 
 xyzdata$z.nm <- xyzdata$z * nm.ppx.z  
 # Return 
 xyzdata } 
Appendix 3 
R processing script to load localisation coordinates from software into R. Script 
written by Alistair Curd at the University of Leeds. 
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# For 3D density calculation and interactive 3D plots 
library(misc3d) 
library(rgl) 
working.dir.script <- getwd() 
# Use functions in get3dpalmdata.r 
source("getpalm3ddata.r") 
palmdata <- getpalm3ddata() 
palmdata <- ConvertNm(palmdata) 
cat("\nGot data.\n") 
cat("Plotting data.\n") 
flush.console()  
# Subset data with correlation value above 0.4 and plot to screen 
gooddata <- subset(palmdata, correl > 0.4) 
plot(y~-x, data = gooddata) 
# Choose directory to save density files in 
cat("Choose a directory to save the density files in. \n") 
flush.console() 
direc <- choose.dir()  
# Define sub-region to analyse (x0-50 y0-50) 
flush.console() 
subgooddata <- subset(gooddata, x.nm < 5000 & y.nm < 5000 & z.nm > 1800 & 
z.nm < 3300) 
# Calculate density of subregion with bandwidth of localisation precision 
# h = bandwidth of kernel density estimation in X, Y and Z 
# n = number of grid points in X, Y and Z 
dens <- with(subgooddata, { kde3d(x.nm,y.nm,z.nm, h=c(8.49, 8.49, 12.74), 
n=c(501, 501, 51)) }  ) 
# Save file 
flush.console() 
filename <- "kde3d_x0-50_y0-50_z20-36_h8-8-12_n501-501-51" 
flush.console() 
path <- paste(direc, "\\", filename, ".dat", sep="")  
f <- file(path, "wb") 
writeBin(dens$d[1:length(dens$d)], f) 
close(f) 
# Calculate density of subregion with bandwith of ~125 nm 
# Create "oversmoothed" file for cluster processing script in ImageJ 
dens <- with(subgooddata, { kde3d(x.nm,y.nm,z.nm, h=50, n=c(501, 501, 51)) } ) 
# Save file 
flush.console() 
filename <- "kde3d_x0-50_y0-50_z20-36_h50_n501-501-51" 
flush.console() 
path <- paste(direc, "\\", filename, ".dat", sep="")  
f <- file(path, "wb") 
writeBin(dens$d[1:length(dens$d)], f) 
close(f) 
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Appendix 4 
R processing script to apply kernel density estimation to localisations and save 
output as binary file. Density estimation code repeated on each sub-region under 
investigation. Two density files for each sub-region are created, first with smoothing 
defined by localisation precision. Second with ~125 nm smoothing to create 
“oversmoothed”. Code originally written by Alistair Curd and modified by Chris 
Bartlett at the University of Leeds. 
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""" Originally written by Alistair Curd 
zdiscneighbours.py 
Find vectors from each localisation to all localisations 
within a chosen distance from it. 
Modified by Chris Bartlett 
""" 
import cPickle, shelve 
from Tkinter import Tk 
from tkFileDialog import askopenfilename 
from tkFileDialog import askdirectory 
import numpy as np 
from scipy.ndimage.filters import gaussian_filter 
import time 
from collections import Counter 
import math 
import random 
from sklearn.neighbors import NearestNeighbors as nn 
def getcorrecteddata(pkldata, locsfile, offset, 
                     qualmin, 
                     x_to_nm, y_to_nm, z_to_nm): 
    """Get co-ordinates for selected data. 
 
    Minimum correlation specified, 
    z extremes truncated to avoid these gluts of poor data. 
    Co-ordinates corrected for drift and converted to nm 
    (user inputs conversion factors). 
    Returns: 
       This data as a numpy array with shape (N, 3), 
       where N is the number of localisations. 
    """ 
    # Separate out offset components for use when corrected x, y and z, below. 
    (xoffset, yoffset, zoffset) = offset 
    # Get raw localisations (not drift-corrected). 
    # locsimages is a shelve, or uber-list of images, called '0' '1', '2', etc. 
    # Each image - locsimages['0'] or locsimages[repr(0)] - 
    # is a list of localisations within that image 
    # Each localisation - e.g. locsimages[repr(1)][1] - 
    # is a dictionary of properties 
    # Each localisation contains position, e.g. 'x', and other information 
    locsimages = shelve.open(locsfile, protocol=2) 
    # Initialise co-ordinates and data quality/correlation arrays 
    # Over all of the images, find drift-corrected coordinates and 'qual' 
    xs = [] 
    ys = [] 
    zs = [] 
    qual = [] 
    for imagecount in range(len(pkldata.images)): 
        for loc in locsimages[repr(imagecount)]: 
            # Exclude poor correlations with calibration stack 
            if(loc['qual'] > qualmin): 
                # Exclude the extremes in z 
                # (where incorrect localisations in z end up) 
                if(loc['z'] > 5 and loc['z'] < 75): 
                    xs.append(loc['x'] - pkldata.drift['x'][imagecount] - xoffset) 
                    ys.append(loc['y'] - pkldata.drift['y'][imagecount] - yoffset) 
                    zs.append(loc['z'] - pkldata.drift['z'][imagecount] - zoffset) 
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                    qual.append(loc['qual']) # May use it later 
    locsimages.close() 
    # Numpy array of coordinates...with each (x,y,z) along one row 
    xyz = np.array([xs,ys,zs])  
    xyz = np.transpose(xyz) 
    # Convert pixels to nm 
    conv_to_nm = np.array([x_to_nm, y_to_nm, z_to_nm])     
    xyz = np.multiply(xyz, conv_to_nm) 
    # Save a little memory/time 
    # We could usually get away with 16-bit 
    # (350 pixels * 167 nm = 58450 nm < 65536) 
    # But do want to keep 1 or decimal places as well. 
    xyz = xyz.astype(np.float32) 
    print ('\n%i localisations found before subsetting.' % len(xyz)) 
    return xyz 
def combineacquisitions(savefolder): 
    """Combine data from multiple acquisitions for analysis. 
    User input required to find acquistion data. 
    Args: 
        Folder in which to save data 
    Returns: 
       Numpy array as in getcorrected data(). 
    """ 
    Tk().withdraw() 
    # Get localisations either from palm3d data files 
    # or from a previous run of this program 
    print('Do you already have an AllCorrectedLocalizations.npy') 
    ans = raw_input('for your FOV/minimum correlation/linking setting? y/n: ') 
    if ans == 'n': 
        print '\nPlease find me the first pickle (pkl)!' 
        pklfile = askopenfilename() 
        print '%s\n' % pklfile 
        print 'Please find me the first localizations file.' 
        print '(Usually in raw data folder, e.g. z=...)' 
        print 'Use _palm_localizations for unlinked localisations' 
        print 'or _palm_particles for localisations after linking.' 
        locsfile = askopenfilename() 
        print '%s' % locsfile 
        # Get acquisition information, including drift. 
        with open(pklfile, 'rb') as f: 
            pkldata = cPickle.load(f) 
        # Initial fiducial position, from which subsequent offsets are calculated 
        veryfirstfidpos = pkldata.drift['initial_xyz'] 
        # Get pixel to distance conversion factors 
        # and minimum correlation with calibration stack 
        x_to_nm = raw_input('\nHow many nm per pixel in x? ') 
        x_to_nm = float(x_to_nm) 
        y_to_nm = raw_input('How many nm per pixel in y? ') 
        y_to_nm = float(y_to_nm) 
        z_to_nm = raw_input('How many nm per pixel in z? ') 
        z_to_nm = float(z_to_nm) 
        qualmin = float(raw_input('\nChoose minimum correlation for the data: ')) 
        print '\nReading these localisations. Please wait...' 
        xyz = getcorrecteddata(pkldata=pkldata, locsfile=locsfile, 
                              offset=np.array([0., 0., 0.]), 
                               qualmin=qualmin, 
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                              x_to_nm=x_to_nm, y_to_nm=y_to_nm, z_to_nm=z_to_nm) 
        while(raw_input( 
            '\nDo you want to include another acquisition run from this FOV? [y]/n: ' 
            ) != 'n'): 
            # Find the data, as before 
            print '\nPlease find me that pickle then (pkl).' 
            pklfile = askopenfilename() 
            print '%s\n' % pklfile 
            print 'Please find me relevant localizations file too.' 
            print 'Use _palm_localizations for unlinked localisations' 
            print 'or _palm_particles for localisations after linking.' 
            locsfile = askopenfilename() 
            print '%s' % locsfile 
            with open(pklfile, 'rb') as f: 
                pkldata = cPickle.load(f) 
            print '\nReading these localisations. Please wait...' 
            # Get the offset relative to the first run 
            firstfidpos = np.array(pkldata.drift['initial_xyz']) 
            offset = firstfidpos - veryfirstfidpos 
            xyz_next = getcorrecteddata(pkldata, locsfile, offset, 
                                        qualmin, 
                                        x_to_nm, y_to_nm, z_to_nm) 
            xyz = np.append(xyz, xyz_next, axis=0) 
        np.save('%s\\AllCorrectedLocalizations' % savefolder, xyz) 
    elif ans == 'y': 
        print('\nCan I have it then please?') 
        xyzfile = askopenfilename() 
        xyz = np.load(xyzfile) 
        print(xyzfile) 
        x_to_nm = raw_input('\nHow many nm per pixel in x? ') 
        x_to_nm = float(x_to_nm) 
        y_to_nm = raw_input('How many nm per pixel in y? ') 
        y_to_nm = float(y_to_nm) 
        z_to_nm = raw_input('How many nm per pixel in z? ') 
        z_to_nm = float(z_to_nm) 
    else: 
        print('Oops - try again with \'y\' or \'n\'.') 
        print('Bye! (Hit enter.)') 
        raw_input() 
        return(ouch) 
    # Subset FOV to the chosen area if desired 
    # Uses 4000 for maximum z in nm 
    print('\nTo subset an area for analysis,') 
    print('use pixel values from a square-bin reconstruction') 
    print('(e.g. from a histogram with 100 nm bins, with 100 nm ppx in x and y).') 
 # user input to subset a region 
 # TO DO: Save number of locs in each subregion into an excel file (.csv) 
 # Run in infinite loop to srop region 
 # Files saved with cropped region size in filename 
    while True: 
        ans = raw_input('\nDo you want to crop a region? y/n: ') 
        if ans == 'y': 
            ymin = float(raw_input('\nMinimum horizontal pixel (0 for full FOV): ')) 
            ymax = float(raw_input('Maximum horizontal pixel (350 for full FOV): ')) 
            xmin = float(raw_input('Minimum vertical pixel (0 for full FOV): ')) 
            xmax = float(raw_input('Maximum vertical pixel (350 for full FOV): '))  
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            xyzmin = np.array([xmin * x_to_nm, ymin * y_to_nm, 0]) 
            xyzmax = np.array([xmax * x_to_nm, ymax * y_to_nm, 4000]) 
            subsetfilter = np.logical_and(xyz >= xyzmin, xyz <= xyzmax) 
            chosenlocs = np.all(subsetfilter, axis = 1) 
            subxyz = xyz[chosenlocs] 
            title = ('RegionX' + str(xmin) + '-' + str(xmax) + 'Y' + str(ymin) + '-' + 
str(ymax)) 
            np.save(title, subxyz) 
            np.savetxt((title+'.csv'), subxyz, delimiter = ',', header = 'X, Y, Z') 
            print('\nSubset conatins %i localisations.' % len(subxyz)) 
        elif ans == 'n': 
            subxyz = [] 
            xmin = 0 
            xmax = 0 
            ymin = 0 
            ymax = 0 
            break 
        else: 
            print('Try again with \'y\' or \'n\'.') 
            pass 
    return(xyz, subxyz, xmin, xmax, ymin, ymax, x_to_nm, y_to_nm, z_to_nm) 
def main(): 
    Tk().withdraw() 
    print 'Where do you want to save the results?' 
    savefolder = askdirectory() 
    print '%s\n' % savefolder 
    # Call getcorrecteddata for each acqn. run 
    # xyz = combineacquisitions() # This calls getcorrecteddata for each acqn. run 
    (xyz, subxyz, xmin, xmax, ymin, ymax, 
     x_to_nm, y_to_nm, z_to_nm) = combineacquisitions(savefolder)  
    return  
if __name__ == '__main__': 
    main() 
    print '\nHit Enter to exit' 
    raw_input() 
 
Appendix 5  
Python processing script to extract super-resolution microscopy coordinates from 
palm3d into NumPy array. User input to select .pkl file and corresponding 
localisations file for coordinate extraction of a processed image series. User input 
the specify x and y pixel corrections factors and correlation strength. Additional files 
can be appended if more than one acquisition run required. User input to define 
region for sub-setting. 
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""" 
Compute DBSCAN at set min_cluster_size 
Plot graph with clusters coloured according to cluster identity 
Calculate cluster size parameters using pairwise distances 
Input 
User input to select min_cluster_size 
Output 
Will save files in directory that script runs from 
.csv file of coordinates with cluster identity with and without "noise" 
Graph of clusters coloured according to identity 
.csv file of size parameters for each cluster 
""" 
import os 
import numpy as np 
from sklearn.cluster import DBSCAN 
import time 
from tkinter import Tk 
from tkinter.filedialog import askopenfilename 
from tkinter.filedialog import askdirectory 
import matplotlib.pyplot as plt 
import scipy.spatial.distance as distance 
from sklearn.neighbors import NearestNeighbors 
def removefiducial(savefolder, data): 
 """   
 Remove fiducial localisations  
 Search filter applied to localisations 
 If localisation has >500 locs within 30 nm cube then consider it fiducial 
 Save all localisations other than fiducial for DBSCAN analysis 
  Returns 
  Array of localisations without fiducial 
 """ 
 print('\nRemoving fiducial localisations...') 
 # Distance to search for localisations 
 # 30 nm is ~localisation precision in Z 
 filter = 30 
 filterarray = np.array([filter, filter, filter]) 
 x = [] 
 y = [] 
 z = [] 
 loc = 0 
 while loc < len(data): 
  # Reference localisation 
  locA = data[loc] 
  # A filter to search for localisation coordinate within filter distance 
  # Returns an np array of True / False 
  testfilter = np.logical_and(data > locA - filterarray, data < locA +  
filterarray) 
  # Find pos of all localisations within filter distance of reference loc 
  chosenlocs = np.all(testfilter, axis = 1) 
  subxyz = data[chosenlocs] 
  # Check how many neighbours reference localisation has 
  # If less than 500 save reference localisation coordinates 
  if len(subxyz) < 500: 
   x = np.append(x, locA[0]) 
   y = np.append(y, locA[1]) 
   z = np.append(z, locA[2])   
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  loc = loc + 1 
 # Save data without fiducial for DBSCAN analysis 
 xyz = np.array([x, y, z]) 
 xyz = np.transpose(xyz) 
 print('Orignal total: %i' % len(data)) 
 print('After total: %i' % len(xyz)) 
 return (xyz) 
def runDBSCAN(savefolder, data, neighbourhood, nlocs): 
 """ Run DBSCAN """ 
 t = time.time() 
 print('\nRunning DBSCAN...') 
 clusterer = DBSCAN(eps = neighbourhood, min_samples = nlocs).fit(data) 
 cluster_labels = clusterer.labels_ 
 # combine XYZ coordinates with cluster identity from DBSCAN 
 dataDBSCANnoise = np.c_[ data, cluster_labels ] 
 np.savetxt('%s\\coordinatesDBSCANnoise.csv'  
% savefolder, dataDBSCANnoise, delimiter = ',', header = 'DBSCAN Clustered 
Data') 
 # Remove coordinates classified as noise by DBSCAN 
 # Value of -1 from DBSCAN assigned as noise 
 row = 0 
 x = [] 
 y = [] 
 z = [] 
 c = [] 
 while row < len(dataDBSCANnoise): 
  if dataDBSCANnoise[row, 3] != -1 : 
   x = np.append(x, dataDBSCANnoise[row,0]) 
   y = np.append(y, dataDBSCANnoise[row,1]) 
   z = np.append(z, dataDBSCANnoise[row,2]) 
   c = np.append(c, dataDBSCANnoise[row,3]) 
  row = row + 1 
 dataDBSCAN = np.array([x, y, z, c]) 
 dataDBSCAN = np.transpose(dataDBSCAN) 
 np.savetxt('%s\\coordinatesDBSCAN.csv' % savefolder, dataDBSCAN,  
delimiter = ',') 
 """ Plot DBSCAN results """ 
 print('\nSaving plots...')  
 # Plot of clusters including noise localisations in black and white 
 # Get X and Y coordinates 
 xdata = dataDBSCANnoise[:,0] 
 ydata = dataDBSCANnoise[:,1] 
 fig = plt.figure() 
 plt.title('Original', fontsize = 20, y = 1.04) 
 noisepts = plt.scatter(xdata, ydata, marker='.', lw = 0, c = 'black') 
 # Set axis limits 
 xmin = np.min(xdata) 
 xmax = np.max(xdata) 
 ymin = np.min(ydata) 
 ymax = np.max(ydata) 
 ax = plt.gca() 
 ax.set_xlim(xmin-500, xmax+500) 
 ax.set_ylim(ymin-500, ymax+500) 
 # Control axis; values and ticks 
 #ax.xaxis.set_ticklabels([]) 
 #ax.yaxis.set_ticklabels([]) 
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 ax.set_xlabel('X (nm)', labelpad = 10) 
 ax.set_ylabel('Y (nm)', labelpad = 10) 
 ax.tick_params(axis = u'both', which = u'both', length = 0, pad = 10) 
 # Set figure aspect ratio 
 xsize = ((xmax-xmin)/1000)+1 
 ysize = ((ymax-ymin)/1000)+1 
 size = plt.gcf() 
 size.set_size_inches(xsize, ysize) 
 # Add scale bar to image 
 scalebar = plt.plot([xmin, xmin+500], [ymin-350, ymin-350], color = 'k',  
linestyle = '-', linewidth = '5') 
 scalelabel = ax.text(xmin-50, ymin-250, '500 nm', fontsize = 10, name =  
'Arial') 
 plt.savefig('%s\\DBSCANnoise.png' % savefolder) 
 # Get X and Y coordinates of DBSCAN clusters 
 # Colour clusters according to cluster identity 
 xdata = dataDBSCAN[:,0] 
 ydata = dataDBSCAN[:,1] 
 colour = dataDBSCAN[:,3] 
 # Plot DBSCAN clusters according to cluster identity on top of original locs 
 pts = plt.scatter(xdata, ydata, marker='.', lw = 0, c = colour) 
 plt.title('Cluster ID', fontsize = 20) 
 plt.savefig('%s\\DBSCANcolouridentity.png' % savefolder) 
 # Plot DBSCAN clusters only 
 noisepts.remove() 
 pts = plt.scatter(xdata, ydata, marker='.', lw = 0, c = colour) 
 plt.title('DBSCAN', fontsize = 20) 
 plt.savefig('%s\\DBSCAN.png' % savefolder) 
 plt.close() 
 """ Calculate cluster parameters """  
 # Save individual clusters and average cluster as binary files 
 # Calculate size parameters of clusters using pairwise distances 
 print('\nSaving clusters...') 
 id = [] 
 num = [] 
 xymax = [] 
 xymin = [] 
 xymean = [] 
 zmax = [] 
 zmin = [] 
 zmean = [] 
 xcentroid = [] 
 ycentroid = [] 
 zcentroid = [] 
 # Array for distance to centroid position 
 distcentroid = [] 
 # Array for saving average cluster 
 xavgcentroidnorm = [] 
 yavgcentroidnorm = [] 
 zavgcentroidnorm = [] 
 # iterate through each cluster 
 clusterid = 0 
 while clusterid < cluster_labels.max()+1: 
  row = 0 
  xc = [] 
  yc = [] 
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  zc = [] 
  # move coords for each cluster into array for distance measurement 
  while row < len(dataDBSCAN): 
   if dataDBSCAN[row, 3] == clusterid: 
    xc = np.append(xc, dataDBSCAN[row, 0]) 
    yc = np.append(yc, dataDBSCAN[row, 1]) 
    zc = np.append(zc, dataDBSCAN[row, 2])  
   row = row + 1 
  # Full cluster coordinates for saving image files 
  xyzclust = np.array([xc, yc, zc]) 
  xyzclust = np.transpose(xyzclust) 
   
  # get centroid position 
  xavg = np.mean(xyzclust[:,0]) 
  yavg = np.mean(xyzclust[:,1]) 
  zavg = np.mean(xyzclust[:,2]) 
  # calculate distance of localisation to centroid position 
  centroid = np.array([xavg, yavg, zavg]) 
  locA = 0 
  while locA < len(xyzclust): 
   locB = xyzclust[locA] 
   cdist = distance.euclidean(locB, centroid) 
   distcentroid = np.append(distcentroid, cdist) 
   locA = locA + 1  
  # XY coordinates for distance measurements 
  xyclust = np.array([xc, yc]) 
  xyclust = np.transpose(xyclust) 
  # Z coordinates for distance measurements in Z axis only 
  # Append column of zeros to array 
  zclust = np.c_[np.zeros(len(zc)), zc] 
  # calculate pairwise distances in clusters for XY, and Z axis 
  xydist = distance.pdist(xyclust, 'euclidean') 
  zdist = distance.pdist(zclust, 'euclidean')  
  # save cluster parameters to array 
  id = np.append(id, clusterid) 
  num = np.append(num, len(xyzclust)) 
  xymax = np.append(xymax, xydist.max()) 
  xymin = np.append(xymin, xydist.min()) 
  xymean = np.append(xymean, xydist.mean()) 
  zmax = np.append(zmax, zdist.max()) 
  zmin = np.append(zmin, zdist.min()) 
  zmean = np.append(zmean, zdist.mean()) 
  xcentroid = np.append(xcentroid, xavg) 
  ycentroid = np.append(ycentroid, yavg) 
  zcentroid = np.append(zcentroid, zavg) 
 # save cluster parameters 
 parameters = np.array([id, num, xymax, xymin, xymean, zmax, zmin,  
zmean, xcentroid, ycentroid, zcentroid]) 
 parameters = np.transpose(parameters) 
 # save distances to centriod 
 # distance of each loc within a cluster to its cluster centroid 
 np.savetxt('%s\\DistancetoCentroid.csv' % savefolder, distcentroid, delimiter  
= ',') 
 # calculate distances between cluster centroids 
 all_centroids = np.array([xcentroid, ycentroid, zcentroid]) 
 all_centroids = np.transpose(all_centroids) 
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 pdist_all_centroids = distance.pdist(all_centroids, 'euclidean') 
 np.savetxt('%s\\PDistCentroids.csv' % savefolder, pdist_all_centroids,  
delimiter = ',') 
 percentclust = ([len(dataDBSCAN) / len(dataDBSCANnoise) * float(100)]) 
 np.savetxt('%s\\DBSCANClusterParameters.csv' % savefolder, parameters,  
delimiter = ',',  
  header = 'ID, Locs/Cluster, XY Max Dist, XY Min Dist, XY Mean Dist,  
Z Max Dist, Z min Dist, Z Mean Dist, X Centroid, Y Centroid, Z  
Centroid', 
  footer = 'Total: %s\nClustered: %s\nPercentage : %s' %  
(len(dataDBSCANnoise), len(dataDBSCAN), percentclust)) 
 print('Clusters: %s' % len(parameters)) 
 # Message completion 
 print('\n%.2f sec to run DBSCAN analysis' % (time.time() - t) )  
 return 
def main(): 
 Tk().withdraw() 
 print('\nWhat region would you like to analyse') 
 xyzfile = askopenfilename() 
 print(xyzfile) 
 search_radius = int(input('\nWhat is the search radius? ') ) 
 min_cluster_size = int(input('What is the minimum number of locs per  
cluster? ') ) 
 directory = str(xyzfile) + '-DBSCAN-Analysis_eps-' + str(search_radius) +  
'_nlocs-' + str(min_cluster_size) 
 os.mkdir(directory) 
 xyz = np.load(xyzfile) 
  
 ansfid = input('\nDo you want to remove fiducial locs? [y]/n: ') 
 if ansfid != 'n': 
  xyz = removefiducial(savefolder = directory, data = xyz) 
 runDBSCAN(savefolder = directory, data = xyz, neighbourhood =  
search_radius, nlocs = min_cluster_size) 
 while True: 
  ans = input('\nDo you want to run another analysis? [y]/n: ') 
  if ans != 'n':  
   # Import data set 
   print('\nWhat region would you like to analyse?') 
   xyzfile = askopenfilename() 
   print(xyzfile) 
   directory = str(xyzfile) + '-DBSCAN-Analysis_eps-' +  
str(search_radius) + '_nlocs-' + str(min_cluster_size) 
   # Check if analysis has already been run 
   if os.path.exists(directory) == False: 
    os.mkdir(directory) 
    xyz = np.load(xyzfile)  
    if ansfid != 'n': 
     xyz = removefiducial(savefolder = directory,  
data = xyz) 
    # run DBSCAN 
    runDBSCAN(savefolder = directory, data = xyz,  
neighbourhood = search_radius, nlocs = min_cluster_size)  
   else: 
    print('\nYou have already analysed this data!') 
    print('Please try again') 
  if ans == 'n': 
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   print('\nFinished DBSCAN analysis - Hit Enter to Exit') 
   break 
if __name__ == '__main__': 
 main() 
 input() 
 
Appendix 6 
Python processing script to run DBSCAN analysis on super-resolution microscopy 
data. User input to select save folder, file for analysis and DBSCAN parameters of 
minimum points and search radius (nm). User input to remove fiducial localisations. 
Fiducial localisations determined from filtering the data set for localisations with 
500th neighbour within 30 nm Euclidean distance. DBSCAN analysis calculates 
cluster size, number of localisations per cluster and distance to centroid. Cluster 
size is defined as mean Euclidean distance (nm) in x-y. Distance to centroid is 
calculated for each localisation in a cluster to its cluster centroid. Distance between 
different cluster centroids are also calculated. Parameters are saved to .csv files in 
directory. Plots of localisations and clusters coloured according to cluster identity 
are plotted using matplotlib.pyplot. 
